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ABSTRACT 
Background: Nearly 40% of adults age 65 and over report using five or more medications and 
one in five prescriptions in primary care are identified as inappropriate. Medication quality of 
care is a critical healthcare concern. To improve primary care, Patient-Centered Medical Homes 
(PCMHs) are considered a promising approach with a focus on systems-based quality and safety 
improvement. Evidence has demonstrated that PCMH adoption has many potential benefits. 
However, gaps exist in our knowledge regarding the potential benefits of PCMH in improving 
patient medication quality of care.  
Objectives: To quantify current ambulatory care practices’ level of PCMH adoption and 
determine practice-based and physician-related factors associated with the degree of PCMH 
implementation and to explore the association between the level of PCMH adoption in a practice 
and its impact on medication processes and outcome of care indicators.  
Methods: This study employed the 2009 and 2010 National Ambulatory Medical Care Survey 
(NAMCS) dataset, using a cross-sectional study design. For missing data, multiple imputations 
by chained equations were used to generate five complete data sets to provide improved 
statistical power. The use of high-risk medication (HRM), drug-disease interaction (DDIS), and 
the occurrence of adverse drug events (ADEs) were the three selected medication process and 
outcome quality indicators. The level of PCMH adoption was predicted, controlling for physician 
and practice characteristics.     
  xi 
Results: Half of the ambulatory care settings in NAMCS adopted some aspect of PCMH during 
the observed study period. Physicians’ characteristics had significant associations with PCMH 
adoption, with older age and being female less likely to adopt PCMH. The prevalence of HRM, 
DDIS, and ADEs among the target populations were 11.2%, 15.0%, and 4.0%, respectfully. The 
adoption of PCMH was not associated with the selected medication quality indicators.   
Conclusion: PCMH was adopted by over 50% of practices throughout the Untied States and 
medication quality remains of concern. While the results did not support the impact of PCMH on 
medication use quality, these findings are limited to HRM, DDIS and ADE. Other quality 
measures, such as prevention and screening or disease-specific measures should be examined in 
the future studies. 
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CHAPTER I. INTRODUCTION  
One in five prescriptions in primary care in the United States is inappropriate, which could 
lead to serious medical consequences and place a substantial economic burden on our health care 
system.1 To ensure patient safety and control healthcare costs, it is critical to monitor medication 
use. This is particularly important if we consider that almost one-half of the U.S. population 
takes at least one prescription medication and 1 in 10 reports taking more medications in the 
preceding month.2 Among the elderly population, inappropriate medication is a particularly 
important problem, given their pharmacokinetic and pharmacodynamic changes arising from 
aging and greater use of high-risk medications. A related concern is that patients with higher 
medication use face an increased risk of inappropriate medication use, and a higher risk of 
experiencing adverse drug events (ADEs).3 In order to monitor inappropriate medication use and 
enhance medication safety, the Center for Medicare and Medicaid Services (CMS) employs 
quality measures developed by the Pharmacy Quality Alliance (PQA) and the National 
Committee for Quality Assurance (NCQA). These measures are directed at assuring medication 
quality which is of interest to the public and determining reimbursements for providers, but more 
broadly with a view toward enhancing accountability.4 Aligned with the goal of providing high-
quality medication services, the Patient Centered Medical Home (PCMH) model was designed as 
an innovative transformation in primary care that emphasizes specific medication management 
approaches aimed at ensuring that medications are distributed to and used appropriately by each 
patient.5   
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Many primary care practices have begun to implement PCMHs in their settings, yet what 
remains largely unexplored is how and to what extent this patient care model can impact 
patients’ process-of-care and health outcomes related to medications. The provision of care in a 
PMCH appears to have the potential to improve health service utilization and patient 
satisfaction.6 But, to date no study has investigated the relationship between the degree to which 
practices have implemented various aspects of PCMH and medication-related quality of care. To 
have a comparable way to quantify the provided services, many practices depend on the 
certification as PCMH by the NCQA PCMH recognition program, which is a voluntary program 
consisting of three levels of achievement, as measured by a scoring rubric.7  
The long-term goal of this investigator is to improve primary care delivery and elucidate 
how practices with PCMH processes of care impact the quality of medication use and related 
outcomes. The study is based on a combined theoretical model, using the well-established 
framework in the Chronic Care Model, and supplemented with structural and organizational 
factors. The rationale of this study is that there is a need to determine whether primary care 
practices using PCMH strategies indeed provide better care that result in better medication-
related outcomes. These results may provide insightful information about the value of having 
medication-related experts, such as pharmacists, in the PCMH care team to strengthen 
medication services.  
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OBJECTIVES 
 The overall objective of this study is to quantify the association between the levels of 
NCQA PCMH recognition in primary care practices and the quality of care related to medication 
use. The central hypothesis is that a practice with higher levels of NCQA PCMH recognition will 
offer better medication quality of care. This central hypothesis, as highlighted by the conceptual 
framework, will be tested by the following two specific aims: 
(1) Quantify current primary care practices’ level of PCMH adoption and determine physician 
and practice related factors associated with the degree of PCMH implementation.  
(2) Explore the association between the level of PCMH adoption in a practice and its impact on 
processes and outcomes of care related to medication use. 
With these aims in mind, the hypothesized statements are as follows: 
(1) Physician characteristics will have a significant association with the adoption of PCMH.  
(2) A higher level of PCMH adoption will be associated with a lower probability of inappropriate 
medication use, defined as high-risk medications and disease-drug interactions, among older 
adults.   
(3) A higher level of PCMH adoption will be associated with less frequently reported ADEs.  
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LITERATURE REVIEW 
This dissertation chapter first offers a general view of the quality of care with a specific 
focus on medication use. It then examines three medication quality indicators, along with a 
justification of why these measures were selected for use. Next, it explains the motivation for 
implementing a PCMH model and provides a systematic analysis of the impact of this model on 
the quality of care. Finally, the chapter describes the association between the PCMH model and 
patient medication use, examining the connection between what this current literature review 
describes and the missed opportunities where improvements can be made. The chapter concludes 
by proposing a theoretical model that can be used to examine the association between the quality 
of medication use and the adoption of the PCMH model.  
Quality of Care 
General Quality of Care 
In the ongoing debates about how to improve the U.S. health care system, a central concern 
has been how to meet the demand for high quality of care. This demand has grown in response to 
two factors. First, the delivery of high quality care can no longer be evaluated by expert opinion, 
namely judged by health care providers who decide what is good or best care. Today, to be 
labeled as good or better care, health care organizations have to meet criteria or standards, be 
accredited by validating institutions, and be evaluated by expert panels as well as consumers.8 
Assessments by the validating institutions not only establish consensus on important health care 
quality issues, but also provide a meaningful seal of quality, as a reliable indicator that an 
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organization is well-managed and delivers quality care, which is important for both patients and 
providers. Second, the transformation of the health care environment has prompted interest in 
examining the quality of care. For example, the growing demand for health care services, rising 
health care costs, constrained health resources, and evidence of a lack of uniformity in treatments 
among clinical practices have all led to increased interest in measuring the quality of care.9  
Quality of care is a concept composed of a variety of elements and is complex as well as 
multi-dimensional.10-12 In the health care literature, definitions of quality of care are fragmented 
and have changed dramatically over the past several decades. One of the early definitions of 
quality was offered by Donabedian (1968) who described quality as the evaluative dimension of 
elements and interactions in the medical care process, judging what is “good” or “bad”. Although 
this definition placed quality in the center of most health care organizations, it has been criticized 
for failing to consider two important aspects.13 For one, the definition does not consider practice 
patterns guided by evidence and for another it does not take into account assessments of patient 
outcomes.14 Donabedian refined his original definition and proposed another view of quality, 
which is now widely endorsed. According to this definition, quality can be examined in terms of 
three aspects: structure, process, and outcome. Structure refers to the attributes of the settings 
where care occurs, and it can include material resources, human resources, and organizational 
structure. Process refers to the duration of giving and receiving care, which would involve, for 
example, patients’ activities related to seeking care or clinicians’ activities in making a diagnosis 
or recommendations for treatment or surgery. Outcomes are defined as the effects of care on 
health status, both at the individual and the population level. A change in a patient’s health 
behavior, the satisfaction with received care, or the effects of a medication treatment can all be 
viewed as outcomes of quality of care.15 Donabedian (1990) also highlighted seven 
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characteristics that factor into the quality of care: efficacy, effectiveness, efficiency, optimality, 
acceptability, legitimacy, and equity.16 
Other scholars have also offered definitions of quality, which center more on patient-care. 
For instance, Steffen (1998) defined quality as the capacity to achieve legitimate medical and 
nonmedical goals, determined by the patients.17 Berwick provided a simple definition for quality 
of care, describing it as meeting the customer’s needs, assuming that patients always have 
sensible, understandable, and reasonable expectations of health care.18 These viewpoints stand in 
opposition to quality of care as viewed from a society’s perspective, which aims to have the most 
efficient and cost-effective care. From this perspective, doing everything medically possible for 
patients to achieve an improvement in health status without calculating the costs of healthcare 
providers or societies may create tension between the goals of individuals and those of society. 
Another scholar, Campbell, took a different approach to defining quality of care. Campbell 
viewed quality of care both from the individual and population levels. From the individual level, 
quality is a matter of (1) whether individuals can access the health structures and process of care 
which they need and (2) whether the care received is effective. On the other hand, quality of care 
at the population level can also be described as “the ability to access effective care on an 
efficient and equitable basis for the optimization of health benefit/well-being for the whole 
population”.9  
Another comprehensive and well-cited definition of quality of care is proposed by the 
United State Institute of Medicine (IOM). According to the IOM, quality of care is the degree to 
which health-care services for individuals and populations increase the likelihood of desired 
health outcomes and are consistent with current professional knowledge.19 The IOM proposed 
six different domains of quality of care, including safety, timeliness, effectiveness, efficiency, 
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equity, and patient-centeredness. This dissertation will adopt the IOM definition of quality of 
care as the working definition for two reasons. First, this definition of quality care is the most up-
to-date in the quality of care literature. Second, this definition of quality of care aligns with the 
aims of the Patient-Centered Medication Home (PCMH), which is the major focus of this 
dissertation. 
The Assessment and Improvement of Quality  
Quality of care can be assessed and improved in several ways, including developing and 
using standards, guidelines, or indicators. Standards are defined as the level of compliance with a 
criterion or indicator. It can be divided as target standards and achieved standards. Target 
standards are set prospectively and stipulate a level of care that providers must strive to meet. 
Whereas achieved standards are measured retrospectively and elaborated whether providers met 
predetermined standards.20 In general, standards play significant roles in the delivery of safe and 
effective care. One study suggested that standards need to be evidence based and professionally 
endorsed.21 Examples of standards refer to hospital quality standards. The definition of standards 
under the hospital quality context is policies about cleanliness and controlling infections or time 
to provide treatment for a heart attack. Guidelines, on the other hand, can be viewed as a form of 
reference, viewing as recommended, non-mandatory controls for helping to support standards,22 
and a clinical practice guideline is one example.23 Different from standards or guidelines, 
indicators are specific and explicit approaches that can be used to examine measurable elements 
of practice. As such, indicators can support the implementation of strategic plans so as to 
improve health care.24-26 Indicators considered here are primarily quality indicators (QIs), such as 
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the number of deaths from major cardiovascular disease (mortality rate) or the number of heart 
attacks or cases of fatal coronary heart disease (incidence rate). The QIs can mostly be found in 
two comprehensive annual reports in the United States: the National Healthcare Quality Report 
and the National Healthcare Disparities Report. These two reports are produced by the Agency 
for Healthcare Research and Quality (AHRQ), aiming to measure trends in effectiveness of care, 
patient safety, timeliness of care, patient centeredness, and efficiency of care. These two reports 
are viewed as the latest available findings on quality of health care in the U.S.  
One of the most common chronic diseases, hypertension, can be used to explain the 
definitions of standard, guideline, and indicator. For example, the general standard states that 
90% of the patients in a practice with a blood pressure of more than 160/90 mm Hg should have 
their blood pressure re-measured within 3 months. The achieved standard may report that 80% of 
the patients in a practice with a blood pressure of more than 160/90 mm Hg had their blood 
pressure re-measured within 3 months. American Society of Hypertension guidelines follow the 
standard and suggest that if a blood pressure reading is raised on one occasion, the patient should 
be followed up on two further occasions within the specific time. The detailed indicators define 
more specifically how to calculate a quantitative measure for the standard. The indicator 
numerator is the number of patients with a blood pressure of more than 160/90 mm Hg having 
had re-measured their blood pressure within 3 months. The indicator denominator includes 
patients with a blood pressure of more than 160/90 mm Hg.27  
Quality indicators are widely-used measures, and their use has several advantages, such as 
the ability to (1) identify health care improvement on a quantitative basis, (2) measure the 
efficacy of specific interventions, and (3) provide a quantitative link between quality of care and 
cost effectiveness.26,28 Quality indicators can be examined in relation to quality of care in stages, 
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namely structure, process and outcome.15,29 Process measures have the advantages that they are 
more sensitive to the differences in the quality of care and they are direct measures of quality. 
Quality indicators are also widely used in evaluations of structure and outcome; however, there 
are some limitations with regard to considering these two stages, specifically for two reasons. 
For one, quality indicators in structure of care are regarded as less than ideal forms of predictors 
of quality because of the inconsistencies across different health care settings. For another, quality 
indicators have been criticized in relation to outcome of care because they are an indirect 
measure, meaning that quality of care in patient outcomes may be influenced by many factors 
and require a large amount of data for analysis.30 For example, physicians can provide the exact 
same high quality processes of care to a set of patients and achieve different outcomes, which is 
attributable to the numerous personal and societal factors that may impact health outcomes.  
Although quality indicators have some disadvantages when used in evaluations of structure 
or outcome of care, it is worth noticing that many quality indicators have been implemented by 
different organizations. To date, quality measures mainly are all evidence-based and are 
developed by government agencies (e.g., Centers for Medicare and Medicaid Service (CMS) and 
the Agency for Health Care Research and Quality (AHRQ)) and private nonprofit organizations 
(e.g., the Joint Commission on Accreditation of Health Care Research and Quality (AHRQ) and 
the National Committee for Quality Assurance (NCQA)). Among all the organizations, the 
Healthcare Effectiveness Data and Information Set (HEDIS) of the NCQA is one of the most 
widely-used tools in the U.S. health care system for measuring, reporting and improving 
healthcare quality. HEDIS offers a wide range of measures aiming to help employers and 
patients know how well their care follows the standards. Nearly 90% of health plans in the U.S. 
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have adopted HEDIS as a common tool to evaluate the quality of care and these plans also 
include Medicare and Medicaid.31  
Given the importance and widespread use of HEDIS indicators, this dissertation will use 
three representative quality indicators related to medication quality of care, representing our 
outcome variables from HEDIS including two of process of care and one of outcome of care. 
The following section will first explain why the dissertation focuses on the quality indicators 
related to medication use, justify what these three medication-related quality indicators are, and 
provide support for why these three medication-related quality indicators were selected.  
Quality in Medication Use  
While quality of care is important for all aspects of health service provision, it is 
particularly important in the realm of patient medication use. This heightened importance of 
medication quality of care can be attributed to three serious issues. First, the growth in 
medication expenditures is considerable. According to a 2011 CDC report, spending on 
prescription drugs was $263 billion, representing nearly 10% of all national health care 
spending.32 Studies have also projected that the expenditures on medications will continue to 
increase for reasons related to the following second issue.33 A second issue is the demand for 
medications in our health care system. As the aging population increases in number, there will be 
an associated increase in the demand for medications that will delay the onset of disease, treat 
disease, and improve quality of life. One study reported that almost 40% of older Americans 
used five or more prescription drugs in the past month.34 A more recent study also found that the 
demand for medication has expanded to all the populations. Accordingly, the use of prescription 
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medications has continued to climb annually for individuals of all ages: 25% of children and 
90% of adults aged 65 and over have taken one or more prescription medications in the past 30 
days.2 The third issue leading to a heightened increase in medication use quality is the potential 
for harm.  
As the use of medications grows, the probability of inappropriate medication use also 
increases. Inappropriate medication use can then lead to serious medical consequences (e.g., 
adverse drug events), which in turn could create a substantial economic burden on the health care 
system (e.g., more expenditures on emergency room visits or hospitalizations).1 Previous studies 
have demonstrated that inappropriate medication use is highly prevalent among older adults, 
affecting approximately 24% of the community-dwelling elderly and 40% of nursing home 
residents in the United States.35,36 This inappropriate medication use has also been shown to have 
a strong association with the increased risks of adverse drug events as well as morbidity, 
mortality, and increased health care utilization.37 Indeed, adverse drug events annually account 
for more than 175,000 emergency room visits among Americans age 65 years and over.38 
Therefore, examining the medication quality of care is an urgent issue.    
In order to examine the medication quality of care among the population, a clear definition 
of the construct is needed, along with an understanding of the approaches to examining 
medication use. Roth Et al. defined quality of medication use as “the degree to which medication 
use for individuals and populations increases the likelihood of desired health outcomes and is 
consistent with current professional knowledge”.39 Roth Et al. also identified inappropriate 
medication use as underuse, overuse, and misuse. Underuse refers to failure to provide a 
medication when it could have a positive outcome for a patient. Overuse refers to the provision 
of a medication to such a degree that it has harmful consequences rather than beneficial ones. 
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Misuse applies when there is a medication failure of a planned action to be completed as 
intended.40  
Among these three types of inappropriate medication use, the focus of this dissertation will 
be the misuse of medication, including high-risk medication use and drug-disease interactions. 
Further, most causes of inappropriate medication use can be attributed to the responsibility of 
prescribers.41 To evaluate the performance of prescribers, several organizations, from non-profit 
alliances to government agencies, have devoted their efforts to establishing medication-related 
indicators at the population level to estimate the level of variation in potentially inappropriate 
prescribing (PIP) across different health care settings.42 The dual goal of having quality 
indicators is to provide a consensus as to what constitutes exceptional pharmacy quality and to 
improve patients’ medication quality of care through developing and implementing performance 
measures. Examples of the most well-known organizations developing medication-related 
indicators include the Pharmacy Quality Alliance (PQA), the NCQA, and the Center for 
Medicare and Medicaid Services (CMS).43-45 
The PQA is a consensus-based, multi-stakeholder membership organization, whose focus is 
on the appropriate use of medication with the goal of optimizing patients' health by improving 
the quality of medication use.43 Its mission is to develop strategies for measuring and reporting 
medication utilization and pharmacy services. The PQA measures were developed to include 
several areas such as medication safety, medication adherence, and medication appropriateness. 
These measures are widely employed in the health care insurance marketplace, and have also 
been adopted by the CMS in Medicare Part D star rating plans. Examples of medication 
performance measures include the use of high-risk medications in the elderly, drug-drug 
interactions, or cholesterol management in coronary artery disease.   
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Another organization which is devoted to establishing the medication quality measures is 
the NCQA. The NCQA is a well-known private non-profit organization whose mission is to 
assure, improve, and elevate healthcare quality. As a major national organization, the NCQA has 
reviewed and accredited healthcare quality throughout the U.S. healthcare system since 1990. 
The NCQA has two major functions: (1) to inform choices and pursuit of the best available care 
for stakeholders through offering a series of quality measurements, and (2) to assist healthcare 
organizations to make informed decisions that can drive quality improvement via providing a 
range of evaluative programs, such as accreditation, certification, and recognition. Among these 
quality measurements and programs in the NCQA, the HEDIS is one of the most widely used 
tools that help health organizations to measure quality in several important dimensions of care 
and services. In particular, the HEDIS offers several measures that address patient medication 
use in a variety of ways such as antibiotic utilization, potentially harmful drug-disease 
interactions in the elderly, and use of high-risk medications in the elderly.44 
CMS, on the other hand, is a government agency that primarily implements quality 
initiatives to assure quality for Medicare Beneficiaries via public disclosure. CMS has an interest 
in establishing quality measure to achieve the following three aims: (1) improve quality of care 
services, (2) pay for quality of care reporting, and (3) provide public quality of care reporting. 
With regard to medication use, the CMS has implemented an innovative project, called the 
Medication Measures Special Innovation, with specific medication measures. The aims of this 
project are to create a more comprehensive means for detecting and preventing medication 
errors, adverse drug reactions, and other harmful patient safety events. Examples of measures 
within the project include adherence to antiplatelet therapy after stent implantation and 
adherence to ACEIs/ARBs for individuals with diabetes mellitus. 
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 After reviewing all the medication quality of care indicators put forth by these 
organizations and considering how they may be assessed in a nationally representative manner, 
three representative medication related QIs for evaluating the prevalence of inappropriate 
medication use were selected including (1) the use of high-risk medications, (2) the existence of 
drug-disease interactions, and (3) the prevalence of Adverse Drug Events (ADEs). The first two 
indicators are classified as medication process of care indicators, whereas the last is considered 
to be a medication outcome of care indicator. These three medication-related quality indicators 
were chosen for three reasons. First, these selected indicators are widely used in assessing 
medication quality of care among practices. Second, the definition of these quality indicators can 
be adapted for examination in the proposed dataset. Third, no previous studies have investigated 
whether an association exists between these medication-related quality indicators and the 
implementation of the transformed delivery model (which will be explained further in the later 
sections). The following sections explore these indicators individually.  
Medication use constitutes a sizeable portion of U.S. healthcare. On average, 75% of U.S. 
outpatient visits involve medication therapies and it is estimated that 2.6 billion medications 
were ordered or provided in 2010.46 Along with the increasing demand for medications is the 
likelihood that potentially inappropriate prescribing (PIP) is also rising. One study reported that 
one in five prescriptions in primary care in the United States is inappropriate (e.g., overused, 
underused, or high-risk), which can lead to serious medical consequences, and place a substantial 
economic burden on our healthcare system.1 This is particularly important if we consider that 
almost one-half of the U.S. population takes at least one prescription medication and 1 in 10 
reports taking more medications in the preceding month.2 Therefore, the assessment of PIP and 
the assurance of medication quality are critical in today’s health care system. 
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PIP is defined as the use of a medication where the risk of ADEs outweighs the clinical 
benefit, especially when a safer or more effective alternative medication is available for the same 
condition.47 PIP, in fact, is a major, well-documented public health concern. In general, PIP 
consists of seven types, including, high risk medication use, inappropriate drug dose, drug 
duplication, drug-drug interaction, drug duration, drug-disease interaction, and any other 
inappropriate medications.41 This dissertation will focus on two of the most common types of 
PIP: high risk medications (HRMs) and Drug-Disease interaction (DDIS). The following 
paragraphs will introduce these two commonly used medication quality of care measures and one 
medication outcome measure (i.e., Adverse Drug Events) individually.    
The Use of High Risk Medications (HRMs) 
Definition and criteria  
The use of HRMs is defined as medications that are prescribed for the elderly population 
without a clear evidence-based indication, which leads to a substantially higher risk of adverse 
side-effects compared to the risk among younger people.48 Generally, the use of HRMs can be 
detected in one of two ways. One is through implicit criteria and the other is via explicit criteria. 
Implicit approaches rely on clinician judgment of appropriateness for each case, which is a time-
consuming process and inconvenient for population-based studies, whereas explicit approaches 
are relatively standardized and quantifiable.49 Since this dissertation proposes to use national 
survey data to estimate the prevalence of HRMs, an explicit measure is the most suitable 
approach to examine the occurrence of HRMs. Current explicit measures of HRM are important 
quality measures that are included in the CMS based Medicare Part D, the NCQA HEDIS and 
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the PQA. To date, the three most widely-used, validated, and explicit measures of HRM among 
the elderly population are Beers, Zhan, and HEDIS criteria. 
The Beers criteria was proposed and developed by Dr. Mark Beers in 1991. It is currently the 
most widely described and used screening tool for inappropriate medication use among the 
elderly population.1 The criteria were rated by an expert panel that determined the effects of risk 
outweigh the potential benefit among the elderly population.47 The original Beers criteria listed 
30 medications to be avoided among the elderly population residing in nursing homes, regardless 
of their diagnosis. Beers criteria were subsequently expanded and revised in 1997, 2002, and 
2012 to include all geriatric care settings.47,50,51 Despite the widespread use of Beers criteria, the 
Beers criteria remain controversial. The first concern is that the medication lists based on Beers 
criteria are not absolutely contraindicated among elderly population. The second concern is 
whether the Beers medication list is comprehensive and up to date. The final concern is that 
Beers criteria are difficult for clinicians to use.48,52 
The second widely used criteria for determining inappropriate medication use are Zhan 
criteria. Zhan criteria, proposed in 2001, were developed by a panel of experts who were familiar 
with the original Beers criteria, the updates, and the measures in the National Medical 
Expenditure Survey. Based on the expert panel’s opinions, Zhan criteria are more specific and 
organized. The selected 33 drugs identified using Zhan criteria are classified into 3 categories: 
(1) should always be avoided, (2) are rarely appropriate, and (3) have some indications, but are 
often misused.53 Even though Zhan criteria for identifying inappropriate medication use among 
the elderly are also widely used in the literature and have been regarded as the best available 
clinical tool for the screening of inappropriate medication use, they have been criticized by 
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several studies for not providing the most up-to-date lists.53,54 A further criticism is that Zhan 
criteria do not consider patient doses, frequency of administration, or duration.55 
Given the drawbacks of Beers and Zhan criteria, the NCQA HEDIS are often used to 
determine inappropriate medication for the elderly population and are the third most widely used 
lists. Initiated in 2006, the NCQA HEDIS established inappropriate medication use indicators 
based on recommendations from an expert panel and references to the most recent version of 
Beers criteria. The NCQA HEDIS categorized in detail inappropriate medication use on the basis 
of two measures: drugs to avoid in elderly populations (i.e., the use of HRMs) and drugs that 
have the potential to cause a harmful DDIS in the elderly. Given the importance of HRM and 
DDIS use among the elderly, these issues will be taken up in the next sections.  
To identify the prevalence of HRMs among the elderly population, this dissertation will 
employ the NCQA HEDIS criteria, specifically those used to identify high-risk medications.56 
The NCQA HEDIS was chosen for three reasons. First, the NCQA HEDIS criteria apply 
morerefined measures for benchmarking the quality of medication management among the 
elderly population. Second, the lists are used among nearly 90% of health organizations and are 
frequently employed in studies.44,52,57 Third, the lists were developed in 2006 and are updated 
annually. Compared to Beers criteria and Zhan criteria, the NCQA lists include the most up-to-
date and comprehensive drug information. The full list of each set of criteria is provided in 
Appendix A.  
Prevalence of HRMs  
        Two review papers systematically reported that the prevalence of HRMs among elderly 
populations varies widely from 2.9% to 62.5%.1,54 The broad range of the incidence of HRMs is 
important to consider and can be attributed to three reasons. First, the studies were conducted in 
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different countries. Physicians in different countries may have distinct prescribing behavior, 
which might account for the HRMs rate. Second, the studies were completed in different practice 
settings, e.g., primary care practices, long-term care facilities, or hospitals, which might also be a 
factor that leads to the variation in HRMs prevalence. For example, a higher prevalence of 
HRMs might be found among hospitalized patients than among those who are seen in primary 
care practices, as the former may have more serious health conditions that require more 
medications for treating conditions, exposing them to higher rates of HRMs. Third, the reviewed 
studies may have applied different “criteria” to identify HRMs. Given the differences among the 
available criteria, it is inevitable that HRM prevalence will also differ. Despite their important 
findings, the two reviews have other limitations in terms of exploring HRM rates. First, the 
studies are not up-to-date and may overlook recent efforts (e.g., health care reform or the 
rearrangement of other non-physician professionals) to prevent the occurrence of HRMs. 
Second, not all the selected articles in the reviews investigated the actual factors affecting 
HRMs; instead, the selected articles in the reviews took into account only patient-related factors 
that may affect the use of HRMs.   
Factors related to HRMs   
Generally, previous articles have concluded that three major patient-related factors were 
associated with HRMs, including gender (female), age (older), and the number (higher) of 
medications.58-64 However, these studies were not comprehensive in that they did not consider 
practice-level characteristics and attributed the use of inappropriate medication mostly to the 
patients themselves. Indeed, it is worthwhile to consider that often exposure to inappropriate 
medication is attributable to the prescribing behavior of the providers. Therefore, an examination 
of studies related to HRMs is needed to consider practice-level characteristics that serve as 
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factors. Practice-level characteristics (e.g., practice type, practice level) are important because 
these characteristics represent the extent to which care may be accessed or offered. This issue 
was not fully discussed/investigated in the review articles.  
To deal more fully with these gaps in previous studies, this dissertation will offer a more 
comprehensive literature review of the prevalence of HRMs and an investigation of factors 
related to this issue (e.g., practice-level characteristics). The selection process for the articles is 
described as follows. The Ovid Medline In-Process was used to search up to 2015, aiming to 
search relevant articles in English by using terms and keywords in the title and abstract. The 
search included terms related to “high risk medication”, “factors”, “inappropriate prescription”, 
“high risk medication” “primary care”, “ambulatory care”, “general practice”, “office practice” 
or “outpatient care”. To be included, studies must have also reported the rate of HRMs and other 
factors of interests (either individual and/or practice level characteristics) affecting HRMs.  
Overall, 16 articles met the inclusion criteria for the detailed analysis. The results of the 
literature search are systematically presented in Table 1.1. Five major themes emerged from the 
selected articles. First, the majority (11 of 16) of the studies of HRMs were conducted in the U.S. 
Second, all the papers included used explicit criteria but the majority (9 of 16) employed various 
forms of the Beers, namely four versions in 1991, 1997, 2002, and 2012. The remaining studies 
used Zhan criteria, NCQA HEDIS, and others (McLeod criteria, Germany’s publish list, and 
Miao criteria). Third, all of the studies focused on elderly populations; they also employed data 
from either large administrative data sets or surveys of a restricted geographic location. A small 
number of studies even narrowly focused on a specific subsample, such as elderly 
veterans.52,57,59,65  
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Fourth, the reported prevalence of HRMs was revealed to vary even more widely than the 
previous two reviews studies reported, ranging from 3.7% (Zhan criteria) to 59.2% (2012 Beers 
criteria). Two explanations are offered for this widely reported variation in HRMs. For one, 
different data sets were employed in the studies and these different data sets differ with regard to 
the composition of their samples. For example, the prevalence of HRM reported as 57% in 
Kondo Et al. study since their study used Beers criteria and the population was targeted at adults 
aged 65 and over and with hemodialysis treatment record in hospital; Whereas the prevalence of 
HRM recorded as approximately 13% in the study of Pugh Et al. using the NCQA HEDIS 
criteria and focused on Veteran population. For another, different criteria to identify HRMs were 
adopted with studies that used Beers criteria, resulting in a higher prevalence of HRMs than did 
studies using other criteria. Most of the studies that adopted Beers criteria to determine the 
prevalence of HRMs found high rates (more than 30%) and might have overestimated HRMs. 
This possible overestimation implies that other criteria would be better options for examining 
HRMs. For the final theme, half of the studies identified factors affecting HRMs at the practice 
level. These findings indicate that increasingly researchers are aware that not only can HRMs be 
attributed to patients’ characteristics, but they can also be explained by the characteristics of the 
healthcare providers as well as the environment in which they work.  
Generally, two research trajectories have examined HRMs. One is based on individual 
characteristics of patients, which have been widely investigated. The other takes both individual 
characteristics of patients and practice characteristics into account. The first line of research (i.e., 
investigation of individual characteristics), has mainly adopted the view of inappropriate 
medication use attributable to patients. Most of the studies in this category have revealed both 
consistent and inconsistent results regarding the factors that affect inappropriate mediation use. 
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Studies have consistently reported higher levels of inappropriate medication use among patient 
who are female,57,59,65-72 are age 65 and over,57,70,72 have demonstrated comorbidity 
conditions,52,57,59,65,73 and take more medications.52,53,57,59,65,66,68-71,74,75 One area of disagreement 
at the individual level, however, is race. Two out of five studies found that white Caucasians are 
more likely to be prescribed inappropriate medications,59,65 whereas the remaining three studies 
reported the opposite results, where non-white populations experienced higher rates of 
HRMs.52,57,68  
Additionally, other factors that can affect HRMs appear only once, such as having poor 
health status,53 residing in metropolitan areas,76 having payment sources of either Medicare or 
Medicaid,5 having been hospitalized in the previous year,57,68 having a higher number of 
outpatient visits,70 using a higher number of over-the-counter drugs,71 and being illiterate.74 
Overall, because these individual factors have been reported to have associations with HRMs, all 
these factors should be considered as significant covariates for the present analysis. The second 
line of HRM research explores both individual and practice characteristics by examining five 
major factors that contribute to HRMs: specialty of the practice,52,57,59 type of the practice,72 
numbers of prescribers,68,75 age of prescribers,70,72 and gender of the physicians.72 
 This section has described two major features of this dissertation. First, the NCQA HEDIS 
criteria have been selected as the standardized measure for HRMs. Second, this dissertation will 
explore the association between quality of care at the practice level and potentially inappropriate 
medication use among the elderly age 65 and over, controlling for both patient and practice 
characteristics. The investigations of practice-level characteristics in the current literature are not 
comprehensive. A variety of factors at the practice level should be considered, such as the 
ownership of the practice (physician group or health care cooperation). Most important of all, no 
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current studies examine whether practice transformation, such as adopting the PCMH, may also 
affect HRMs. Since the PCMH emphasizes the importance of providing better health services to 
patients, it is important to know whether practices transformed into PCMH may enhance the 
medication quality of care (i.e., lower onset of HRMs). Overall, this approach is important 
because most of the relevant studies did not link such a timely issue with the occurrence of 
HRMs.  
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Table 1.1. Factors Associated with HRM Use, the Reported Prevalence of HRM with Adopted Criteria, and the Characteristics of Studies (2001-
2015) 
Reference Factor affecting HRM 
(individual level)  
Factor affecting 
HRM (practice 
level) 
Prevalence Criteria Study 
Population 
Data 
Resource 
Top most frequently 
prescribed HRM 
Zhan, 
2001 
Health Status (Poor 
health) and Number of 
Medication use (More) 
N/A 21.3% Zhan Community-
dwelling 
elderly 
MEPS Propoxyphene, 
Amitriptyline, 
Dipyridamole, 
Promethazine, and 
Hydroxyzine 
Goulding, 
2004 
Gender (Female), 
Number of Medication 
use (More) 
N/A 7.8% / 
3.7% 
Beers/ 
Zhan 
Adults age 
65 and over 
NAMCS + 
NHAMCS 
(Drug class) Pain relievers 
and central nervous system 
drugs 
Pugh, 
2005 
Gender (Female), Race 
(White), Comorbidity 
condition (psychiatric), 
and Number of 
Medication use (More)  
N/A 23% Zhan Veteran National 
Veteran 
inpatient and 
outpatient 
administrative 
and outpatient 
pharmacy data 
(Drug class) Pain relievers, 
Benzodiazepines, 
Antidepressants, and 
Musculoskeletal agents 
Vis-
wanathan, 
2005 
Referred patient, 
Location in metropolitan 
area 
N/A 13.4% 
8.8% 
4.2% 
2002 
Beers 
1997 
Beers 
Zhan 
Adults age 
65 and over 
NAMCS+NH
AMCS 
Propoxyphene, Doxazosin, 
Amiodarone, 
Nitrofurantoin, 
Amitriptyline 
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Reference Factor affecting HRM 
(individual level)  
Factor affecting 
HRM (practice 
level) 
Prevalence Criteria Study 
Population 
Data 
Resource 
Top most frequently 
prescribed HRM 
Pugh, 
2008 
Gender (Female), Race 
(White), Comorbidity 
condition, and Number 
of Medication use 
(More) 
Specialty of the 
practice (Geriatric 
care) 
26.2 % Zhan Veteran National 
Veteran 
inpatient and 
outpatient 
administrative 
data  
Not report 
Pugh, 
2011 
Gender (male), Ethnicity 
(Hispanics), Number of 
Medication Use (More), 
Comorbidity condition  
Specialty of the 
practice (Geriatric 
care) 
Range 
from 
12.3% to 
13.1% 
NCQA 
HEDIS 
Veteran National 
veteran 
outpatient and 
pharmacy data  
Endocrine Drug, 
Gastrointestinal 
Antispasmodies, Cardiac 
Medications, Antibiotics  
Bao, 2011 Number of Medication 
(more), Payment source 
(Medicare or Medicaid) 
None of the 
predictors were 
significant 
38% 2002 
Beers 
criteria 
Healthy 
patients 65 
years of age 
or older on at 
least one 
medication 
National Home 
and Hospice 
Care Survey 
Narcotics, Antiadrenergics, 
Antihistamines, 
Antiarrhythmics, Tricyclic 
antidepressants,  
1. Stafford, 
2011 
Number of Medication 
(more), Take 
psychotropic 
medication, 
Health Status (illness) 
N/A 35.3%/ 
18.7% 
2003 
Beers 
criteria 
McLeod 
criteria 
Adults age 
65 and over 
Survey of  
residents of 
care homes 
across 
Tasmania in 
Australia  
Benzodiazepines, 
Amitriptyline, Oxybutynin, 
Non-steroidal anti-
inflammatory drugs. 
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Reference Factor affecting HRM 
(individual level)  
Factor affecting 
HRM (practice 
level) 
Prevalence Criteria Study 
Population 
Data 
Resource 
Top most frequently 
prescribed HRM 
Gellad, 
2012 
Age (older), Gender 
(female), Race (non-
white), Number of 
Medication Use (More), 
Comorbidity condition 
(More), 
ER/Hospitalization in 
previous year (yes)  
Specialty of the 
practice (Geriatric 
care) 
4.7% NCQA 
HEDIS 
Veteran National 
veteran 
outpatient and 
pharmacy data  
(Drug class) Opioid, 
Antihistamine, Skeletal 
muscle relaxant 
Oliveira, 
2012 
Patient literacy status 
(illiteracy), Number of 
Medication (more) 
N/A 34.5% Beers 
criteria 
Adults age 
65 and over 
Prospective 
survey of the 
medication use 
Short-acting nifedipine and 
Methyldopa 
Holmes, 
2013 
Gender (female), 
Ethnicity (black), 
Income status (low), 
Hospitalization status, 
and Number of 
Medication Use (More) 
Numbers of 
prescribers  
31.9% 2003 
Beers 
criteria  
Texas 
Medicare 
Part D 
beneficiaries 
Medicare 
claims and 
Medicare Part 
D event files 
Propoxyphene, 
Nitrofurantoin, Clonidine, 
Cyclobenzaprine, 
Amitriptyline 
Schubert, 
2013 
Gender (female), 
Number of Medication 
Use (More) 
N/A 22.0% Ger-
many’s 
recently 
publishe
d list 
Adults age 
65 and over  
Health 
Insurance 
claim data in 
Germany 
Amitriptyline, Tetrazepam, 
Doxepin, Acetyldigoxin, 
Doxazosin  
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Reference Factor affecting HRM 
(individual level)  
Factor affecting 
HRM (practice 
level) 
Prevalence Criteria Study 
Population 
Data 
Resource 
Top most frequently 
prescribed HRM 
Pannoi, 
2014 
Age (older), Number of 
Medication Use (More), 
outpatient visit (less) 
Age of the 
prescribers (older) 
28.1 % 2012 
Beers 
criteria 
Adults age 
65 and over 
From a district 
hospital in 
Southern 
Thailand  
(Drug class) 
Benzodiazepine, Non-Cox-
selective NSAIDs, Alpha-1-
blockers, Tertiary Tricyclic 
Antidepressants 
1. Kondo, 
2014 
Number of Medication 
Use (More), 
Comorbidity condition 
(More) 
Number of 
Provider (more), 
Without 
multidisciplinary 
professionals, 
Practice type 
(clinic) 
57 % Beers 
criteria 
Adults age 
65 and over 
and received 
hemodialysis 
treatment at a 
hospital or 
clinic. 
The Japan 
Dialysis 
Outcomes and 
Practice 
Patterns Study  
(Drug class) H2 blockers, 
Antiplatelet agents, and α-
blockers  
2. Baldoni, 
2014 
Gender (female), Self-
medication, use of OTC 
medication, use of 
psychotropic 
medication, Number of 
Medication Use (More) 
N/A 48.0 % / 
59.2 % 
2003/20
12 Beers 
criteria 
Adults age 
65 and over 
 Clonidine, Amitriptyline, 
Metformin, Fluoxetine, 
Dexchlorpheniramine 
Amos, 
2015 
Age (older), Gender 
(Female) 
Age of physician 
(older), Gender of 
physician (male), 
and practice type 
(Solo) 
28 % 2011 
Miao 
criteria 
Adults age 
65 and over 
Large database 
in Italy 
Ticlopidine, NSAIDs, 
Doxazosin, Digoxin, 
Antiarrhythmics 
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Drug-disease interactions (DDIS)  
Definition and criteria  
While most studies typically have adopted the use of high-risk medications as an 
indicator of PIP, studies are beginning to expand their scope to include other indicators, such 
as DDI and DDIS.77 DDI is defined as an occurrence when two drugs known to interact are 
concurrently prescribed. Further, DDIS is defined as a condition in which a prescribed 
medication subsequently exacerbates a coexisting chronic condition.41,78  
Both DDI and DDIS have in fact become critical risks for the elderly population.79-81 Two 
reasons can explain why the elderly population is more likely to experience these two types 
of PIP. First, the elderly population has a higher prevalence of comorbidity conditions, which 
are associated with greater demands for pharmacotherapy. Second, the greater demand for 
pharmacotherapy leads to a higher probability of polypharmacy, which could induce both 
DDI and DDIS and increase the risk of adverse effects.82 Given the prevalence of DDI and 
DDIS and the importance of their association with potential adverse health outcomes among 
the elderly population, these two indicators can be significant proxies for inappropriate 
medication use.77 As such, DDIS has been selected as one indicator of PIP in this dissertation. 
Another motivation for this choice is that while a number of studies have assessed the 
prevalence of DDI, the prevalence of DDIS is relatively less investigated.77 Similar to HRMs, 
DDIS also can be estimated by using explicit or implicit measures of potentially 
inappropriate medication prescribing.83 Since this dissertation will depend on a large data set 
to explore the research questions, an explicit measure will be adopted to investigate the 
prevalence of DDIS.  
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Among the explicit measures of DDIS, six tools are widely used in the current literature 
for determining DDIS, including McLeod’s criteria,84 the Improving Prescribing in the 
Elderly Tool (IPET),85 Updated Beers criteria,50 Zhan criteria,86 the NCQA HEDIS criteria,31 
and the Screening Tool of Older Person’s Prescriptions (STOPP).87 In order to maintain the 
clarity of the meaning of tools for determining DDIS, two points should be clarified before 
introducing these six tools. First, the following paragraph will use “criteria” to represent the 
explicit measures for determining the DDIS. The rationale for using this terminology for 
DDIS explicit measures is that all the DDIS related studies employ “criteria”. Second, the 
names of some criteria (i.e., Beers criteria, Zhan criteria, and the NCQA HEDIS criteria) are 
exactly the same as some discussed in the previous section for high-risk medications. 
However, the contexts are completely different. For Beers and the NCQA HEDIS criteria, the 
reference articles are the same as in the previous section, but only focus on the DDIS. For 
Zhan criteria, the medication lists for DDIS are not the same as those on the list of high-risk 
medication. The Zhan criteria for high-risk medication were published in 2001, whereas the 
criteria for DDIS were released in 2005.   
McLeod’s criteria are the first consensus-based PIP list created by a Canadian expert 
panel that mentioned DDIS. According to McLeod Et al., 38 PIP criteria were classified into 
three groups: 16 drugs generally to be avoided, 11 DDI, and 11 DDIS. Six diseases are 
included in the discussion of DDIS including cardiovascular diseases (i.e., hypertension, 
angina, and atrial fibrillation), insomnia, depression, dementia, osteoarthritis, and gout.84  
IPET is a revised version of McLeod’s criteria also developed by several Canadian 
scholars.88 IPET has several advantages over McLeod’s criteria including (1) a more up-to-
date medication list, (2) relative conciseness as a tool, and (3) widespread acceptability and 
use in Canada and Ireland.83 IPET consists of 14 questions to identify PIP along with 8 types 
of disease for assessing the DDIS, namely chronic obstructive airways disease, 
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cardiovascular disease (i.e., congestive heart failure, heart block, and hypertension), gout, 
glaucoma, active metabolites, peptic ulcer disease, osteoarthritis, and diarrhea.   
The first updated Beers criteria included DDIS classifications, whereas the original 
Beers criteria did not consider the inappropriateness of diagnosis or concurrent use of 
medications.50 With the work of Fick and his research team, the updated Beers criteria 
identified 20 diseases/conditions linked to medication/medication classes that patients should 
avoid. These diseases/conditions were heart failure, hypertension, gastric, seizures, blood 
clotting disorders, bladder outflow obstruction, stress incontinence, arrhythmias, insomnia, 
Parkinson disease, cognitive impairment, depression, anorexia and malnutrition, syncope or 
falls, hyponatremia, seizure disorder, obesity, chronic obstructive pulmonary disease, and 
chronic constipation. 
The next tool for detecting DDIS is Zhan criteria.86 The 2005 Zhan criteria focused on 
inappropriate DDI and DDIS, identified by evaluations of an expert panel. The 2005 Zhan 
criteria, which incorporated both McLeod and Beers criteria, identified six DDI combinations 
and fifty DDIS combinations along with more detailed clinical significance. Clinical 
significance was categorized into three levels including high, moderate, and lower or 
uncertain. Based on the review and discussion of the expert panel, three of the six DDI were 
regarded as high clinical significance, one of moderate clinical significance, and two of lower 
or uncertain clinical significance. High or moderate clinical significance implies that 
evidence of the interactions is well established or an altered pharmacological response is 
possibly to occur, whereas low or uncertain clinical significance means the evidence of the 
interaction is not well established. Among the DDIS, fifteen are considered high; twenty-one 
DDIS are classified moderate; and thirteen DDIS are viewed as low or uncertain clinical 
significance. Fifteen types of diseases or conditions are mentioned in the Zhan’s DDIS 
classification, including cardiovascular disease (i.e., hypertension, postural hypotension, heart 
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failure, peripheral vascular disease, arrhythmia, and heart block), urinary incontinence, 
benign prostatic hypertrophy, constipation, glaucoma, peptic ulcer, dementia, syncope/falls, 
insomnia, asthma/chronic obstructive pulmonary disease, diabetes, raynaud disease, seizures, 
chronic renal failure, and gout.  
The NCQA HEDIS criteria are the most widely used criteria and have been adopted by 
more than 90 percent of health plans in the United States. The DDIS criteria of the NCQA 
HEDIS are relatively concise and sufficient. Developed in 2007 and updated annually, the 
NCQA HEDIS criteria are based on modifications of the McLeod and Beers criteria.78 
According to NCQA HEDIS criteria, a patient will be identified as having been exposed to 
DDIS if he/she meets the following three conditions: (1) a patient is 65 years old and over, 
(2) a patient must have one of the following health conditions, including fall/fractures, 
dementia, and chronic renal failure, and (3) a patient has an ambulatory prescription for a 
contraindicated medication concurrent with or after a diagnosis. The three conditions linked 
to the corresponding medication groups are as follows: (a) fall/fractures: tricyclic 
antidepressants, conventional or atypical antipsychotics, and specific sleep agents (e.g., 
zolpidem), (b) dementia: high anticholinergic agents (i.e., gastrointestinal antispasmodics, 
skeletal muscle relaxants), and (c) chronic kidney disease: nonsteroidal anti-inflammatory 
drugs (NSAID). Finally, the STOPP is another tool for detecting DDIS. Proposed by 
Gallagher and his research team, STOPP is based on Beers criteria and was designed to 
estimate the PIP for community dwelling older adults as well as hospitalized patients in 
Ireland in 2008.87 The STOPP includes 17 diseases/conditions that may cause drug 
interactions. These diseases/conditions includes heart failure, hypertension, duodenal ulcers, 
epilepsy, blood-clotting disorders, stress incontinence, arrhythmias, insomnia, cognitive 
impairment, depression, anorexia and malnutrition, syncope or falls, hyponatraemia, seizure 
disorder, obesity, chronic obstructive pulmonary disease, and constipation.    
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Despite the many criteria, this dissertation will adopt the NCQA HEDIS criteria as the 
working definition of DDIS for three reasons. First, the NCQA HEDIS criteria are a national 
quality measure and can be easy applied in large administrative datasets. Second, the NCQA 
version is the most widely used measure to monitor quality of prescribing by most of 
managed care organizations in the United States, providing important context for the findings 
in this study.89 Third, the criteria contain the most up-to-date DDIS (Appendix B). In order to 
have an advanced understanding of DDIS, the following two sections (1) summarize the 
prevalence of DDIS according to relevant studies, and (2) explore factors that affect the 
occurrence of DDIS.  
Prevalence of DDIS  
 The Ovid Medline In-Process was used to identify up-to-date relevant articles written in 
English using specific terms and keywords in the title and abstract. The key terms include 
“drug-disease interaction”, “medication prescribing”, “inappropriate prescription”, and 
“factors”. The selected articles contained the information about the prevalence of DDIS as 
well as the exploration of factors that affect the DDIS. Seven articles met the inclusion 
criteria and the findings of these 7 articles are summarized in Table 1.2.  
The median rate of reported DDIS among the elderly was 22.4% with a range from 2.6% 
to 64.0%. This wide variation has three possible explanations. First, the studies used different 
explicit criteria to determine the prevalence, which is likely to produce different estimates of 
the extent of the problem. The different types of criteria have various definitions of DDIS, 
which can cause varying prevalence. For example, the Beers criteria contain 20 types of 
DDIS, Zhan criteria have 50 types of DDIS, and NCQA HEDIS has 3 types. Indeed, the 
highest prevalence of DDIS among all the selected articles used Zhan criteria, whereas the 
lowest prevalence of DDIS employed NCQA HEDIS criteria. This finding strongly suggests 
that including more criteria for DDIS will result in a higher prevalence of DDIS. The Zhan 
  32 
and NCQA HEIDS criteria are the most two common methods in the selected papers (i.e. 
four out of seven articles),52,57,79,86 while the remaining criteria, e.g., Beers criteria or others, 
appear only once.78,80,81  
The second reason for the DDIS range is the different populations in the selected papers. 
Three out of seven articles reported the prevalence of DDIS at more than 20%, and two of 
these three articles were centered on hospitalized populations.78-80 Since the inpatient 
population normally has greater medications demands, the likelihood of being exposed to 
DDIS risk might also increase.  
Finally, the third reason for the high discrepancy of DDIS may be the use of different 
data sources. For the studies using national data sets, the prevalence of DDIS was generally 
less than 5%.52,57,86 For the other studies, which employed regional data sets, reported rates 
were all more than 10%.78-81 This difference implies that the use of national datasets might 
result in having lower rates of DDIS because it may provide data that are more representative.  
Based on the above reasons for explaining the potential dissimilarity of drug-disease 
interaction rates, two outcomes are expected in this dissertation. First, the rate of drug-disease 
interaction is expected to be low because the target sample of this dissertation will be general 
individuals age 65 and older who use outpatient visits as opposed to inpatients and HEDIS 
NCQA has criteria for three DDIS. Second, the rate of drug-disease interaction may range 
between 2.6% and 15.2%, which was reported by Zhan (2005) and Pugh (2011), respectively. 
Zhan employed NAMCS data and different criteria while Pugh explored Veteran data using 
the NCQA HEDIS. 
Factors related to DDIS   
Similar to the exploration of HRMs, two research trajectories have explored the use-
related factors that affect the prevalence of drug-disease interactions. One is based on the 
individual perspective exclusively and the other considers both individual and practice 
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perspectives together. As to the former approach, six of seven articles focused on individual 
characteristics. The results of these studies are consistent, showing that patients with higher 
numbers of medications,52,78-81,86 older age,57,78-80 being married,78 Hispanic race,52 having 
more chronic diseases,52,78,79 and having no co-payments52 were more likely to have drug-
disease interactions. Although this dissertation focuses on how practice-level characteristics 
affect the prevalence of drug-disease interactions, these identified individual characteristics 
are still valuable references for inclusion in the model as covariates.  
As to the focus on patient and practice characteristics, only one out of seven articles 
considered both of these factors. This study showed that if a patient was seen in a facility 
with geriatric education, then he/she has lower odds of having drug-disease interactions, 
suggesting that such practices enhance medication quality.57 The results also indicated that if 
a patient is seen in a facility caring for fewer older veteran patients (over 65), then the odds of 
a patient receiving a drug-disease interaction will increase. This implies that the capacity of a 
facility can affect the occurrence of inappropriate medication prescribing. In other words, the 
results suggest that if the size of a facility is larger (i.e., caring for more patients), then the 
exposure to DDIS may be lower. The rationale is that a larger practice has more healthcare 
professionals/staff, which in turn may translate to high quality medication gate keepers to 
monitor appropriate medication use.  
The review of the relevant literature revealed two noticeable limitations, which can be 
improved upon in this dissertation. First, few studies recognized DDIS as a significant area of 
inappropriate medication use beyond HRMs. Exploring factors that affect the prevalence of 
DDIS is indeed a critical issue to investigate, particularly as the population ages, has multiple 
chronic conditions, and takes more prescribed medications. Second, few practice-level 
characteristics were examined, even though other practice-level characteristics, such as 
practice type, location, ownership, and the composition of staffs within a practice could also 
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affect prescribing practices. Previous studies indicate that the characteristics of healthcare 
professionals, e.g., physicians or pharmacists, can affect patients’ medication use because 
these professionals have complete authority and responsibility for prescribing behavior.90,91 
In other words, they have a direct impact on patient medication use, as well as patient drug-
disease interaction. What is more, other practice characteristics, e.g., the types or the adoption 
of a new model for delivering enhanced primary care, may also influence patient disease 
treatment and outcomes.92-94 For the purposes of this dissertation, if a practice provides a 
better quality of care environment, this should enhance patients’ appropriate medication use 
(i.e., lower the chances of drug-disease interactions). In this dissertation, having a PCMH 
model will serve as an innovative proxy of improving the quality of care.  
The review of the relevant literature revealed three gaps in our current knowledge of 
DDIS. These gaps can be addressed/filled in this dissertation. First, few studies have 
recognized DDIS as a significant and unexplored area within the issue of inappropriate 
medication prescribing and use apart from HRM. An exploration of factors affecting the 
prevalence of DDIS is indeed a critical issue that needs to be investigated as the U.S. 
population is aging and is being diagnosed with multiple chronic conditions that require 
prescribed medications. Additionally, the higher demand for prescribed medication among 
the elderly population may induce polypharmacy, which is a harmful public health issue due 
to its potential to cause adverse drug effects and DDIS.95 Two points need to be highlighted 
here. First, the NCQA HEDIS measure of DDIS will be served as one of the medication 
quality of care indicators. Second, the models analyzed in this study will consider more 
individual characteristics and add more practice-level characteristics to expand our 
understanding of the factors impacting DDIS. The individual characteristics will include (1) 
patient socio-demographic information, (2) patient clinical characteristics, and (3) patient 
medication use. The practice characteristics will contain (1) the organizational structure of a 
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practice, (2) the type of office setting, (3) the average number of physicians in a practice, (4) 
the ownership of the practice, (5) the primary expected source of payment, and (6) the region 
of the practice. Most important of all, the degree of quality of service (i.e., the 
implementation of a PCMH model) which a practice offers will be examined. 
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Table 1.2 Factors associated with DDIS, reported prevalence with adopted criteria, and the characteristics of studies (2001-2015) 
Reference Factor affect 
DDIS 
(individual 
level) 
Factor affect 
DDIS (practice 
level) 
Prevalence Criteria Study 
Population 
Data Resource Top most frequently 
prescribed DDIS 
Goldberg 
(1996) 
Number of 
medication use, 
age (older) 
N/A 21.5%  SOAP 
computer 
software 
program 
Patients either 
receive 3 or 
more 
medication or 
any patients age 
50 and over and 
at least have 
two medications 
From a   
community 
hospital,  
Emergency 
department and 
a  general  
hospital 
teaching facility 
(1) Albuterol, 
Prednisone, 
Ibuprofen with 
hypertension 
(2) Furosemide, 
Albuterol, 
Prednisone with 
diabetes 
 
Zhan 
(2005) 
Number of 
medication use 
N/A 2.6% of 
visits  
Zhan 
criteria 
 
Outpatient visits 
by patients aged 
65 and older 
NAMCS and 
NHAMCS 
Patients with benign 
prostatic hypertrophy 
had at least one of six 
drugs that should be 
avoided. 
Lindblad 
(2005) 
Number of 
medication use 
(more), age 
(older), marriage 
status (being 
married), and 
comorbidity 
conditions 
(more) 
N/A 40.1% Combine 
Beers 
and 
McLeod 
criteria 
397 frail veteran 
age 65 and over 
and has an 
inpatient visit 
The 11 Veterans 
Affairs Medical 
Centers 
Heart failure and 
calcium-channel 
blockers; Diabetes 
and β-blockers 
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Reference Factor affect 
DDIS 
(individual 
level) 
Factor affect 
DDIS (practice 
level) 
Prevalence Criteria Study 
Population 
Data Resource Top most frequently 
prescribed DDIS 
Doubova 
(2007) 
Number of 
medicines use (5 
more), age 
(older), suffering 
from 
cardiovascular 
diseases 
N/A 64.0% Zhan 
criteria 
Ambulatory 
patients over 50 
years of age, 
with non-
malignant pain 
Two family 
medicine clinics 
in Mexico City 
N/A 
Pugh 
(2011) 
High disease 
burden (physical, 
psychiatric, 
number of 
medications), 
Race 
(Hispanics), and 
individuals with 
no copayments 
N/A 15.2% NCQA 
HEDIS 
Age 65 and 
over who 
received 
Veteran 
outpatient care 
National 
Veteran 
inpatient, 
outpatient and 
pharmacy data 
N/A 
Gellad 
(2012) 
Age (older) Without formal 
geriatric 
education; With 
practices 
accommodate 
fewer older 
adults 
3.2% NCQA 
HEDIS 
Veterans age 65 
and over with 
received either 
one outpatient 
or inpatient 
care; with 
history of falls 
or hip fractures, 
National 
Veteran 
outpatient and 
inpatient data 
 
1. Dementia/ 
anticholinergic 
2. Chronic renal 
failure/non-
steroidal anti- 
inflammatory 
drug 
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Reference Factor affect 
DDIS 
(individual 
level) 
Factor affect 
DDIS (practice 
level) 
Prevalence Criteria Study 
Population 
Data Resource Top most frequently 
prescribed DDIS 
dementia, or 
chronic renal 
failure 
Mand 
(2014) 
Number of 
medication, age 
(older) 
N/A 10.4% Beers 
criteria 
Age 65 and 
over with at  
least one  
diagnosis  
named in Beers 
criteria  
From a total of 
148 family 
practitioners’ 
practices in 
Germany 
Patients who take 
hypertension 
medication, using 
central acting 
sympathomimetic 
drug 
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Adverse Drug Events 
Adverse drug events (ADEs) have been highlighted as a national patient safety and 
public health concern in today’s healthcare system.96 The aging population and their growing 
demand for medications have raised the prevalence of ADEs.97 Existing studies indicate that 
approximately 20% of individuals experience ADEs in ambulatory care settings, and 50% of 
individuals experience ADEs in hospitalization settings.98 The prevalence of ADEs is a cause 
for concern because of the economic and health burdens they impose. It is estimated that 
annually ADEs account for $3.5 billion spent on extra medication expenditures.99 The annual 
emergency department and inpatient visits related to ADEs are estimated to be 700,000 and 
120,000, respectively.38 ADEs are also associated with greater healthcare utilization, causing 
individuals to have longer hospitalizations and higher health expenditures.100 The serious 
effects of ADEs have been investigated in inpatient settings; however, relatively few studies 
are reported in  ambulatory settings.   
Due to concerns surrounding ADEs and the limited findings in ambulatory settings, this 
dissertation will include ADEs as one measure of medication use quality. To begin, a 
definition of ADEs will be provided, followed by methods of ADE detection. This will be 
followed by a discussion of ADE prevalence and an exploration of risk factors. Finally, a 
critique of ADE studies will be given followed by the introduction of a new approach to 
examining ADEs.   
Definition and Detection of ADEs   
The definition of ADE is simple and straightforward: an injury resulting from medical 
intervention related to a drug.101 In the current ADE literature, there are two major 
approaches to examining the incidence of ADEs: one is preventability and the second is 
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severity. From the preventability perspective, two types of ADEs are discussed where one is 
preventable and the other is non-preventable. Preventable ADEs arise as a result of 
medication used in error, and the events are considered preventable. According to the 
National Coordinating Council for Medication Error Reporting and Prevention, medication 
errors can be defined as “any preventable event that may cause or lead to inappropriate 
medication use or patient harm while the medication is in the control of the health care 
professional, patient, or consumer. Such events may occur in any one of the following 
procedures, including prescribing; order communication; product labeling, packaging, and 
nomenclature; compounding; dispensing; distribution; administration; education; monitoring; 
and use.”102 Previous studies have shown that nearly one-third of ADEs that occur in primary 
care settings are preventable.103,104 Non-preventable ADEs, on the other hand, are considered 
adverse drug reactions (ADR), and are defined as injuries resulting from the use of a 
medication but not associated with any errors.101,105 WHO also defines ADRs as “an effect 
that is noxious and unintended which occurs at doses used in man for prophylaxis, diagnosis, 
or therapy.”106 In the current literature, ADEs are commonly refers to both the occurrence of 
preventable ADEs and ADRs.107  
The severity of ADEs is classified as one of two types, with either four levels of severity 
(i.e., fatal, life-threatening, serious, and significant)101,108 or three levels of severity (i.e., 
minor, moderate, and severe).99,109 The events leading to an ADE can include errors in 
ordering (by physicians or pharmacists), transcribing (by a secretary, a nurse, a physician 
assistant, depends on the unit and time of day), dispensing (by pharmacy), and administering 
(by nursing).101 There is also an alternative ADE topic to explore the incidence of potential 
adverse drug events (pADEs). pADEs are defined as medication errors with the potential to 
cause an injury but do not necessarily cause any harm.101 This type of ADE is also an 
important research area in which efforts are needed, and studies have shown that the 
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occurrence of pADEs are more likely in pediatric inpatients.105,110  
 Generally, four major methods for detecting ADEs have been described in the current 
literature including (1) voluntary reporting, (2) chart review, (3) computerized monitoring, 
and (4) claim data screening. Since the methods are complementary, some studies have used 
multiple methods to identify ADEs, while others use only one approach.102  
 The first strategy to detect ADEs is via voluntary reporting, including spontaneous 
and stimulated reporting. Spontaneous reporting depends on healthcare providers, such as 
physicians, nurses or pharmacists, to report any ADE occurrence that is identified in daily 
practice. Stimulated reporting is based on prompting healthcare providers via interviews to 
solicit ADE information.99 The advantage of using voluntary reporting lies in its low cost. 
This disadvantage of both spontaneous and stimulated strategies is that they heavily rely on 
providers’ verbal reports, which may cause under-reporting.       
 The second strategy to identify ADEs is by retrospective chart review, in which ADEs 
are identified through examination of patient medical charts. This method detects ADEs in a 
more comprehensive manner than voluntary reporting can. Studies that use chart review to 
detect ADEs typically report a higher prevalence of ADEs compared to other approaches.98 
However, this approach can be costly and time consuming, as well as require medical 
professionals training/involving for proper identification of ADEs. Furthermore, chart review 
is often a more subjective approach since the process highly depends upon reviewers’ 
judgments.111    
 The third strategy to identify ADEs is through computerized monitoring, which is 
regarded as a promising comprehensive technique.112 Through the use of computer tools that 
include certain rules and events such as medication stop orders, antidote ordering, and certain 
abnormal laboratory values,113 ADEs can be easily detected. These processes of 
computerized monitoring produce relatively sensitive results that can calculate the occurrence 
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of ADEs automatically. A further advantage is that studies have reported that using 
computerized monitoring can be more cost-effective than other alternatives and cover a larger 
population.3,99,114 However, the pitfalls of using computerized monitoring include the cost of 
implementing the information system and the lack of consistency for ADE identification 
criteria in different information systems.    
The fourth strategy to detect ADEs is screening using ICD-9-CM diagnosis codes. The 
ICD-9-CM is the International Classification of Diseases, Ninth Revision, Clinical 
Modification, which is based on the World Health Organization's Ninth Revision. The ICD-
9-CM code is defined as the official system of assigning codes to represent patients’ 
diagnoses and procedures.115 The ICD-9-CM code mainly consists of three sections: (a) a 
tabular list containing a numerical list of the disease code numbers in tabular form, (b) an 
alphabetical index to the disease entries, and (c) a classification system for surgical, 
diagnostic, and therapeutic procedures (alphabetic index and tabular list). The E code is one 
part of the ICD-9-CM code sections (the third one), which is an index that represents external 
causes of injury and poisonings along with the extent and the place where the adverse events 
occurred. The RFV code is a unique classification in the NAMCS and NHAMCS data sets to 
determine whether a visit is injury related. The definition of injury includes not only physical 
injury but also poisoning and adverse effects (e.g., carpal tunnel syndrome, allergic reactions, 
alcohol and drug abuse, birth trauma, and others were all viewed as injury-related visits). The 
identifying codes for ICD-9-CM and RFV are not identical. Coding is determined by 
researchers’ judgment.  
This is the most common approach for studies which use large datasets to detect the 
incidence of ADEs.116 The advantages of adopting this approach are that it is inexpensive, 
does not require advanced information systems, and can be used in a large scale observation. 
However, this approach has been criticized because it is much less sensitive than chart review 
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or computerized monitoring and fewer rules can be applied to detect ADEs. Considering that 
each approach to ADEs detection has drawbacks, there is no gold standard for tracking 
ADEs, and the approach to ADE detection depends on the researchers’ study design and 
resources. Among the selected studies that investigated the prevalence of ADEs via large-
scale datasets, all of them used the ICD-9-CM and E codes to infer the role of medications 
which patients used that may be indicative of ADEs. Sarkar’s study employed the most 
intricate approach to define ADEs.117 Using the NAMCS dataset, the authors selected one 
survey question “Is this visit related to: adverse effect of medical/surgical care or adverse 
effect of medicinal drug?” to identify candidate ADE visits. The second step that the authors 
applied was based on experts’ clinical review and consensus through reviewing all the 
potential diagnostic (ICD-9-CM code) and RFV codes for all ADE candidate visits. 
According to their study, the potential ADE visits were counted if both approaches are 
identified the visits as ADEs. This dissertation will adopt Sarkar’s survey question approach 
to identify potential ADE visits. Furthermore, in order to have a more comprehensive 
inclusion of ADE visits, this study will also include the other codes shown in the remaining 
papers. 
Prevalence of ADEs   
          According to previous studies, the prevalence of ADEs ranges from 1.6% to 
52.9%.98,118 This range in prevalence can be attributed to different detection methods, clinical 
settings, and subjects, consistent with the variability in HRM and DDIS. ADEs reported by 
patients/family members or identified by medical record/chart review detect many more 
ADEs compared to voluntary reporting. Most reported rates of ADEs are lower in ambulatory 
care-based studies than hospital-based studies. The prevalence of ADEs has been reported to 
be the highest among the elderly population, which is reasonable considering the health 
issues of this population.98    
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Factors related to ADEs   
Since this dissertation focuses on the medication quality of care in ambulatory care 
settings, the explorations of ADE prevalence and associated factors will center on the 
ambulatory care-based studies. The Ovid Medline In-Process was used to identify relevant 
studies published from 1995 to 2015. The key search terms included “ADE,” “prevalence,” 
“primary care,” “ambulatory care,” and “factors.” The selected articles contained information 
on the prevalence of ADEs as well as explorations of factors that affected ADEs. Nine 
articles met the inclusion criteria and are considered (in Table 1.3). The number of articles 
that focus on children, adults, elderly, or all ages are two, one, three, and three, respectively. 
Three key points emerged from these papers. First, studies that target the elderly 
population reported the highest prevalence (50.1 per 1000 person years) among all targeted 
groups. While the unit of analysis differs slightly among the selected papers, those that used 
national survey data reported the rate of ADEs per 1000 person years, whereas the other 
studies employing regional data used actual ADE prevalence. Second, the prevalence was 
higher if the methods for identification used patient self-report or chart review.99,110 For those 
studies that used nationally representative data, the reported prevalence of ADEs was found 
to be relatively lower than self-reported or chart review. Third, for those studies which used 
nationally representative data, the diagnostic codes (e.g., E codes and/or ICD-9-CM codes) 
and the Reason for Visit codes (RFV) were applied to identify ADEs.  
In considering the factors associated with ADEs, four of nine studies found several 
significant factors that were associated with the onset of ADEs. The explored factors included 
patient age, gender, race, region, number of chronic conditions, education level, number of 
medications taken, whether the patient used natural health products, disability status, type of 
practice or type of prescribing that a patient received, and the duration of continuous care. 
Generally, the findings of these studies have consistently shown that patients with a higher 
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number of medications,99,117,119 being older,119,120 being female,119 having disability status 
(particularly cognitive impairment),120 using less natural health products,120 and using more 
primary care visits117 are more likely to experience ADEs. Among those factors, the number 
of medications taken is the factor that appears the most frequent. Besides examining the 
prevalence of ADEs and its related factors, this study will report the most commonly used 
medications that are associated with ADEs. Considering these articles, the most commonly 
medications associated with ADEs include antimicrobial agents, central nervous system 
agents, psychotropic agents, anticonvulsants, hormones, analgesics and gastrointestinal 
agents.   
Compared to previous studies focused on individual-level characteristics associated with 
ADEs, this dissertation takes into account practice-level characteristics for a more 
comprehensive consideration. Most importantly, this dissertation will use ADEs as a 
medication outcome indicator and examine whether recent implementation of the PCMH 
model may reduce ADEs in primary care settings. This assumption has not been explored in 
previous literature and is expected to have two aims. The first is to examine whether the 
prevalence of ADEs has been improved in recent years. The other contribution is to inform 
how the PCMH may impact patient medication use.   
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Table 1.3 Prevalence, assessment criteria, factors associated with ADEs, and drug group associated ADEs, in outpatient ambulatory care settings 
Reference Prevalence, 
n/N (%) 
Method of 
ADEs 
identification 
Factors associated with 
ADEs 
Medication  (the 
most frequent drug 
categories) 
Correspond Codes Data 
Resource 
Pediatric 
Kaushal 
(2007) 
13% with non 
preventable 
ADEs, 3% 
with 
preventable 
ADEs   
Determine 
ADEs by 
prescription 
review, 
survey, and 
chart review 
Not discussed - ADEs 
occurred most at the drug 
administration stage. 
Improved patient 
communication appears to 
have strong potential as 
prevention strategies. 
Penicillin or 
derivatives, Inhaled 
drugs – steroids, 
antifungal, 
bronchodilators 
Topical antihistamine  
No information 6 office 
practices 
in Boston 
area 
Bourgeois 
(2009) 
7.78 visits with 
ADEs per 1000 
children  
E code and 
ICD-9-CM 
code 
Present national estimates 
and demographic 
characteristics of patients 
with ADEs: age, gender, 
race, payment source, 
clinical settings, and region 
Antimicrobial agents, 
Central nervous 
system agents, and 
Hormones 
E930–E949/ E850–E858* 
ICD-9-CM code 995.0, 
995.2, 945.4, 535.4, 692.3, 
693.0,  779.4,292.1–292.9,  
708.0, 357.6, 960 –979 
NAMCS+
NHAMCS 
Adults (including elderly) 
Gandhi 
(2003) 
24.5%, 
(162/221) 
Patients self-
report, 
physician-
independent 
review, 
physician 
chart review, 
and patient 
Only number of 
medications taken was 
significantly associated 
with ADEs 
Selective serotonin-
reuptake inhibitors, 
Beta- blockers, 
Angiotensin- 
converting-enzyme 
inhibitors, Non-
steroidal anti-inflam- 
matory agents, 
No information Regional 
survey in 
Boston 
Area 
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Reference Prevalence, 
n/N (%) 
Method of 
ADEs 
identification 
Factors associated with 
ADEs 
Medication  (the 
most frequent drug 
categories) 
Correspond Codes Data 
Resource 
telephone 
survey 
Calcium-channel 
blockers 
Elderly only  
Hanlon 
(1997) 
35%  Patient self-
reported study 
Not show any significant 
difference in age, race, 
education, self-perceived 
health, number of 
prescriber, and previous 
ADEs history 
Cardiovascular and 
central nervous system 
medication classes 
were the most 
commonly implicated  
No information General 
Medicine 
Clinic at 
the 
Durham 
Veteran 
Medical 
Center 
Gurwitz 
(2003) 
50.1 per 1000 
person- 
years 
(1523/30397) 
27.6% of 
ADEs are 
preventable 
Multiple 
resources 
Present characteristics of 
patients that observed in 
the study: age, gender, 
number of outpatient visits, 
number of prescription 
medications, 
Cardiovascular, 
antibiotics, diuretics, 
nonopioid analgesics, 
anticoagulants 
ICD-9-CM code 960-977 
(except 963), 909, 692, 693, 
357, 708, 535 
Within a 
multispeci
alty group 
of practice 
Ganjavi 
(2007) 
9.9% (24/242) Depends on 
the report of 
patients and 
caregivers and 
the assessment 
Older age and greater 
cognitive impairment were 
associated with ADEs; the 
use of Natural health 
Central nervous 
system, cardiovascular 
system, analgesic, 
anticholinergics, 
gastrointestinal 
No information Two 
clinics in 
Toronto 
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Reference Prevalence, 
n/N (%) 
Method of 
ADEs 
identification 
Factors associated with 
ADEs 
Medication  (the 
most frequent drug 
categories) 
Correspond Codes Data 
Resource 
of clinical 
reviewers 
products predicted a lower 
risk of ADEs. 
All ages 
Zhan 
(2005) 
15 visits per 
1,000 
population 
E code and 
ICD-9-CM 
code 
Not discussed  Antibiotics and  other 
anti-infective, 
hormones and  
synthetic  substitutes, 
analgesics, 
antipyretics, and 
antirheumatics 
E930-E947  E850-E858 
(excluding E935)  
ICD-9-CM code 292, 692, 
6930, 760, 763, 779, 782, 60-
969, 909, 970-979  
NAMCS+
NHAMCS 
Bourgeois 
(2010) 
9.1 per 1000 
persons in 
1995  
 
16.9 per 1000 
persons in 
2005 
E code and 
ICD-9-CM 
code 
-Age older (65 years and 
older), Greater number of 
medications taken by 
patient, Gender female  
 
antihypertensives, 
estrogen/ 
progesterones, 
nonopioid-based 
analgesics/ 
antipyretics, 
antidepressants, and 
mood stabilizers. 
E930 –E949* E850 –E858 
ICD-9-CM code 995, 945, 
535, 692, 693, 779, 292, 708, 
357, 960- –979* 
NAMCS+
NHAMCS 
Sarkar 
(2011) 
0.5 percent of 
all visits 
RFV code and 
ICD-9-CM 
code 
-Number of prescribed 
medications, With more 
primary care visits 
 RFV** code 5905.0 
ICD-9-CM code 960-979*, 
995, 692, 693, 292, 708, 357 
NAMCS+
NHAMCS 
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Patient Centered Medical Home 
 The Patient-Centered Primary Care Collaborative (PCPCC) defines the Patient 
Centered Medical Home (PCMH) as “ a model or philosophy of primary care that is patient-
centered , comprehensive, team-based, coordinated, accessible, and focused on quality and 
safety.”121  The emergence of the Patient Centered Medical Home (PCMH) was considered a 
highly innovative transformation in U.S. primary care.122 As an important innovation, the 
PCMH is also regarded as a promising approach to addressing the recent fragmentation, poor 
quality, and high costs of the health care system. With endorsements from several accredited 
organizations, such as the PCPCC, and support in the Patient Protection and Affordable Care 
Act of 2010, numerous PCMH initiatives have been established in a wide variety of practice 
settings across the country.123 According to several studies, PCMH initiatives have 
demonstrated the potential to improve patient-related care quality/outcomes (e.g., patient 
satisfaction or quality of care) and reduce costs/utilizations.124-126 Despite the potential 
benefits in these areas, what remains largely unexplored is how and to what extent this 
PCMH implementation can affect patients’ medication quality of care.  
 The following section is divided into three parts. First, the concept and the evolution 
of the PCMH are presented, including several different PCMH definitions. Second, the 
current literature related to the PCMH adoption is explored. Third, a systematic review of the 
current literature related to the effect of PCMH implementation is also presented. The final 
section will draw general conclusions, identify gaps in the current literature, and propose a 
new contribution to examine the adoption of the PCMH.   
  50 
The Concept and Evolvement of the PCMH 
The PCMH is defined as a transformative healthcare model that (1) aims to provide 
more accessible, high-quality, and comprehensive patient care, led by a specific physician, 
and (2) emphasizes a team-based approach as well as whole-person orientation during all 
stages of care, including primary, secondary, and tertiary care.121 The concept of the PCMH 
has its origins in pediatrics in the 1960s. As most physicians caring for patients, pediatricians 
generally have two purposes. One is to undertake a first-contact role solving any concerns 
related to vulnerable children with chronic conditions and their caregivers needed. The other 
is to act as a referral agent to pass relatively seriously ill patients to appropriate specialists.127 
This PCMH concept has gradually evolved, emphasizing general patient-centered care within 
physician practices. In the PCMH, physicians are expected to be leaders of a group of non-
physician professionals in practice, to facilitate collaborative care, to provide continuous, 
comprehensive care, and to meet all types of patients’ health needs. Additionally, this concept 
specifically aims to personalize, prioritize and integrate care for whole-person care rather 
than focusing on disease treatment.  
 During the past decade, the PCMH model has evolved and been modified by several 
organizations. In 2007, the original features of the PCMH were first described by several 
primary care physician associations, also referred to as the Patient-Centered Primary Care 
Collaborative (PCPCC). These physician associations endorsed a PCMH model, known as 
the Joint Principles (also known as the Seven Joint Principles), outlining seven significant 
areas for effective PCMH care: (1) Personal physician, (2) Physicians directing the medical 
practices, (3) Whole-person orientation, (4) Coordinated care, (5) Quality and safety care, (6) 
Enhanced access to care, and (7) Payment reform. The original Seven Joint Principles were 
modified by the Agency for Health Research and Quality (AHRQ) into the five principles of 
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the PCMH, encompassing: (1) Comprehensive Care, (2) Patient-Centered Care, (3) 
Coordinated Care, (4) Accessible Services, and (5) Quality and Safety. AHRQ asserts that the 
modification is more efficient and clear than the original PCMH model.128 Further 
modifications to the model were made in 2010 by a prominent private foundation, the 
Commonwealth Fund, which drew from the Seven Joint Principles of the PCPCC to establish 
its approach to define and measure the PCMH. Their model consists of four concepts 
including (a) the fundamental tenets of primary care (accessibility, comprehensiveness, 
integration, and relationship), (b) new ways to reform the organizational setting, (c) the 
development of practices’ internal capabilities, and (d) changes of the health care system and 
reimbursement.129 Shortly after this modification, in 2011, the National Committee for 
Quality Assurance (NCQA) further framed a series of PCMH recognition standards with 
detailed rating scores and supplemental elements for each evaluated domain. The NCQA 
PCMH standard includes six domains: (1) Enhancing access and continuity, (2) Identifying 
and managing patient population, (3) Planning and managing care, (4) Providing self-care 
support and community resources (5) Tracking and coordinating care, and (6) Measuring and 
improving performance. Each domain is further divided into three to seven sub elements.130  
 Despite the different definitions of the PCMH, the original Seven Joint Principles will 
be used as the fundamental PCMH concept for the following two reasons. First, the PCPCC-
defined Seven Joint Principles remains the most commonly used framework in examinations 
of PCMH implementation in practices.131 Second, the seven domains covered in the Seven 
Joint Principles are comprehensive and concise relative to the modified models. Specifically, 
compared to the initial Seven Joint Principles, the remaining models either focus too 
narrowly on a specific domain, such as patient safety and quality, or neglect one significant 
aspect, such as the importance of redesigning financial reimbursement systems. In reality, 
each domain is crucial and should be equally examined.  In the current literature, two lines of 
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research have evaluated the implementation of the PCMH. One investigates the extent to 
which practices adopt the PCMH, and the other demonstrates the effects of PCMH 
implementation. 
Evaluating PCMH      
     The establishment of PCMH in practices is expensive and time consuming but the 
effectiveness of PCMH is worthy to explore. Apart from financial resources needed for 
technology to integrate information into the care delivery system, significant efforts are 
required to engage all the healthcare professionals in collaborative work as well as to 
establish trust between patients and providers.132 Explorations of the extent to which primary 
care practices have implemented the PCMH are critical for two reasons. First, many PCMH 
pilot projects have been implemented. For example, several major national health 
plans/organizations have numerous PCMH demonstration pilot projects in 18 states.123 
Furthermore, in 2008, CMS also conducted Medicare Medical Home Demonstration pilot 
projects in 400 practices in 8 states, aiming to provide targeted, accessible, continuous, and 
coordinated care to Medicare beneficiaries with chronic or prolonged diseases.133 Second, 
whether these PCMH programs have evolved past the pilot stage is unknown. Many 
stakeholders, such as the federal government and private organizations, have a considerable 
interest in evaluating whether the PCMH represents an effective model for transforming the 
delivery of health care.  
      To determine the extent of PCMH adoption, appropriate methods or measures must be 
chosen. Since PCMH is a multi-dimensional concept, evaluating its effectiveness is 
challenging. PCMH evaluation must be comprehensive, taking both the context of 
transformation and experiences of diverse stakeholders into account.134 The context of 
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transformation consists of the major components of PCMH, namely practice information, 
team-work environment, culture of trust, and the degree of communication, whereas the 
experiences of diverse stakeholders can be derived directly from a survey of patient, staff, 
and clinician satisfaction. Generally, two research methods are employed to evaluate PCMH 
effectiveness. One approach involves qualitative methods and the other is quantitative. 
Qualitative methods have two advantages. They allow for the exploration of a contextualized 
and comprehensive examination of what occurs in practices that may influence the 
implementation of PCMH, and they complete or explain the findings obtained through 
quantitative methods.135  
Currently, two types of qualitative methods have been used in PCMH-related studies. 
One involves observational evaluation and the other is the interview evaluation. 
Observational evaluation includes direct observation of staff, patients, or caregivers within 
the practice environment, allowing researchers to directly observe how a practice 
functions.134 Using this approach, Nutting and his research team investigated a national 
project to observe the transformation of family practices into PCMHs.136 The findings 
showed that transforming a practice to a PCMH requires strong willingness and efforts from 
both professionals and practices. The study also concluded that although most practices are 
equipped with basic core functions of PCMH, few of them had a systematic strategy to 
transform their practices to the more comprehensive care characteristics of a PCMH.  
Interview evaluation generally consists of in-person individual interviews, aiming to 
elicit information or attitudes in interviewees’ own words.137-139 Individual baseline 
interviews, follow-up interviews with clinicians, or patient interviews are examples of 
interview evaluation methods. This type of qualitative research is conducted to probe more 
deeply into providers or patients’ experiences and opinions about the implementation of 
PCMH.140-142 In their 2015 interview study, Aysola and his research group used patient-
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reported results to characterize patients’ experiences with care after PCMH adoption and their 
understanding and perceptions of the PCMH model. The aim in collecting this information 
was to compare patient responses in relation to the degree of practice-level PCMH adoption. 
The results demonstrated that patients generally were aware of the PCMH concept, yet they 
perceived no PCMH-related structural changes, regardless of the extent to which their 
practice had implemented PCMHs. 
Although qualitative methods have advantages for examining PCMH implementation, 
these approaches are not ideal for conducting larger-scale investigations. For such studies, 
quantitative methods or mixed methods are more suitable.143 A quantitative method generally 
follows one of three approaches. First, a survey of the practice, clinician, and staff can collect 
demographic information of the providers and staff and allow for an analysis of the extent to 
which providers perceive transformations within the PCMH.126 For example, Baxter Et al. 
conducted a national survey of nearly 200 physicians to explore the potential of PCMH 
implementation for small medical practices as well as to examine physicians’ perceptions of 
the PCMHs.144 Embedded in the survey instrument were three components: a survey of 
practice characteristics (e.g., practice size or ownership), a survey of physicians’ perceptions 
of the PCMH (containing 16 specific questions), and a validated culture rating instrument 
(consisting of 45 items examining 9 dimensions of organizational culture). The findings of 
the study indicated that physicians were aware that a PCMH might improve the quality of 
primary care; however, they also highlighted tension that existed between societal benefits 
and rising costs for practices, which was a challenge for PCMH implementation. 
The second quantitative approach used in studies involves patient surveys. In the PCMH 
literature, exploration of patient satisfaction and reviews of patient-report outcomes are the 
two major types of patient surveys.94,124,145,146 In their 2010 survey research, Jaén and his 
research team used patient-reported outcome questionnaires administered to patients from 36 
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family medicine practices across the United States to evaluate whether PCMH 
implementation could improve patient outcomes (e.g., access to care, patient empowerment, 
and self-rated health status). The results showed that implementation of the PCMH was 
positively associated with patients’ condition-specific quality of care, but not with patients’ 
experiences with the services offered by a PCMH. While most other studies of PCMH have 
revealed positive patient-report outcomes, some studies found inconsistent results in patient 
satisfaction with PCMHs.147,148     
The third quantitative approach is the meta-measurement of PCMH. Meta-measures are 
a well-established tool that can assess baseline needs of practices and monitor transformation. 
Examples of this technique include the NCQA PCMH guidelines and the practice self-
evaluation PCMH assessment. To date, many studies have already used the guidelines or 
modification of them published by the NCQA to define a PCMH practice.125,142,149-160  
The NCQA PCMH program consists of three levels of achievement, as measured by a 
scoring rubric. In the 2008 NCQA PCMH evaluation, the scoring system was designed to 
evaluate how well a practice was performing on nine standards that aligned with the core 
components of primary care: (1) access and communication, (2) patient tracking and registry 
functions, (3) care management, (4) self-management support, (5) electronic prescribing, (6) 
test tracking, (7) referral tracking, (8) performance reporting and improvement, and (9) 
advanced electronic communication. Subsumed under these nine standards were 30 specific 
elements including 10 designated as “must pass” elements for purposes of medical home 
recognition. The detailed list is provided in Appendix C. An example is the ninth standard, 
advanced electronic communication, which consists of three elements and is worth a total 
score of 4 points. Element A of this standard focuses on the availability of an interactive web 
site for patients and their families (1 point). Element B centers on whether the practice has 
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electronic patient identification (2 points), while Element C assesses whether the practice 
care management team uses electronic communication to manage patient chronic conditions.  
The scoring for PCMH designation involves two parts: (1) the degree to which the 
procedure meets the standard and (2) the level of performance. The former is determined 
directly by the score each practice receives, whereas the latter is based on a combination of 
the number of “must pass” elements and “the scores” for those items Based on the NCQA 
PCMH recognition program, to be certified as a Level 1 PCMH, a practice has to meet 4 of 
the 10 must-pass elements and have a score of 25 - 49. Level 2 practices have to pass all 10 
must-pass elements with the score of 50 - 74. Likewise, Level 3 practices have to pass all 10 
must-pass elements with the score over 75. A higher score/level is indicative of a more 
comprehensive PCMH.89 To be evaluated for the NCQA PCMH recognition program, 
practices first should voluntarily complete a Web-based survey and attach documentation to 
support their responses. This documentation is reviewed by a certified NCQA PCMH trainer, 
and 5% of applications will go through an on-site audit. These applications will undergo three 
rounds of internal review. After the review, the practice will receive a level of recognition 
based on both their total evaluated scores and their performance on 10 “must pass” elements.   
Among the various types of techniques described above, this dissertation will adopt the 
meta-measure, specifically, the approach implemented for the NCQA PCMH recognition for 
three reasons. First, the NCQA PCMH recognition program is currently the most widely used 
evaluation method, although there is no required official accreditation for practices to brand 
themselves as PCMHs. The second reason for choosing the NCQA PCMH accredited 
program is because it is a well validated and updated program. The very first NCQA PCMH 
recognition program was developed in 2006 with guidance from the American College of 
Physicians, the American Academy of Family Physicians, the American Academy of 
Pediatrics and the American Osteopathic Association. It is reviewed, updated, and published 
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every 5 years in response to a joint effort of related professionals. The final reason for 
choosing the NCQA PCMH recognition program is that it has a well-defined scoring system 
and standardized guidelines. This well-designed program allows practices managers/owners 
to assess the operation of their practices in relation to the NCQA PCMH standards. This well-
used program also allows health services researchers to evaluate and compare the adoption of 
PCMH at a national level. Based on the research findings, only Hollingsworth’s study 
employed the NCQA PCMH scoring rubric to map the survey items from a nationally 
representative dataset to demonstrate the actual implementation of PCMHs across the United 
States.156 Their study found that nearly half of the practices nationwide lacked sufficient 
PCMH infrastructure. To extend the knowledge of PCMH in primary care practices, this 
dissertation will build on Hollingsworth’s study and advance their work to examine the 
effectiveness of PCMH with regard to medication quality of care. 
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The Effect of Implementing PCMH 
      Apart from examining the extent of PCMH implementation among practices, another 
interest of the PCMH literature is to evaluate the effects of PCMH implementation and to 
compare results of PCMH implementation across practices. Generally, four domains of 
PCMH outcomes are well explored, including patient experience, economic outcomes, 
process measure and clinical outcomes.  
 The first domain is experience outcomes, including both patient and staff experience with 
PCMH implementation. Studies related to patient experience outcomes have reported 
consistent results. Specifically, patients have generally reported higher satisfaction with the 
care they received, reported positive relationships with providers and overall good 
experiences based on the results from after PCMH adoption or comparisons of pre-post time 
periods.94,142,145,161,162 Findings, however, are mixed for staff experiences with PCMH 
implementation. Some studies of PCMH implementation have examined physicians’ 
experiences, whereas other studies have investigated the opinions of non-physician 
professionals.145,163-165 For instance, Richardson Et al. surveyed physicians to determine their 
satisfaction with the PCMH. The results indicated that the physicians’ satisfaction was 
notably lower than expected (i.e. nearly two-third of the interviewees reported being only 
somewhat or very satisfied overall with their practice after PCMH transformation). Fontaine 
and his research team used a qualitative approach to interview thirty-one administrative and 
clinical leaders to explore their experiences with PCMH implementation in Minnesota. The 
findings showed that interviewees regarded the implementation of PCMH as beneficial for 
patients, even though barriers existed, such as the lack of quality in electronic medical 
records and unclear reimbursement plans.153,164 Additionally, Reid Et al. used the 22-item 
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Maslach Burnout Inventory to measure the level of emotional exhaustion, depersonalization, 
and sense of personal accomplishment among staff in practices with a recognized PCMH 
program. The results showed positive evidence that implementing PCMH reduced staff 
burnout at 12 months post implementation.145   
 The second outcome domain is the economic outcomes of PCMH, including 
utilization and cost. This focus is the most common in current PCMH-related studies.125,150-
152,154,157,158,166-171 To measure economic outcomes, studies have investigated primary care 
visits,125 specialty care visits,154 telephone visits,151 30-day readmission rates,170 inpatient 
admissions,125,154,157,158,160,168,172,173 and emergency department visits.122,125,160,172 Likewise, 
the measures of cost in the PCMH literature are total costs,125,160,166,168,169 inpatient 
costs,154,157,160,168,174 outpatient costs,150 emergency room costs,157,160,174 specialty care 
costs,154,157,174 and medication costs.174 The findings of the economic outcomes for practices 
adopting the model have been inconsistent. Many of the studies provided empirical evidence 
to show that practices which had adopted PCMH could reduce utilization and cost of high-
cost medical interventions, such as emergency room visits, hospitalization and 30-day 
readmission.173,175 On the other hand, some preliminary studies showed opposite results and 
practices that adopted PCMH did not experience reductions in utilization of hospitalization, 
emergency room visits, or total costs.125,151,173 These mixed findings can be attributed to two 
reasons, namely the selected population and the observation time. The choice of a cohort with 
chronic diseases that does not need intensive care to control their diseases might not yield a 
significant improvement in utilization. Furthermore, a lag between PCMH implementation 
and observations of effects on patients’ outcomes may be another reason for explaining the 
mixed results.   
 The third domain of exploring PCMH outcome is the assessment of process-of-care 
indicators. This domain can be divided into two categories: preventive services and chronic 
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illness care services. The measures of preventive services which have been used or 
recommended as the outcome of PCMH-related studies include adult weight screening and 
follow-up, cancer screening (breast and cervical), chlamydia screening in women, lipid 
screening, influenza vaccination, and behavioral counseling.92,159,169,176 Studies of preventive 
services have consistently reported positive effects of PCMH, in that screening or vaccination 
rates have increased. As to the chronic illness care services, measures listed/suggested by the 
types of chronic conditions, such as respiratory, cardiovascular, and diabetes have all been 
used to evaluate PCMH outcomes.122,145 Compared to the measures for respiratory and 
cardiovascular conditions, diabetes care is the most common proxy for chronic illness care 
services in the PCMH context. The recommended measures for diabetes care include 
Hemoglobin A1c (HbA1c) testing, body mass index (BMI) record, eye exam performed, LDL-
C screening, and medical attention for nephropathy.122,177 Studies have reported consistent, 
positive results in regard to the effect of PCMH implementation on diabetes care 
management.155,178-180 Interestingly, the majority of preventive service and chronic illness 
care service measures are adapted from HEDIS.  
 The final domain of PCMH exploration is clinical outcomes. Clinical outcome measures 
that have been used for examining the implementation of PCMH include hemoglobin A1c 
values, blood pressure control, low density-lipoprotein cholesterol control and high-density 
lipoprotein cholesterol control.160,180,181 Studies using these outcome measures have 
consistently found positive results among the PCMH-related studies, particularly when the 
PCMH provided pharmacist-involved services. However, none of these studies have 
investigated the quality of medication use more generally. To fill the gap, this dissertation 
will investigate the association between the PCMH adoption and several medication-related 
quality measures. 
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Theoretical Considerations 
 The focus of this dissertation is a series of explorations and analyses of two areas in 
PCMH adoption: (1) the factors affecting the level of PCMH implementation in practices and 
(2) the influence of PCMH implementation on the use of medications. The goals of 
healthcare reform are to improve the quality, safety, efficiency, and effectiveness of U.S. 
health care, and it is important to know the extent that practices implement PCMH and how 
that implementation affects medication use. This study will be based on a theoretical 
framework that incorporates elements from two widely used behavioral theories, namely 
Wagner’s Chronic Care Model and Hogg’s primary care organization model.182,183 The 
following section provides an overview of each theoretical model and elaborates on the 
rationale for their selection in this study. Finally, the modified merged conceptual framework 
is presented.   
Wagner’s Chronic Care Model 
Wagner’s Chronic Care Model, also known as the Chronic Care Model (CCM), was 
developed in 1996 by the MacColl Institute for Healthcare Innovation, led by the director, Dr. 
Edward Wagner. This model emerged in response to the increasing burden of chronic 
diseases and the apparent disparity of approaches for disease management. The CCM was 
designed to help practices improve patient health outcomes, particularly for those patients 
with chronic diseases. The CCM does not offer a quick and easy solution; instead, it provides 
a multidimensional solution to complex health situations in primary care. The ultimate goal 
of the CCM is to transform daily care for patients with chronic conditions from acute and 
reactive to proactive and planned care.  
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Generally, six essential, interrelated elements constitute the CCM.182 The first element is 
community resources and policies. This element emphasizes the linkages between providers 
or organizations and community-based resources, which can be a means for practices with 
limited resources to improve patients’ chronic care. Examples of community-based resources 
include exercise programs at community centers or meals at senior centers. The second 
element is the healthcare organization, addressing the structure, goals, and values of a 
provider organization and its relationship with purchasers, insurers and other providers.  
The third element is self-management support. Since the CCM model centers on the 
development of effective chronic care guidelines, teaching patients about disease 
management and following major management strategies such as diet, exercise, and 
medication use are all important issues. The fourth element is delivery system design. This 
element stresses the importance of redesigning the care approach to one of a team-based care 
to serve patients for both acute and chronic care. To achieve this goal, physicians should help 
patients with acute problems and intervene in stubbornly difficult chronic cases. Non-
physicians should also have direct patient care services, and their goals are to offer expert 
support to patients with chronic disease who need to maintain a self-care protocol and the 
other is to arrange routine periodic planned visits for patients.  
The fifth element is decision support, which underlines the significance of evidence-
based clinical guidelines. Evidence-based guidelines are expected to provide the most up-to-
date standards for optimal chronic care. The final element is the clinical information system, 
which highlights the importance of implementing computerized electronic medical systems 
within practices. The rationale for implementing clinical information systems is that they 
serve as reminder systems that assist healthcare professionals to adhere to guidelines and as 
registries for planning individual patient care and conducting population-level care. All six 
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elements must be inter-related to improve interactions between providers and patients and to 
improve outcomes. 
The CCM was chosen as one of the behavioral models for this dissertation for the 
following three reasons. First, the CCM can be viewed as part of the PCMH model. In other 
words, the concepts of CCM are fundamental elements of the PCMH model.184 However, 
there exist some dissimilarities between the CCM and the PCMH model. For example, the 
CCM is centered on care for patients with chronic conditions, whereas the focus of PCMH is 
on direct patient care as well as population health management. Furthermore, the PCMH 
model emphasizes a whole person orientation, offering care ranging from preventive services 
to tertiary care and this differs from the CCM which targets chronic disease management. 
Additionally, the PCMH model allows an examination of some specific mechanisms within 
practices, such as the collaboration between physicians and non-physicians and EMR 
functionality, while the CMM is more general. In order to develop a comprehensive 
theoretical model, this dissertation added concepts from Hogg’s primary care organization 
model and merged them with CCM for the research framework. 
Hogg’s Primary Care Organization Model 
The primary care organization model (PCOM) was proposed by Dr. Hogg and his 
research team in 2008. This model consists of blended perspectives of organizational theory 
and other primary care models to establish a comprehensive primary care model with a focus 
on delivery of services.185 Generally, the PCOM can be viewed from two perspectives 
including structure and performance domains. The structure domain has three significant 
components, namely the healthcare system, the context of practices and the organization of 
practices. The healthcare system can be regarded as a system level structure that includes 
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policies, stakeholders, and other components that influence primary care organizations and 
providers. Other aspects of the healthcare system are governance and accountability as well 
as resources and technical provisions. The context of practices refers to the characteristics of 
the surrounding communities and the availability of connecting other medical resources or 
services in the area. Examples of context include local medical and social services or 
population and community characteristics. Finally, the organization of the practices is related 
to the characteristics of practices that might affect performance and include health human 
resources, office infrastructure, organizational structure and practice integration.  
Within the performance domain are two subcategories: healthcare service delivery and 
technical quality of clinical care. The healthcare service delivery depicts and evaluates the 
provision of healthcare services. The following six features summarize the health care 
services delivery: access, patient-provider relationship, continuity, service integration, 
comprehensiveness, and provider satisfaction. The technical quality of clinical care, on the 
other hand, is defined as “the degree to which clinical procedures reflect current research 
evidence and/or meet commonly accepted standards for technical content or skill.”28 There 
are four subcomponents of technical quality of care including health promotion and primary 
prevention, secondary prevention, care of chronic conditions and care of acute conditions.  
The Modified Conceptual Framework 
In order to examine the level of PCMH implementation in practices, as measured by 
the NCQA, and to fully explore the influence of this level of care on medication quality of 
care, the chronic care model and PCOM were merged to create a new model. In this modified 
framework, the PCOM was adopted as the grounded model for two reasons. One is that the 
mechanism of the PCOM emphasizes the processes of structure and performance. 
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Additionally, the PCOM outlines specifically how the structure domain influences primary 
care performance. The other reason is that the model focuses on exploring the factors that 
affect the extent to which quality services are delivered. However, because the PCOM does 
not highlight or explain how the performance of primary care affects patient outcomes, the 
outcome domain was borrowed from CCM. The modified theoretical framework is shown in 
Figure 1.1. 
In this modified model, three domains constitute the general framework: structure, 
performance or process and outcomes. In the structure domain, two components are 
embedded, namely the practice context and organization of the practice. Similar to the 
PCOM, factors such as type of practice, office type, practice size, ownership statue, 
geographic region of the practice, metropolitan status of the practice, and Medicare/Medicaid 
penetration of the practice are taken into account as the practice context. In addition, 
physician demographic characteristics, including age, gender, specialty, and identity are 
considered as part of the organization.  
As to the performance or process domain, the level of PCMH recognition will be used 
as the proxy of how a practice provides care. Specifically, each practice will be categorized 
into four different level of the PCMH. The evaluation method used by Hollingsworth Et al. to 
determine whether a practice offers services beyond the traditional primary care service 
offerings (e.g., provide more team-based care or accessible care to the patients) will be 
expanded. Building on the Hollingsworth study, this dissertation includes three important 
features: (1) it uses the most up-to-date national data and medication quality indicator lists, 
(2) it determines the adoption of PCMH with a more restricted criteria (i.e., categorization of 
different levels of PCMH in terms of must-pass elements), and (3) it investigates the 
association between the adoption of PCMH and medication quality of care. The outcomes of 
our new model are the medication use quality indicators, namely quality indicators 
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categorized as process of care and outcome of care. To determine medication process of care, 
(1) the use of high risk medication and (2) the use of DDIS were chosen. As to the 
medication outcome of care indicator, ADEs were selected for the evaluation. Finally, patient 
characteristics are added as covariates for these models, as they play a crucial role in the 
quality of medication use. Examples of patient characteristics include age, gender, race, 
comorbidity conditions, number of medications used, and household income. 
CONCLUSION 
This dissertation will examine the relationship between level of PCMH and quality of 
medication use. This relationship will be explored using a nationally representative dataset. 
This important policy question will help us understand how quality of medication use may be 
affected by this healthcare reform.  
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CHAPTER II. PAPER 1: PHYSICIAN-RELATED CHARACTERISTICS AND THE 
ADOPTION OF PATIENT-CENTERED MEDICAL HOME: RESULTS FROM A 
POPULATION-BASED NATIONAL SURVEY 
Introduction 
The Patient-Centered Medical Home (PCMH) is one important innovation in today’s 
healthcare reform. The emergence of the PCMH model can be viewed as a partial solution for 
the fragmented primary care system and the challenge of providing more accessible, continuous, 
comprehensive, and collaborative services to patients.1 Despite the increased focus on the 
adoption of PCMH and its effect on health utilization and quality of care, the adoption of PCMH 
has remained below fifty percent of overall primary care practices.2,3 In seeking to understand 
PCMH adoption, many studies have targeted the characteristics of practices that have pursed this 
healthcare model. For example, practice size,2,4 ownership,3,4 and location4,5 have all been linked 
to PCMH adoption. Other factors related specifically to physicians have been investigated, and 
results show that physician specialty, particular primary care physician, does have a positive 
association with the adoption of PCMH.3,4,6 Despite this focus, explorations of physician 
demographic characteristics that might influence the adoption of PCMH have not been 
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undertaken. To address this gap in knowledge, this study is the first in the PCMH literature to 
evaluate a broad set of physician-related factors that are associated with PCMH adoption.   
Exploration of physician characteristics is important in understanding PCMH adoption 
for three reasons. First, personal demographic characteristics of physicians may determine the 
diffusion of PCMH adoption, especially when considering Roger’s diffusion of innovation 
theory, which assumes that individual characteristics affect the spread of new ideas.7 For 
example, this theoretical model has been applied in health services research to explore the 
adoption of electronic medical records (EMR).8,9 These findings show that older age of 
physicians who work in smaller-size practices lag in their adoption of electronic medical 
records.10 Whether a similar association between physician characteristics and practice size 
exists for PCMH adoption is not known because the theory has not yet been applied to the 
PCMH context. Furthermore, individual characteristics such as physician gender and type have 
been associated with adopting technological and administrative innovations such as new drug 
prescribing and EMR.11-13  
A second reason to explore individual characteristics in relation to PCMH adoption is 
that provider characteristics have been relevant in studies applying Hogg’s primary care 
model.14,15 In Hogg’s model, the structural domain includes provider characteristics, 
infrastructure of practices, and healthcare system characteristics. These factors have been shown 
to impact primary care, as the value of having non-physician professionals participating in 
primary care added to the improvement of primary care delivery services in Canadian’s’ 
community health centers.16 Studies have concluded that understanding the specific components 
of the structural domain may facilitate improvement in primary care sector performance.  
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Finally, the third reason to investigate physician characteristics is because the role of 
physicians currently has a greater influence on adoption PCMH than other non-physician 
professionals in medical practices. Specifically, the Seven Joint Principles, which is one of the 
most popular definitions of PCMH, emphasizes the important role of the physician.17 Among 
these principles, including enhanced access, whole person orientation, coordination of care, 
personal physician, physician-directed practice, safety and quality, as well as the payment 
reform, the physician role is particularly highlighted.18 Thus, physicians often play significant 
roles as leaders of non-physician professionals as well as first-line providers in the PCMH 
model. Previous studies have emphasized physician knowledge and attitudes as invaluable in 
supporting healthcare reform, yet the association between their demographic characteristics and 
the adoption of PCMH has not been examined thoroughly.19-21 In summary, population-based 
national estimates about the impact of physician characteristics on the adoption of PCHM will be 
important in its continued adoption.  
In order to study the extent of PCMH adoption, a suitable measure to quantify the 
adoption of PCMH is needed. To date, there is no single, national measure to determine whether 
practices have appropriately branded themselves as PCMHs. To explore the extent to which 
practices adopt PCMH, however, it is possible to use an accreditation approach. Accreditation 
standards primarily evaluate the structural, technological and process components of PCMH and 
have stated measurements of each component.22 Of these accreditation approaches, the Physician 
Practice Connections-PCMH tool from the National Committee for Quality Assurance (NCQA) 
is the most widely used in the PCMH literature to measure the adoption of PCMH among 
practices.23-27 This NCQA PCMH recognition program is a self-reported, well validated, and 
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regularly updated voluntary program that results in four levels of achievement (not accredited, 
level 1, level 2, and level 3), as measured by a complicated scoring rubric.28  
An exploration of factors related to PCMH adoption may aid in the further adoption of 
PCMH among other practices, which may improve patient quality of care and reduce 
unnecessary healthcare utilization. This study has merged diffusion of innovation theory and 
Hogg’s primary care model to explore the adoption of PMCH (Figure 2.1). The purpose of this 
study was to (1) determine the prevalence of PCMH adoption among practices using a nationally 
representative survey and (2) quantify the relationships between extent of PCMH adoption and 
physician and practice characteristics.   
Methods 
Study Design and Data Sources  
This study is a cross-sectional study using two years of data (2009-2010) from the National 
Ambulatory Medical Care Survey (NAMCS). The NAMCS is a complex, multistage, stratified 
probability sample representative of the national provision and use of ambulatory medical 
services in the U.S. All results from this study are based on a sample of visits to non-federal, 
employed, office-based physicians. Detailed descriptions of NAMCS can be found in previous 
studies.29 This study used both publicly available and restricted NAMCS survey questions. The 
publically available survey includes a series of NAMCS questions designed to capture the 
characteristics about service delivery, visits, practices and physicians and can be found on the 
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Centers for Disease Control and Prevention/National Center for Health Statistics’ (NCHS) 
website at http://www.cdc.gov/nchs/namcs.htm and practice characteristics. The remaining 
restricted data were collected through a series of questions focused on practice organizational 
structure (single or multi practices), numbers of physicians within a practice, physician age and 
physician gender. All data were accessed through the Research Data Center (RDC) at the 
University of Michigan and in a process approved by the NCHS Research Ethics Review Board 
(ERB).  Analysis of restricted data available at the Research Data Center was also approved by 
the NCHS ERB, and this study was designated as exempt by the University Of Michigan 
Institutional Review Board.  
Measures  
Determining PCMH 
 The primary variable of interest in this study was the extent to which practices adopted 
PCHM, as measured by the NCQA PCMH recognition program. The NCQA PCMH recognition 
program has clear scoring algorithm and has been widely used in previous studies to determine 
the extent of practices’ PCMH adoption.3,4 The NCQA scoring method is designed to capture the 
essential characteristics of PCMH including nine standards, thirty elements, and ten must pass 
elements to result in four levels of PCMH. Since there is no single question in the NAMCS that 
can identify whether a practice has implemented PCMH or not, this study adopted an innovative 
mapping technique which was employed in a previous study using NAMCS data.3  
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 The determination of the level of PCMH adoption required a two-step process: (1) 
determination of the PCMH score and (2) categorization of the PCMH level. The first step used 
survey items from 2009 and 2010 NAMCS, which were compared and mapped to the 2008 
NCQA PCMH guidelines so as to determine whether a practice was a medical home. 
Hollingsworth mapped NAMCS survey items to the NCQA rubric to estimate the extent to 
which a practice was recognized as a medical home.3 Unlike Hollingsworth, we employed the 
most recent year to capture the PCMH adoption, while also adding the must-pass elements to 
define the level of PCMH and exploring additional relevant variables affecting the PCMH 
adoption. Extending this work, our study mapped 15 elements of the NCQA PCMH standards, 
representing seven standards in the 2009 NAMCS, and 15 elements of the NCQA PCMH 
standards, representing six standards in the 2010 NAMCS. Each practice received a “passed” 
(1=yes) point for each measurable element and a cumulative point total by summing points 
across all passed elements. A PCMH infrastructure score for each practice was calculated by 
dividing the cumulative points by the total number of available points. This number was 
expressed as a percentage. The maximum denominators for this score were 55 points and 60 
points in the 2009 and 2010 NAMCS, respectively. The reason that 2009 and 2010 have different 
denominators is because some items were added and some were eliminated by the design of the 
survey. The detailed mapping technique is shown in Appendix E. Note that even though the 
PCMH scores were first calculated using visit-level data, these data were aggregated to practice 
level estimates by using appropriate practice-level weights.  
  The second step involved categorizing the percentage into the different levels of PCMH. 
Once the score for each practice was determined, each practice was assigned to an NCQA 
PCMH level of recognition, determined by the cut-off of cumulative points and numbers of 
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“MUST PASS” elements that each practice received, consistent with the NCQA PCMH 
guideline. The original NCQA PCMH guideline contained three levels of PCMH recognition 
including not accredited (less than 25% of total points), Level 1 (25 to 49 percent of the total 
points and 5 of 10 must-pass elements passed), Level 2 (59-74 percent of the total points and all 
10 must-pass elements passed), and Level 3 (75 percent and more of the total points and all 10 
must-pass elements passed). Because not all of the elements of the NCQA PCMH were captured 
in NAMCS, this study defined the classification of the NCQA PCMH level recognition as 
follows: not recognized (less than 25 percent of total points), Level 1 (25-49 percent of the total 
points and 2 out of 4 must-pass elements pass), Level 2 (50-74 percent of the total points and all 
4 must-pass elements pass), and Level 3 (over 75 percent of the total points and all 4 must-pass 
elements pass). The comparison between the original NCQA PCMH criteria and the modified 
version based on NAMCS survey items is shown in Appendix E. 
Physician and Practice Characteristics 
 In considering Roger’s diffusion of innovation theory and Hogg’s primary care model, 
five physician characteristics and six practice characteristics were selected to examine the level 
of PCMH adoption. Physician variables included age (less than 40/40-54/55-64/65 and over), 
gender (female/male), employment status (employee or contractor/owner), specialty (primary 
care/medical care/surgical care), and type (doctor of osteopathy/doctor of medicine).  Practice-
level characteristics focused on region (Northeast/Midwest/West/South), metropolitan status 
(Non-MSA/MSA), organizational structure (single/multi-specialty practices), organizational type 
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(public/private), ownership (physician group/ HMO or else), and size (solo/small group/medium 
group/large group).   
Statistical Methods 
 All analyses used appropriate NAMCS sampling weights to compute unbiased population 
estimates of the descriptive and regression parameters of interest. Codes in the NAMCS public-
use data sets identifying sampling strata and sampling clusters were also employed in all 
analyses to compute appropriate design-based estimates of standard errors for the weighted 
estimates.  Some variables were missing about 50% of their values, and multiple imputation by 
chained equations was used to provide more statistical power to analyze the relationships of 
interest.29 These imputations generated five completed data sets with all missing values imputed 
based on other observed variables. The five completed sets of analyses were combined with the 
original data set to generate a final overall set of multiple-imputation estimates for each analysis. 
Because the purpose of this study was to investigate adoption of PCMH at the practice 
level, the unit of analysis was practice and the practice-level estimates were used based on a 
previous paper published by NCHS.30 Practice-level estimates were determined by dividing the 
physician sample weight by the number of physicians in the practice.29  Physician estimates were 
also used for the description of physician characteristics. With the appropriate weights for 
different levels of estimates, the data can reflect accurate national practice or physician 
estimates.  
 Descriptive statistics were used to determine the proportion of practices that met NCQA 
PCMH criteria. Design-adjusted Rao-Scott chi-square tests were employed to test the bivariate 
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associations between the level of PCMH variable and physician characteristics. Two sets of 
analyses were conducted. Because of the exploratory nature of these analyses, a backward 
selection approach was used when fitting the regression models to determine the subsets of 
predictors having significant associations with the dependent variable. First, a multivariate 
logistic regression model was employed to quantify the associations between baseline physician 
and practice characteristics with adoption of any level of PCMH (not accredited versus Level 1, 
Level 2, and Level 3). Second, a multinomial logistic regression was fitted to study the 
associations among the four levels of PCMH classifications and baseline physician and practice 
variables, with “not accredited” specified as a reference category. A two-tailed p-value less than 
0.05 indicated statistical significance. The -svy- commands in Stata version 13.0 were used for 
all analyses.   
Results 
These estimates presented here are nationally representative, as appropriately weighted 
estimates and multiple imputation procedures were used. About 60% of all physicians were age 
54 years or younger; nearly three-quarters were male (74.5%); 66% were owners; half (49.8%) 
were primary care physicians, and most (93.7%) held doctor of medicine degrees (Table 2.1). As 
to the practice characteristics, 36.4% of practices were in the South geographic region; most of 
the practices (88.6%) were located in a metropolitan area; almost all of the practice type was 
private (90.9%); the ownership of the practices were physician groups (84.9%), and slightly 
more than half of the practice sizes (56.5%) were solo or having fewer than 3 partners (Table 
2.1).      
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More than half of the practices (54.3%) were classified as having some level of PCMH 
implementation, whereas less than half of the practices (45.7%) met none of the PCMH criteria 
(Table 2.2). A small number of physician characteristics varied by level of PCMH adoption 
including physician age, employment status, and specialty. Practice characteristics including 
organizational structure, and practice size also varied by level of PCMH adoption. As expected, 
for the practices with the highest accredited PCMH recognition, the reporting physicians were 
younger, with more employees or contractor status, identified as primary care physicians, and 
worked in multiple specialties as well as larger practices.  
Results of a multinomial logistic regression considering the four specific levels of PCMH as 
the dependent variable are presented in Table 2.3. In general, three physician variables and one 
practice variable were associated with the adoption of PCMH.  Female physicians were found to 
be less likely to adopt PCMH. The adjusted odds ratio (AOR) was statistically significant when 
comparing PCMH level 2 to the not accredited PCMH (AOR= 0.6; 95% CI, 0.43, 0.93). Being 
an older age physician (i.e., age 55 and over) was found to significantly decrease the odds of 
participation in the PCMH implementation. Physician specialty also was associated with the 
adoption of PCMH; in particular, being a primary care physician was found to significantly 
increase the odds of having a higher level of PCMH. As to practice characteristics, larger 
practices had statistically significant higher odds of adopting the PCMH model.     
Table 2.4 displays the specific PCMH elements with four physician characteristics, 
including gender, age, employment status, and specialty individually. As shown, three out of 
seven PCMH elements had statistically significant differences in relation to gender: access and 
communication; offer advanced self-management support, and performance reporting and 
improvement. Female physicians received higher scores for the three PCMH elements. As to the 
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other characteristics, a clear pattern emerged where younger age physicians and 
employee/contractor physicians had significantly higher scores in most of the PCMH elements. 
The results also indicate that primary care physicians have higher scores than do medical or 
surgical physicians on the following elements: the elements of proving patient tracking and 
registry, offering better care management, and using electronic prescribing, and elevating test 
tracking.    
Discussion 
The main contribution of this study is the examination of PCMH adoption on the basis of 
a composite PCMH measure and the exploration of associations in a large, representative sample 
of U.S. physicians. While previous studies have focused on practice characteristics and their 
associations with PCMH adoption3,4,5 , this study is the first using national data to incorporate 
physician characteristics to examine the relationship with PCMH adoption. The results showed 
that PCMH adoption was influenced by physician characteristics (i.e., being female, being age 
fifty-five and younger, and being a primary care physician). The results of physician 
characteristics corresponded to previous studies using the diffusion of innovation theory that 
female physicians and older physicians were relatively slower to adopt innovative ideas in 
practices.7,8,9  As to the physician specialty, this is the first study that demonstrated that primary 
care physicians were more likely affected by new ideas than other specialties. For the remaining 
covariates, larger practice size significantly increased the rate of PCMH adoption, and this result 
was similar to results reported by Hollingsworth Et al.3 
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 The greater prevalence of PCMH adoption in 2010 is positive and may be greater than 
the overall prevalence conveys. Although the study followed an approach similar to that of 
Hollingsworth Et al., which mapped the 2008 NCQA PCMH guideline with the 2007 and 2008 
NAMCS survey items, this study used the most recent data and employed more restrictive 
criteria by including four must-pass elements for evaluating the PCMH adoption.3 Having the 
additional requirements with four must-pass elements, including whether a practice had 
enhanced access and communication, used electronic systems to take clinical notes, identified 
patient medication problem lists, and viewed lab results with out-of-range values highlighted, has 
significant implications. The present study showed that PCMH adoption(i.e., PCMH adoption 
rate was 54.3% in this study) was similar but more in-depth, as the distribution was shifted 
toward a higher level of adoption (level 2) versus a basic level of PCMH adoption (level 1) in the 
previous study (i.e., PCMH adoption rate in Hollingsworth was 54.0%).3 In addition, the 
definition used in this study was stricter, suggesting greater adoption of PCMH. 
 The PCMH elements that were mapped in the NAMCS are important to note. The 
mapped items emphasized the importance of establishing electronic medical systems within 
practices. Specifically, 12 of 15 mapped items related to the adoption of PCMH variables were 
focused on EMR. This implies that fewer items in the PCMH adoption variables were related to 
other components of PCMH, such as coordination of care and team-based care. If other NCQA 
PCMH items could have been mapped, the estimate for PCMH adoption may have been affected. 
Overall, the adoption of PCMH still has room for improvement as 45% of practices were not 
identified as PCMH.  
 Diffusion of innovation theory suggests that characteristics differentiate individuals who 
adopt innovations earlier versus later.31,32,33 However, this theory does not explicitly consider the 
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influence of external environments, such as practice infrastructure or organizational structure, 
which could also affect the adoption of innovations. With the combination of the Hogg’s primary 
care model, this study can more comprehensively explain the factors that affect the rate of 
PCMH adoption from four perspectives. First, this study found that older physicians lagged in 
their adoption of PCMH in their practices. This finding is consistent with previous research that 
applied diffusion of innovation theory to explain the adoption of electronic medical systems and 
to investigate physicians’ support of recent health care reform,8,34 where older physicians lagged 
behind their younger counterparts in the adoption of innovation.   
Second, the results of this study showed that gender plays a significant role in PCMH 
adoption. In particular, male physicians were more likely to adopt the PCMH model, and this 
result aligns with previous studies showing that male physicians favored new medication 
treatments or other novel interventions, whereas female physicians were relatively conservative, 
spending more time on patient counseling and ordering laboratory tests for their patients.12,35 The 
authors of each study suggest that male physicians might be more confident than female 
physicians to initiate new medical treatments. Other studies have also supported findings of 
gender disparity in clinical decision-making.36 Whether female physicians are indeed more 
conservative in the case of PCMH adoption is still debatable since the PCMH is not a completely 
new concept. The PCMH model blends both traditional attributes of primary care (i.e., first 
contact access, comprehensiveness of care, integration/coordination of care, and continuity of 
care) and new approaches (i.e., organizing practice and development of practices’ internal 
capabilities) of healthcare delivery.37 Ottmar Et al. showed that female family physicians were 
more likely to review patient records and contact patients to invite them in for care (i.e., 
population management).38 In the present study, the sub-analysis also demonstrated that female 
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physicians obtained better scores in four of the NCQA PCMH elements, including enhancing 
access and communication, offering better care management and advanced self-management 
support, elevating test tracking, and performing reports and improvements. However, the 
composite measure of PCMH adoption included 15 items and the overall scores were 
cumulative. Therefore, the final multinomial logistic regression suggested that male physicians 
may be more capable of practice transformations (e.g., using the electronic medical systems), but 
female physicians were more focused on comprehensive care for patients.   
 Third, with respect to physician types, the results of this study provided interesting 
findings, wherein primary care physicians were more likely to adopt PCMH than surgical care or 
medical care physicians. From a policy perspective, primary care practices have been targeted by 
payers to implement PCMH, so this finding is not surprising.3,39,40,41 However, these findings are 
inconsistent with three earlier studies that showed physician specialty was not associated with 
practices’ adoption of either electronic medical systems or PCMH.3,13,42 Hollingsworth’s study, 
which investigated the adoption of PCMH, showed that physicians who resided in multi-
specialty practices had a greater rate of PCMH adoption than those in single-specialty practices. 
One explanation for the inconsistent findings is that this current study included more physician 
demographic characteristics than previous studies. This study included age and gender while 
Hollingsworth Et al. did not. To the extent, that age and gender may be confounded with 
specialty, e.g., specialty physicians may be older and more likely to be male, the inclusion of age 
and gender in this analysis allows the effect of specialty to be quantified independently. 
Additionally, previous studies also indicated that compared to specialist physicians, primary care 
physicians have more knowledge and awareness of patient-centered care; therefore, it may be 
easier for them to accept the PCMH concept and apply this model in their regular daily care.43 
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Last but not least, the results are consistent with previous studies in terms of practice size.3,39 
This study found clear evidence that larger practices were more likely to adopt PCMH, and this 
is anticipated as larger practices may have more capacity to accommodate the PCMH adoption.  
The findings of this study should be evaluated in light of certain limitations. First, the 
NAMCS is a cross-sectional survey, but the data provides national estimates of PCMH adoption, 
extending previous studies that had a regional focus. Second, physician factors were limited to 
demographic characteristics; the NAMCS does not include questions focused on attitudes, 
intentions, beliefs, or motivation of physicians. Therefore, we cannot evaluate the adoption of 
PCMH from physicians’ attitudinal perspectives. Previous studies using a qualitative approach or 
surveys showed that physicians’ decisions to pursue NCQA PCMH recognition program were 
mainly determined by financial incentives.44 Although we cannot assess physicians’ intentions 
toward financial incentives for adopting the PCMH, we provide more generalizable results to 
identify physician factors that were associated with the adoption of PCMH at a national level in 
the United States.  
Third, the study relied on self-reported information, as NAMCS is a physician/office-
reported survey. Despite this limitation, the results reflect the most up-to-date PCMH adoption 
scenario at the national level. Finally, the inability to capture all the NCQA PCMH elements in 
NAMCS is another concern. Because the survey questions in NAMCS cannot perfectly map onto 
the NCQA PCMH elements, the raw scores and level of PCMH adoption was refined based on 
the limited data. The approach used in this study was conservative, using the most must-pass 
criteria as possible for the available data. Furthermore, the measure of PCMH adoption 
emphasized the implementation of EMR. This systematic error of measuring the composition of 
PCMH may not reflect all the significant components of PCMH. This mapping approach was 
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consistent with previous research and used all available data in NAMCES so that national 
estimates could be determined.  
As policymakers and stakeholders work to stimulate PCMH adoption in today’s 
healthcare delivery system, the exploration of how to increase this uptake is important. Policy 
makers may consider promoting PCMH adoption among physicians with the identified 
characteristics. For example, policy makers should target older and female physicians who are 
more likely to resist adapting to new transformative care for patients. Furthermore, health policy 
makers should keep in mind that the transformation of practices cannot be completed quickly. 
This process requires the cooperation of practices and time for physicians to change their clinical 
behaviors. For physician practices, adoption of the model may require them to give more 
authority to non-physician professionals to care for their patients. For example, one previous 
study has shown that physicians can transfer the authority for handling chronic medication 
management to medication professionals such as pharmacists, allowing the physicians to work 
on more acute and/or serious patient concerns.45 Additionally, the incorporation of other non-
physician professionals may also mitigate the estimated shortage of primary care physicians.46 It 
is also important to educate physician students/trainees about the importance of both 
collaborative work with other non-physician professionals and the adoption of new practice 
innovations such as PCMH.  
In terms of future work, important changes to the questions in NAMCS will provide 
additional opportunity to continue to study the adoption of PCMH.47 Questions specifically 
asking the whether the practice is certified as a patient-centered medical home and what types of 
non-physician professionals are on staff at the office location were added in the 2013 survey, 
providing an important opportunity to study the uptake of non-physician personnel into physician 
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practices. In addition, the findings from this study suggest that the interaction between physician 
age and practice size or physician gender and practice size are two important interaction effects 
that future studies could consider.  
 
Conclusion 
An estimated 54% of physician practices in the United States have adopted some aspect 
of PCMH, and 12% have achieved Level 3 status according to NCQA PCMH accreditation 
standards, given data that are available in the NAMCS. Several characteristics of physicians 
were associated with PCMH adoption. Consistent with the diffusion of innovation framework, 
physicians who are female, older, and specialists were less likely to adopt PCMH into their 
practices. Physicians working in larger practices were also more likely to adopt PCMH.  
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Table 2.1 Weighted Multiple Imputation Estimates of Physician and Practice Characteristics 
(n=15,468)1 
Physician Characteristics2 Practice Characteristics3 
 % [95 % C.I.]  % [95 % C.I.] 
Physician Age  Practice Region  
 Less than 40 13.0 (11.3-14.6)  Northeast 20.8 (17.4-24.2) 
 40-54 46.7 (44.2-49.1)  Midwest 19.4 (17.0-21.8) 
 55-64 28.7 (26.6-30.8)  West 36.4 (33.3-39.5) 
 65 and Over 11.7 (10.2-13.2)  South 23.4 (20.8-26.1) 
Physician Gender  Practice Metropolitan Status  
 Female 25.5 (23.3-27.6)  Non-MSA 11.4 ( 7.7-15.1) 
 Male 74.5 (72.4-76.7)  MSA 88.6 (84.9-92.3) 
Employment Status   Organizational Structure  
 
Employee/Contractor 33.8 (31.0-36.6) 
 Single Specialty Practice 
31.6 (29.2-34.0) 
 Owner 66.2 (63.4-69.0)  Multi Specialty Practice 11.9(10.5-13.3) 
Physician Specialty   Solo 56.5 (53.7-59.3) 
 Primary Care 49.8 (48.8-51.9) Practice Type  
 Medical Care 28.9 (27.2-30.7)  Public   9.1( 7.8-10.5) 
 Surgical Care 21.2 (19.6-22.8)  Private 90.9(89.5-92.2) 
Physician Type  Practice Ownership  
 Doctor of 
Osteopathy   6.3 ( 5.4- 7.3) 
 Physician Group 
84.9 (82.9-87.0) 
 Doctor of Medicine 93.7 (92.7-94.6)  HMO/Else 15.1 (13.0-17.1) 
Interviewed Year  Practice Size  
 2009 50.7 (48.4-52.9)  Solo/Partner 56.5 (53.7-59.3) 
 2010 49.3 (47.1-51.6)  Small Group (3-5) 23.9 (21.6-26.2) 
   Medium Group (6-10) 13.5 (12.0-15.0) 
     Large Group (+11)  6.1(  5.1- 7.0) 
(Source: 2009-2010 NAMCS restricted data) 
1 Based on the results of a multiple imputation analysis with M=5 imputed datasets 
2.Based on physician sample weight 
3.Based on practice weight =(Physician sample weight)ij/Sij, Where Sij = number of physicians 
within practice j reported by physician i (Hing, 2007)  
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Table 2.2 Weighted Multiple Imputation Estimates of Bivariate Associations Between Physician 
and Practice Characteristics and Level of PCMH 
 Not 
Accredited 
n=179,694 
(45.7%) 
PCMH  
Level 1 
n=75,637 
(19.2%) 
PCMH  
Level 2 
n=90,313 
(22.9%) 
PCMH  
Level 3 
n=47,984 
(12.2%) 
p 1 
Physician Age     <0.01 
 Less than 40  9.1 12.0 15.7 19.1  
 40-54 40.7 48.8 49.9 53.7 
 55-64 31.9 29.0 27.5 22.2 
 65 and Over 18.3 10.2  6.9  5.0 
Physician Gender      0.05 
 Female 24.0 26.7 23.0 32.3  
Employment Status      <0.01 
Employee/Contractor 23.7 31.8 40.0 51.6  
Owner 76.3 68.2 60.0 48.4 
Physician Specialty     <0.01 
 Primary Care 42.0 47.4 49.8 73.5  
 Medical Care 34.0 25.8 29.8 18.0 
 Surgical Care 24.0 26.8 20.4 8.4 
Physician Type      0.49 
    D.O. 8.0  5.1 4.8 6.3  
    M.O. 92.0 94.9 95.2 93.7  
Interviewed Year     <0.00 
 2009 54.1 52.2 52.1 37.2  
 2010 45.9 47.8 47.9 62.8 
Practice Region      0.05 
 Northeast 21.5 24.0 17.0 20.1  
 Midwest 18.4 21.5 20.6 17.7 
 West 38.6 32.6 38.6 30.0 
 South 21.5 21.9 23.9 32.2 
Metropolitan Status      0.62 
 Non- MSA 10.1 14.9 11.0 11.4  
 MSA 89.9 85.1 89.0 88.6 
Organizational Structure <0.01 
Single Specialty 24.2 32.1 40.2 42.4  
Multi Specialty  6.6 10.2 19.1 20.7 
Solo 69.2 57.6 40.7 36.9  
Practice Type     <0.01 
Public  5.3 7.1 12.6 20.5  
Private 94.7 92.9 87.4 79.5 
Practice Ownership     <0.01 
Physician Group 91.2 86.5 76.9 74.3  
HMO/ Else 8.8 13.5 23.1 25.7  
Practice Size     <0.01 
Solo/Partner 69.2 57.6 40.7 36.9  
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Small Group   (3-5) 19.7 23.2 29.2 30.8  
Medium Group (6-
10) 8.6 12.8 19.2 22.0 
 
Large Group   (11 +)     2.4 6.4 10.8 10.3  
(Source: 2009-2010 NAMCS restricted data) 
Note. 1 p-values correspond to Rao-Scott chi-square test statistics  
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Table 2.3 Weighted Multiple Imputation Estimates of Adjusted Odds Ratios (AOR) and Design-Based 95% CIs for the Multinomial 
Logistic Regression Model for Factors Associated with Different Levels of PCMH 
 PCMH Level 1 PCMH Level 2 PCMH Level 3 
 AOR 95 % CI p-value AOR 95 % CI p-value AOR 95 % CI p-value 
Physician Characteristics          
Physician Gender (referent: Male)       
  Female 0.9 0.63-1.35 0.68 0.6 0.43-0.93 0.02 0.7 0.44-1.06 0.09 
Physician Age Group  
(referent: age less than 55) 
        
55 and Over 0.7 0.49-0.95 0.02 0.6 0.42-0.79 0.00 0.4 0.24-0.59 <0.01 
Employment Status  
(referent: Employee or Contractor) 
       
Owner 0.7 0.43-1.06 0.09 0.9 0.58-1.32 0.52 0.7 0.45-1.16 0.18 
Physician Specialty (referent: Surgical Care)       
Primary Care  1.0 0.66-1.38 0.80 1.5 1.06-2.10 0.02 4.4 2.53-7.49 <0.01 
Medical Care 0.7 0.46-0.98 0.04 1.1 0.74-1.55 0.72 1.5 0.73-2.92 0.28 
Practice Characteristics          
Practice Region (referent: Northeast)       
Midwest 0.9 0.55-1.52 0.74 1.1 0.71-1.79 0.61 0.7 0.40-1.37 0.33 
South 0.7 0.45-1.15 0.17 1.2 0.77-1.86 0.42 0.7 0.39-1.38 0.34 
West 0.9 0.54-1.43 0.60 1.3 0.79-2.22 0.28 1.3 0.78-2.30 0.28 
Practice Ownership  
(referent: Physician or Physician Group) 
       
HMO or Else 0.9 0.54-1.64 0.84 1.7 0.90-3.11 0.10 1.1 0.53-2.21 0.83 
Practice Type (referent: Public)       
Private 1.0 0.64-1.59 0.98 0.8 0.48-1.46 0.53 0.4 0.19-1.02 0.06 
Practice Size (referent: Solo/Partner)       
Small Group      (3-5) 1.2 0.83-1.71 0.35 2.1 1.46-3.07 0.00 2.2 1.34-3.50 <0.01 
Medium Group  (6-10) 1.4 0.96-2.09 0.08 3.0 2.03-4.32 0.00 3.0 1.81-4.86 <0.01 
Large Group    (11 +) 2.6 1.62-4.14 <0.01 5.7 3.65-8.94 0.00 4.9 2.73-8.67 <0.01 
Note: Baseline outcome category: Not accredited PCMH 
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Table 2.4 Primary Care Practice Attainment of Individual NCQA Elements, Stratified by Physician Characteristics 
NCQA Elements Physician Gender Physician Age Category 
 Male Female p-value less than 55 55 and over p-value 
Enhance access and communication       
Allow same day appointments 61.1 69.1 <0.00 65.6 59.5 0.03 
Improve patient tracking and registry       
Has system for managing patient data  80.2 81.7 0.51 84.0 75.4 <0.00 
Has electronic system for clinical data 51.6 52 0.89 58.8 41.3 <0.00 
Use electronic clinical data 50.6 45 0.06 53.3 43.1 <0.00 
Able to organize clinical data 52.8 50.9 0.49 59.8 41.3 <0.00 
Identify patient important 
diagnosis/conditions 46.6 46.1 0.86 51.8 38.7 <0.00 
Track patient medication lists 50.5 53.1 0.48 58.8 39.7 <0.00 
Provide better care management       
Has preventive services reminders 37.2 42.1 0.07 44.0 30.3 0.00 
Has other non-physician assistance 29.9 26.3 0.21 30.7 26.3 0.08 
Visits patients besides outpatient visits 54.9 61.3 0.02 55.9 57.6 0.48 
Offer advanced self-management support      
Provide health education 41.4 49.4 <0.00 44.9 41.4 0.15 
Prescribing electronically       
Has computerized systems for prescribing 49.4 50.6 0.68 55.1 41.7 <0.00 
Prescribing with warning signs 39.4 42.2 0.29 45.4 32.3 <0.00 
Elevate test tracking       
Has out-of-range levels highlighted 44.5 49.7 0.07 50.2 39.4 <0.00 
System sends tests electronically 30.2 35.4 0.05 36.3 24.3 <0.00 
Can view the results electronically 55.6 58.9 0.25 62.2 48.0 0.04 
Performance reporting and improvement       
Has electronic public health report 15.6 23.6 0.01 17.2 11.3 0.04 
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Continue 
NCQA Elements Employment Status Specialty 
 Employee/Contractor owner p-value Primary care Surgical Medical p-value 
Enhance access and communication        
Allow same day appointments 67.8 59.0 <0.00 79.0 46.3 43.4 <0.00 
Improve patient tracking and registry        
Has system for managing patient data  86.7 71.8 <0.00 77.1 81.3 69.1 0.10 
Has electronic system for clinical data 61.7 39.8 <0.00 49.7 43.1 39.9 0.05 
Use electronic clinical data 57.6 37.1 <0.00 42.1 51.2 36.1 0.01 
Able to organize clinical data 61.8 39.9 <0.00 46.4 47.2 42.5 0.79 
Identify patient conditions 55.2 36.2 <0.00 45.1 39.8 35.4 0.11 
Track patient medication lists 63.8 35.1 <0.00 47.1 36.9 40.7 0.04 
Provide better care management        
Has preventive services reminders 43.8 29.6 <0.00 40.4 27.5 25.8 <0.00 
Has other non-physician assistance 34.7 24.0 <0.00 32.0 23.4 20.5 0.01 
Visits patients besides outpatient visits 52.9 60.4 0.01 65.8 50.8 52.4 <0.00 
Offer advanced self-management support       
Provide health education 46.6 42.9 0.14 46.7 32.7 47.1 <0.00 
Prescribing electronically        
Has computerized systems for 
prescribing 56.5 37.8 <0.00 47.2 37.1 38.7 <0.00 
Prescribing with warning signs 46.7 29.2 <0.00 39.2 23.8 31.6 <0.00 
Elevate test tracking        
Has out-of-range levels highlighted 55.2 34.7 <0.00 47.3 30.0 34.9 <0.00 
System sends tests electronically 38.9 22.0 <0.00 33.9 17.6 20.2 <0.00 
Can view the results electronically 65.8 44.1 <0.00 55.7 45.1 42.7 <0.00 
Performance reporting and improvement        
Has electronic public health report 24.3 11.5 <0.00 21.1 10.0 6.8 <0.00 
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Figure 2.1. Proposed Theoratical Framework 
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CHAPTER III. PAPER 2: DOES THE EXTENT OF PATIENT CENTERED MEDICAL 
HOME ADOPTION REDUCE THE USE OF INAPPROPRIATE MEDICATION 
AMONG OLDER ADULTS? 
Introduction 
 Almost one-half of the U.S. population takes at least one prescription medication, leading 
to nearly $326 billion in prescription sales.1 It is critical to ensure the appropriateness of 
medications so that adverse events can be minimized. A medication is considered inappropriate 
if the risk of harm from the medication is judged to outweigh the potential clinical benefit after 
considering the patient’s clinical circumstances.2 Moreover, previous studies indicate that one in 
five prescriptions ordered in the primary care setting in the United States is considered 
inappropriate.3 This high prevalence of inappropriate medication use suggests a high likelihood 
of poor medication quality of care, which is a major public health concern.4,5 The inappropriate 
use of medications may lead to serious medical consequences that place a substantial economic 
burden on our health care system. Evidence for this is provided by studies revealing that on 
average $7.2 billion in healthcare expenditures is associated with inappropriate medication use 
among older adults age 65 and older each year. Further, nearly 17% of U.S. emergency room 
visits are related to at least one potentially inappropriate medication (PIM).6  
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Apart from the economic burden, appropriate medication prescribing and use is especially 
critical among adults, given that nearly 40% of adults age 65 and over reported being on five or 
more medications.7 Evidence shows that greater numbers of medications are associated with a 
greater risk of having a potentially inappropriate medication (PIM).3 PIM is defined as 
medications that are deemed potentially harmful to the elderly population. The growing concern 
about PIM has caused both the Federal government and quality organizations to address 
medication quality of care through the development of national action plans as well as 
establishing standardized medication indicators. For example, the National Action Plan for 
Adverse Drug Event Prevention aims to promote and coordinate Federal resources to prevent 
adverse drug events (ADEs), which are associated with PIMs.8 Similarly, medication indicators, 
such as the use of high-risk medications and the potentially harmful drug-disease interactions, 
have been developed in the Healthcare Effectiveness Data and Information Set (HEDIS) for 
stakeholders to evaluate the appropriateness of medication use.9 In fact, previous studies have 
demonstrated that several PIM medication indicators (e.g., Beers criteria, Zhan criteria, and 
HEDIS) can serve as proxies to evaluate the quality of appropriate medication use in various 
settings and populations.10-14 These studies have not only reported the prevalence of PIM, but 
also examined the associated factors.15-19  These studies have focused on patient characteristics, 
revealing that being female, older age, poorer health condition, poorer health literacy, greater 
number of chronic diseases, greater number of medications, greater number of visits, greater 
number of prescribers, and living in the south region were more likely to be associated with PIM. 
Although patient factors are not the only predictors of PIM, a few studies have examined 
structural characteristics, such as practice size and type. These studies have shown that physician 
characteristics also affect the occurrence of PIM, including physicians residing in solo practice, 
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and those identified as geriatric specialties, older age, and being female.19,20 Indeed, the cause of 
PIM can be attributed to prescribing behaviors among providers and the types of practices in 
which patients reside. Surprisingly, no studies have considered the occurrence of PIM within the 
context of healthcare reform, which has introduced new models of integrated healthcare delivery 
and promised improved quality of care. One such model is the Patient-Centered Medical Home 
(PCMH). 
 The PCMH is defined as a transformative and innovative model, aiming to provide 
comprehensive, patient-centered, team-based, accessible and coordinated primary care with a 
focus on systems-based quality and safety improvement.24,25 By adopting the PCMH model, 
practices are expected to increase access to care, improve the quality of delivered care and 
reduce overall health care expenditures.26 The NCQA PCMH standards and guidelines are the 
most widely used voluntary program to assess primary care practices as medical homes in the 
current literature.27 Importantly, these guidelines have been used in several national PCMH 
projects.28 The NCQA PCMH guideline program identifies three levels of PCMH attainment, as 
measured by a complex scoring rubric, to evaluate the extent to which a practice adopts a PCMH 
approach to care. When the level of achievement is high, the practice has a relatively more 
comprehensive care environment and is expected to offer a better quality of care, reduced cost of 
care, enhanced experience of care and better professional experience.29 Thus, the level of PCMH 
adoption should be related to the quality of care, as assessed by a variety of processes and 
outcomes of care. Process indicators for medication use quality may include those specified by 
the HEDIS, such as routine high blood pressure checking, HbA1C, LDL-C and persistent 
medication monitoring among patients with diabetes.30,31 Along with these types of process 
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indicators, outcome indicators, such as diabetes outcome measures, are also recommended by the 
Commonwealth Fund to evaluate PCMH adoption among practices.32   
Several studies of PCMH have demonstrated that the integration of non-physician 
professionals, such as pharmacists, can strengthen the PCMH. This is because pharmacists 
provide a range of critical services, including medication management (e.g. Medication Therapy 
Management, or Collaborative Drug Therapy Management), which are essential to improve 
medication quality of care.33,34 There are mixed results supporting the impact of PCMH, and the 
potential benefits of PCMH in relation to appropriate medication use remain largely unexplored. 
It is important to consider appropriate medication use in the context of PCMH adoption, as 
medications are the mainstay of treatment in primary care, and pharmacists may be able to 
improve medication management among patients with chronic diseases such as diabetes and 
hypertension.35 No study has examined the value of adopting PCMH on the quality of patient 
medication use.  
To address these gaps in knowledge, the objective of this study was to explore the 
association between the PCMH adoption and its impact on PIM among older adults. In order to 
evaluate the extent to which a practice may impact medication use, this study employed features 
of the NCQA PCMH recognition program and used a nationally representative database. Two 
medication indicators were selected to represent the extent of PIM associated with a patient visit, 
including the use of high-risk medications (HRM) and potentially harmful drug-disease 
interactions (DDIS), which are expected to be lower in prevalence for practices with higher 
levels of PCMH adoption.  
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Methods 
Study Design and Data Sources 
In this retrospective study, the extent of PCMH adoption was the exposure variable and 
inappropriate medication use was the outcome. Data for this study came from the National 
Ambulatory Medical Care Survey (NAMCS). The NAMCS is a nationally representative, 
multistage probability sample survey, which was originally created by the National Center for 
Health Statistics (NCHS), Centers for Disease Control and Prevention. The NAMCS is designed 
to provide objective, reliable information about the provision and use of ambulatory medical care 
services among patients of all ages in the United States. The data in the survey are weighted to 
produce national estimates of the utilization of ambulatory services. All of the responses in the 
NAMCS are based on a sample of visits to non-federally employed office-based physicians who 
are primarily engaged in direct patient care.  
The NAMCS randomly selects those physicians, assigns them to one of 52 weeks in a 
year, and expects them to report information on a systematic random sample of patients treated 
during their assigned week.36 For the sampling, the NAMCS utilizes a multistage probability 
sample design that involves 3 stages: (1) sampling of geographic locations (or primary sampling 
units [PSUs]), (2) sampling of physician practices within sampled geographic locations 
(stratified by physician specialty), and (3) sampling of visits within sampled physician practices.  
Patient, clinical, physician, and practice information are collected for each selected visit 
and then recorded on patient record forms by participating physicians or office staff. This study 
included data from surveys conducted in 2009 and 2010, which are the most recently released 
publicly available NAMCS data. Each patient visit recorded up to 8 medications prescribed, 
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administered, injected or provided. The patient visit was the unit of analysis. Patient visits were 
in scope if the patient was aged 65 and over and without any medication records, based on 
HEDIS criteria.9  This study was declared exempt by the Institutional Review Board of the 
University of Michigan. 
Measures 
Determining Level of PCMH Adoption   
 To designate levels of PCMH adoption in the NAMCS, this study builds on a calculation 
method reported in Hollingsworth Et al. that mapped the 2009 and 2010 NAMCS survey items to 
the 2008 NCQA PCMH guidelines so as to designate a practice as a medical home.37  We further 
advanced their work to generate a stricter PCMH recognition calculation method by adding the 
must-pass elements to define the level of PCMH, and examined the relationship of level of 
PCMH adoption with the extent of PIM prescribing. 
 The original NCQA PCMH guidelines contain nine standards with thirty subsumed 
elements, and for each element “passed”, specific points are awarded. Among the thirty 
elements, ten were designated as “MUST PASS” elements for the purpose of categorizing 
different levels of PCMH.38 Using survey items from the 2009-2010 NAMCS, we mapped the 
2008 NCQA PCMH guideline elements for medical home recognition. This approach allowed 
for the derivation of nationally representative estimates of the proportion of practices that qualify 
as medical homes. Due to the frequent changes of NAMCS instruments, we mapped 15 elements 
of the 2008 NCQA PCMH standards, representing seven and six standards for the 2009 and 2010 
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NAMCS items individually. The unit of observation in NAMCS is patient visit. The level of 
PCMH adoption for each visit was determined by using the practice characteristic variables in 
each visit record, and the PCMH scores will be the same for the visits from the same practice. 
Each visit received a “passed” (1=yes) point for each measurable element and a cumulative point 
total by summing points across all passed elements. A PCMH infrastructure score was calculated 
by dividing the cumulative point total by the total number of available points, expressed as a 
percentage. The maximum denominators for this score were 55 points and 60 points in 2009 and 
2010, respectively. The reason that 2009 and 2010 have different denominators is because some 
items were added and some were eliminated for those years. The detailed mapping technique is 
shown in Appendix E.   
Once the score for PCMH adoption was determined, the score was assigned to an NCQA 
PCMH level of recognition, determined by a cut-off of cumulative points and numbers of 
“MUST PASS” elements, consistent with the NCQA PCMH guidelines. In the original NCQA 
PCMH guidelines, there were three levels of PCMH recognition: not accredited (fewer than 25 
percent of total points), Level 1 (25 to 49 percent of points and a pass on 5 of 10 MUST PASS 
elements), Level 2 (59-74 percent of total points and a pass on all 10 MUST PASS elements), 
and Level 3 (points more than 75 percent and a pass on all 10 MUST PASS elements). Because 
not all elements of the NCQA PCMH were included in the NAMCS, this study defined the 
classification of the NCQA PCMH level recognition as follows: not recognized (fewer than 25 
percent of total points), Level 1 (25-49 percent of total points and a pass on 2 out of 4 MUST 
PASS elements), Level 2 (50-74 percent of total points and a pass on all 4 MUST PASS 
elements), and Level 3 (over 75 percent of total points and a pass on all 4 MUST PASS 
elements). The comparison between original NCQA PCMH criteria and the modified version 
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based on NAMCS survey items is shown in Appendix E.   
Defining Potentially Inappropriate Medications 
 The outcomes for this study were two age-appropriate medication quality of care 
indicators (1 = yes, 0 = no) coded for each visit, including (1) the use of high-risk medications 
(HRM) and (2) potentially harmful drug-disease interactions (DDIS), which were both defined 
by NCQA for HEDIS.  The prevalence of HRM was measured as the proportion of patient visits 
where the record designated an individual age 65 and over and received at least one medication 
which was on a list of medications to be avoided.9 To identify whether older adult visits in 
NAMCS involved exposures to any HRM medications, the Multum drug codes were employed 
to match the medication lists in NAMCS with the high risk medication lists provided by NCQA. 
DDIS prevalence was measured as the proportion of patient visits where the record contained 
information about the individual that indicated a diagnosis of dementia (ICD-9-CM codes 290, 
294, 331, and 046), falls (ICD-9-CM codes 226, 340, 820, and 821), or chronic renal failure 
(ICD-9-CM codes 585), and a contraindicated medication for any of these diagnoses.21  The 
contraindicated medication groups included: (a) dementia: high anticholinergic agents (i.e., 
gastrointestinal antispasmodics, skeletal muscle relaxants), (b) fall/ hip fractures: tricyclic 
antidepressants, conventional or atypical antipsychotics, and specific sleep agents (e.g., 
zolpidem), and (c) chronic kidney disease: nonsteroidal anti-inflammatory drugs (NSAID). 
These two outcome measures were coded for each visit as two dummy variables (0 = no, 1 = yes) 
and were used to represent the extent of PIM, which was expected to be lower for practices with 
higher levels of PCMH adoption. 
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Other Covariates  
 This study focused on examining the impact of transforming traditional care to PCMH 
(i.e., process of care) on medication quality (i.e., outcomes) based on the proposed theoretical 
model (i.e., the Wagner’s chronic care model and the Hogg’s primary care organization model). 
Yet, patient individual characteristics and other structure elements needed to be considered.   
  Based on the previous HRM and DDIS related literature, patient individual-level 
characteristics played significant roles on the exposure of inappropriate medication use.4,5,6 
Therefore, variables including (1) age, (2) gender (female/male), (3) race (White/Black/Other), 
(4) number of chronic diseases (sum of fourteen chronic conditions including arthritis, asthma, 
cancer, cerebrovascular disease, chronic renal failure, congestive heart failure, chronic 
obstructive pulmonary disease, depression, diabetes, hyperlipidemia, hypertension, ischemic 
heart disease, obesity, osteoporosis), (5) number of medications (sum of up to 8 listed 
medications), (6) number of past visits within the last year, (7) household income in patient’s zip 
code, and (8) primary expected source of payment for the visit (Private insurance 
/Medicare/Medicaid/Others) were included.    
Since the modified theoretical model considered practice organizational structure into 
account for its influence on outcome, several system-level covariates were included in this study. 
These variables included (1) practice type (Solo/Non Solo), (2) practice region 
(Northeast/South/West/Midwest), (3) practice metropolitan status (Metropolitan Statistical 
Area/non-Metropolitan Statistical Area), (4) physician specialty group (Primary care 
specialty/Surgical care specialty/Medical care specialty), (5) employment status of physician 
(Owner/Employee/Contractor), and (6) type of physician (Doctor of Medicine/Doctor of 
Osteopathy).  
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Statistical Methods 
 All analyses used appropriate NAMCS sampling weights to compute unbiased population 
estimates of the descriptive and regression parameters of interest. Codes in the NAMCS public-
use data sets identifying sampling strata and sampling clusters were also employed in all 
analyses to compute appropriate design-based estimates of standard errors for the weighted 
estimates.  Some variables were missing about 50% of their values, and multiple imputation by 
chained equations was used to provide more statistical power to analyze the relationships of 
interest.39 These imputations generated five completed data sets with all missing values imputed 
based on other observed variables. The five completed sets of analyses were combined with the 
original data set to generate a final overall set of multiple-imputation estimates for each analysis. 
Design-based Rao-Scott Chi-square tests and Wald tests were employed to test the 
bivariate associations between the dichotomous outcomes (high risk medication use and DDIS) 
and patient/provider characteristics. Design-based multivariate logistic regression models were 
used to examine the associations between PCMH adoption and the use of inappropriate 
medication, controlling for the aforementioned covariates. An investigation of interaction 
between patient age and number of medication uses was employed as an exploratory analysis. 
The Archer–Lemeshow goodness-of-fit tests were used to assess the fits of the logistic regression 
models in each of the five imputed data sets.40 All data management and analysis was conducted 
using Stata (Version 13.0), and the Stata code used is available upon request. 
Results 
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The NAMCS data provide information for a total of 63,150 sampled outpatient clinic visits, 
which are representative of approximately two billion ambulatory visits between 2009 and 2010. 
Of these visits, 13,156 outpatient clinic visits met the selection criteria, namely patients being 65 
and over and prescribed at least one medication at the outpatient visit. This sample provides 
population estimates for 432 million outpatient visits from 2009 to 2010 for the target 
population. Nearly 11% (95% confidence interval [CI] = 10.0% to 12.4%) of the visits in the 
target population involved prescription of an HRM. Approximately 15% (95% CI = 15.8% to 
25.5%) of the visits in the target population with specific diseases indicated involved exposure 
to drug-disease interactions. The characteristics of the target population of visits, those with 
HRM, and those with DDIS are reported in Table 3.1. Based on this sample of 13,156 visits, an 
estimated 58% (95% CI = 53.2% to 62.8%) of visits in the target population occurred in 
practices without any PCMH accreditation. For the visits associated with HRMs and DDIS, the 
rate of occurrence in practices without any PCMH accreditations was 53% (95% CI = 46.6% to 
59.4%) and 55 % (95% CI = 40.0% to 71.0%), respectively. The rates of HRM-associated and 
DDIS-associated visits were particularly higher for visits when patient gender was female with 
lower household income and private insurance, when the visit was to a solo practice, and when 
the visit was conducted by primary care physicians.     
For HRM, the 10 most frequent medications were (in descending order): Acetaminophen-
Propoxyphene Napsylate, Conjugated estrogens, Nifedipine, Cyclobenzaprine, Diazepam, 
Nitrofurantoin macrocrystals, Diphenhydramine, Thyroid desiccated, Hydroxyine 
hydrochloride, and Dicyclomine. For DDIS, Quetiapine with fall or facture was the most 
common combination documented in the patient visits, followed by (medication/condition) 
quetiapine (Dementia), zolpidem (Fall/Hip fracture), cyclobenzaprine (Dementia), naproxen 
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(CKD), olanzapine (Fall/Hip fracture), oxybutynin (Dementia), ibuprofen (CKD), risperidone 
(Fall/Hip fracture), and celecoxib (CKD) (Tables 3.2 and 3.3). For HRM, most of the listed 
medications were identified as continued ones, whereas three out of ten DDIS medication were 
newly administered.  
The multiple imputation estimates of bivariate associations between level of PCMH, other 
covariates, and use of HRM during a patient visit demonstrated that patient age (younger than 
75), gender (female), race (black), number of medications used (greater), income (lower), region 
(residence in South), and physician specialty (seen by primary care doctor) were significantly 
associated with a higher risk of HRM (Table 3.4). For the DDIS-related visits, the results of the 
Wald tests showed that number of chronic conditions (less) and number of medications used 
(greater) were statistically associated with higher risk of DDIS during a patient visit. 
The final multiple imputation estimates of logistic regression models with adjusted odds ratios 
(ORs) for HRM and DDIS are presented in Table 3.5. The level of PCMH was not associated 
with the odds of the patient visit involving HRM when adjusting for the other covariates. 
However, for the HRM model, visits where the gender was female ([OR]=2.00, [95% CI]=1.64-
2.43), had more past visits ([OR] =1.02, [CI] =1.00-1.03), had more medications ([OR] =1.26, 
[CI] =1.20-1.32), lived in the southern region ([OR] =1.59, [CI] =1.06-2.39), and was seen by 
primary care physicians ([OR]=1.27, [CI]=1.05-1.53) were significantly more likely to involve 
HRMs. Visits with age being younger ([OR] = 0.98, [CI] =0.97-0.99) and with more than two 
coexisting chronic conditions ([OR] =0.62, [CI] =0.48-0.80) were significantly less likely to 
involve HRMs.   
For the logistic regression for DDIS-related visits, the level of PCMH was not associated 
with the odds of the patient visit involving DDIS. The odds of receiving DDIS medications 
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increased for each additional medication use by a factor of 1.27 ([OR] =1.27, [CI] =1.12-1.45), 
or decreased for those patients visits reported having two and more chronic conditions with an 
OR of 0.23 ([OR] =0.23, [CI]=0.08-0.67).  The fits of the two logistic regression models were 
assessed using the Archer–Lemeshow goodness-of-fit test for each of the five imputed data sets. 
The range of goodness-of-fit test statistics for the HRM and DDIS models suggested that the fits 
were good in each imputed data set, with the range of p-values always greater than 0.05.  
Sensitivity analyses were conducted to assess whether different definitions of outcomes, 
PCMH categorizations, and physician types substantially changed the predictive models. 
Specifically, we redefined and reran the following analyses: (1) the medication quality indicators 
were limited to new HRM and new DDIS medications; (2) we redefined the PCMH 
categorizations, using the Hollingsworth Et al. approach (i.e., without having must pass criteria) 
and dichotomizing it into a binary variable (e.g., meet none versus some PCMH criteria); and (3) 
we limited analyses to primary care physicians. For the sensitivity analysis and the model with 
interaction terms for both HRM and DDIS models, there were no substantial changes. Therefore, 
only the results for primary analysis are presented.  
Discussion 
 This study is one of the first to use the NAMCS database to determine if adoption of 
PCMH model is associated with better clinical performance in terms of medication use among 
older adults. Data were analyzed applying several NCQA HEDIS measurements, namely the 
high risk medication and drug-disease interaction indicators. These two medication quality of 
care indicators were selected as important quality indicators of the adoption of PCMH. 32,41After 
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adjusting for patient- and practice-level characteristics, our findings showed that the level of 
PCMH adoption was not associated with the quality of medication use indicators. For the 
remaining covariates, our study found that number of medications used was the most significant 
factor that affected the occurrence of HRM and DDIS.  
Although it was anticipated that adopting PCMH would be associated with quality of 
medication use, the lack of association is consistent with two previous studies.42,43 Holmboe et 
al used a web-based survey of 254 physicians chosen from metropolitan regions of eighteen 
cities in thirteen states to investigate the relationship of practices’ “systemness” as PCMH and 
the quality of care they provided. They developed a series of survey questions that captured the 
primary characteristics of PCMH based on the NCQA scoring algorithm and generated a risk-
adjusted composite measure of quality for chronic, acute, and preventive care. Their initial 
findings demonstrated that overall scores were a composite of several structural elements of 
PCMH and was not associated with higher quality of patient care. Likewise, Shi Et al. employed 
the Safety Net Medical Home Scale (SNMHS) to capture the features of PCMH and to assess 
the relationship between PCMH adoption in the Health Resources and Services Administration-
funded safety net health centers and four clinical measures (vaccination rates among children, 
pap smear rates among eligible women, HbA1c values among patients with diabetes, and blood 
pressure rates among patients with hypertension). Employing the SNMHS algorithms and 
generating total PCMH and subscale scores (i.e., accumulated by each domain), they also found 
no associations between the aggregated total PCMH scores and any of the four performance 
measured outcomes.    
Several reasons may explain these discouraging results. One reason is whether the design 
of the PCMH recognition program can appropriately assess the right PCMH elements that 
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practices tend to offer. In other words, the NCQA PCMH is one of the tools that aims to 
evaluate practices' quantify the delivery of care using principles embodied in the PCMH. With 
regard to this issue, we may question whether the NCQA PCMH guidelines or the SNMHS 
scoring method fully capture the essence of PCMH characteristics so as to allow for an accurate 
evaluation of healthcare delivery. The NCQA PCMH guidelines can identify the presence or 
absence of structural and process elements of practices and at best assess only the potential 
capability that practices can draw on to serve patients. However, the NCQA PCMH guidelines 
are the most common approach in the literature for assessing PCMH. A second reason is that 
our mapping approach of the NCQA guidelines to the NAMCS may have lost some important 
concepts of PCMH, such as referral tracking and advanced electronic communication elements. 
This concern highlights the pitfall of assessing the PCMH components thoroughly. Furthermore, 
several significant elements are not included in the NCQA PCMH recognition guideline but 
emphasized in previous studies as necessary to provide better-quality of care, including (a) the 
interpersonal relationships among providers and patients as well as within professionals, (b) the 
skills and interdependence of the health professionals working in various practice settings, and 
(c) physicians’ leadership, attitudes and interactions within complex adaptive systems.44 The 
failure to capture such measurements of practice structure may prevent an accurate assessment 
of the quality of patient care.    
 Another reason for the lack of association between the adoption of PCMH and the 
quality of medication use may be related to the selection of the two inappropriate medication 
quality indicators. A growing number of PCMH demonstration projects have shown 
improvements in healthcare access and quality of care, yet most of the previous studies reported 
inconclusive results and/or rarely focused on the quality of medication use.29,45 Indeed, previous 
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studies that demonstrated the effectiveness of PCMH in relation to quality of care generally 
focused on preventive services, disease specific medication indicators (e.g. rates of 
immunization, cancer screening, ACE or ARB prescribed for diabetes/chronic heart failure 
patients, or narcotics prescribed for patients with low back pain), or medication adherence rates 
in chronic disease conditions.29,45 No previous study has investigated the overall use of 
medications for all the population, without targeting in specific chronic diseases. In other words, 
our study is more advanced in that it hypothesizes the PCMH can be beneficial for a more 
general population, i.e., older adults.  
 Despite the findings of our study, our results deliver an important message, namely that 
patients need improved medication use in the PCMH model. Particularly, more and more studies 
are emphasizing the importance of whether patients are taking medication appropriately. 
Additionally, the selection of appropriate medications has already become as an important issue 
for primary care settings.32,41 Our study findings also suggest that medication experts such as 
clinical pharmacists may be needed to participate in the PCMH collaborative team. Previous 
studies have shown some positive results when pharmacists are included in the PCMH. For 
example, studies have shown improvements in blood pressure outcomes and diabetes control, 
and patients also had a significantly lower rate of hospitalizations utilization.33,46, 47 The findings 
of our study signal an opportunity to pharmacists that there is still a need for ensuring the 
appropriate medication use within the PCMH model. 
 This study showed that the prevalence of HRM and DDIS in outpatient visits involving 
older U.S. adults were 11.2% and 15.0%, respectively. These findings were in accordance with 
a previous study that used the same criteria (i.e., HEDIS HRM and DDIS measures) to define 
the list of inappropriate medication use.21 Pugh Et al. reported that the prevalence of HRM and 
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DDIS were 12.3% and 15.2%, respectively, in 2006. No comparison can be made to other 
studies that used other criteria for defining inappropriate medication, such as Beers or Zhan 
Criteria, because of differences in the medication lists. Apart from this general finding of 
potentially harmful medications, we also identified the top 10 inappropriate prescribed HRM 
and DDIS medications in the U.S, which has rarely been reported in previous studies.12,16 This 
finding provides valuable information to clinicians and/or prescribers who need to be aware of 
which specific inappropriate medications should be targeted. For HRM, propoxyphene and 
nifedipine were the most prescribed inappropriate medications, which were consistent with 
previous literature.10 Additionally, our results identified that most of the high risk medications 
were reported as continued medications, implying that either the risks outweigh the benefits or 
that prescribers engaged in poor prescribing quality in an ongoing manner.48 With regard to the 
top list of DDIS, our study was the first to describe the specific drug-disease interactions. Our 
findings showed that patient visits with fall/hip fracture recorded the most medication 
interactions. These results can be an important reference for clinicians to consider when 
prescribing for this subpopulation.  
 This study offers an up-to-date analysis of risk factors for potentially inappropriate 
medication use. For HRM, we found that visits where the individuals were female gender and 
had more medications were more likely to be exposed to risks, which is consistent with prior 
studies.5,16,20,21,23,49 Additionally, the number of past outpatient visits, the type of physicians that 
the patient contacted, and region are three variables that have not been investigated in the 
inappropriate medication use literature. It is plausible that patients with a greater number of 
visits and seen by primary care physicians are the ones who are more vulnerable and have 
greater need for medications, leading to higher chances of HRM exposure. As to the south 
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region being a factor for higher exposure to HRM, this may indicate regional disparity in 
medication quality of care.50 In our study, it was somewhat surprising that the finding of the 
effect of comorbidity conditions was inconsistent with that reported in previous studies.11,14,49 
One possible explanation for that was the number of medications in the dataset was restricted to 
eight medications per visit; this restriction may have failed to capture all medications on the 
HRM lists. This is reasonable in light of a previous study using national representative survey 
and reporting that the average prescription medication used for older adults is five or more.51 As 
for the exposure to DDIS, only the number of medication used variable shown significant 
association with the exposure.  
 A number of potential limitations should be noted. First, we acknowledge that mapping 
technique of measured NAMCS items to NCQA elements was subjective. For example, not all 
the NCQA elements are contained in the NAMCS database. In addition, the measure of PCMH 
adoption variables centered on the evaluation of EMR and with few items for other important 
elements, such as collaborative and coordinated care. However, we used an approach similar to 
Hollingsworth Et al.. As well, there is currently no national database in the United States that 
can measure PCMH infrastructure across a variety of practices.  
Another potential limitation was the limited medication history in NAMCS. The 
medication history of each patient visits were up to eight medications. However, this medication 
list would then provide an under-estimate of these indicators, as medications may be missing 
that would qualify for the outcome. Third, the data are from a systematic random sample, but 
physician or office staff may misrepresent data and data were missing. NAMCS provides 
specific instructions in terms of the way to collect the data; nevertheless, respondent bias may 
exist. Strong imputation methods were used to reduce the impact of missing data. Finally, this 
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analysis used a cross-sectional study design and causality cannot be made. Using a longitudinal 
study design may enable investigators to observe the patterns of the use of inappropriate 
medication and the PCMH adoption over time, but the design of NAMCS precluded this 
approach.    
Future studies of this topic are still needed. Examining PCMH sub-elements and the quality 
of medication use may be insightful to identify whether specific aspects of PCMH are related to 
medication quality. As well, qualitative studies focused on healthcare professionals’ opinions of 
medication use to understand why HRM and DDIS occur would be helpful. The latter is an 
important consideration as HRM is a star measure for Part D plans and a HEDIS measure.  
Conclusion 
 Our study found no association between adoption of PCMH and medication quality of 
care. The most prevalent high risk medications were propoxyphene and nifedipine. Individual 
physician characteristics were more important than practice characteristics in predicting the 
quality of medication use.   
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Table 3.1 Weighted Multiple Imputation Estimates of Patient and Practice Characteristics of 
Target Population, of Population with HRM, and of Population with DDIS  
 
 
 
Total populationa 
[N=432,284,932] 
[100 %] 
With HRMb 
[N=48,430,635] 
[11.2 %] 
With DDISc 
[N=8,865,883] 
[15.0 %] 
Patient Characteristics Est. % [95% CI] Est. % [95% CI] Est. % [95% CI] 
Mean age [95 % CI] 75.5  [75.3-75.8] 74.8  [74.2-75.5] 79.7  [78.1-81.2] 
Gender    
  Female 57.7  [56.3-59.1] 72.1  [68.6-75.7] 62.4  [50.5-74.2] 
Race    
  White 88.4  [86.5-90.3] 86.7  [82.7-90.7] 79.9  [68.3-91.6] 
  Black  8.2   [ 6.5 - 9.9] 10.9  [7.0 -14.8] 16.9  [ 5.5 -28.2] 
  Others  3.4   [ 2.5 - 4.3] 2.4  [1.0 - 3.8]  3.2  [ 0.0 - 6.9] 
Number of Chronic disease1    
  None 13.9   [12.5-15.3] 13.9  [11.2-16.6]  9.2  [ 3.1 -15.4] 
  One 23.7   [22.2-25.1] 21.4  [17.9-24.9] 15.1  [ 7.2-23.1] 
  Two and over 62.4   [60.0-64.9] 64.7  [60.4-70.0] 75.7  [63.6-87.7] 
Total number of visit 
medications 
 4.6    [ 4.4- 4.8] 5.9  [ 5.6 - 6.3]  6.3  [ 5.7- 6.8] 
Number of visits last year  4.7    [ 4.4- 4.9] 5.2  [ 4.6- 5.7]  4.9  [ 3.7- 6.1] 
Reported Household income    
  Below $ 40,627 44.3   [40.0-48.6] 50.0  [43.8-56.1] 56.1  [41.1-71.1] 
  $ 40,627 and over 55.7   [51.4-60.1] 50.0  [43.9-56.2] 43.9  [28.9-58.9] 
Insurance Type    
  private insurance 15.7   [13.9-17.5] 16.0  [12.6-19.4] 21.4  [10.2-32.5] 
  Medicare/Medicaid 82.8   [80.8-84.7] 82.3  [78.9-85.7] 77.8  [66.8-88.9] 
  Else  1.5    [ 1.1- 2.0] 1.7  [ 0.6 - 2.9]  0.8  [ 0.0- 1.7] 
Practice Characteristics Among Visits 
PCMH Level     
  Not accredited 58.0   [53.2-62.8] 53.0  [46.6-59.4] 55.5  [40.0-71.0] 
  Level 1  14.7   [11.8-17.5] 16.5  [11.7-21.4]  9.6  [ 1.1-18.1] 
  Level 2 10.5   [ 7.8 -13.2] 12.2  [ 7.1-17.2] 14.0  [ 4.6-23.4] 
  Level 3 16.8   [13.7-20.0] 18.3  [14.1-22.6] 20.9  [ 7.9-33.9] 
Region    
  Northeast 15.8   [12.6-19.0] 11.8  [ 7.7-15.9] 15.3  [ 4.3-26.3] 
  Midwest 25.0   [19.8-30.1] 23.3  [16.5-30.0] 16.9  [ 6.3-27.5] 
  South 38.5   [32.8-44.0] 45.5  [36.4-54.6] 48.0  [31.9-64.1] 
  West 20.7   [17.0-24.5] 19.4  [13.0-25.8] 19.8  [ 9.0-30.6] 
Metropolitan Statistical Area    
  No 13.0   [ 5.9- 20.1] 13.9   [ 5.1-19.9] 11.5  [ 1.8-21.2] 
  Yes 87.0   [79.9-94.1] 86.1  [77.4-94.9] 88.5  [78.8-98.2] 
Type of Practice    
  Solo 31.4   [27.7-35.2] 68.0  [62.3-73.7] 55.3  [40.9-69.7] 
  Group practice 68.6   [64.8-72.3] 32.0  [26.3-37.7] 44.7  [30.3-59.1] 
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Type of Physician 
  Doctor of Medicine 94.6   [93.3-95.9] 94.6  [92.4-96.9] 97.5  [95.1-100.0] 
  Doctor of Osteopathy 5.4    [ 4.1- 6.7] 5.4  [ 3.1 - 7.6]  2.5  [ 0.0 - 4.9] 
Physician Specialty Group 
  Primary Care Specialty 47.3   [43.4-51.1] 55.1  [49.8-60.4] 48.4  [33.3-63.4] 
  Surgical Care Specialty 21.4   [19.1-23.8] 16.5  [13.3-19.8]  6.7  [ 2.2 -11.1] 
  Medical Care Specialty 31.3   [28.1-34.5] 28.4  [23.5-33.3] 44.9  [30.0-59.8] 
Employment Status of 
Physician 
   
  Owner 73.9   [69.7-78.1] 72.4  [66.1-78.6] 76.3  [63.6-89.0] 
  Employee or Contractor 26.1   [21.9-30.3] 27.6  [21.4-33.9] 23.7  [11.0-36.4] 
(Source: NAMCS 2009-2010) 
Data reported as mean or proportion (%). Estimates of means and proportions are based on patient visits 
in U.S. Reported Estimates at top of table represent: 
(1) Weighted estimate of % of visits recording age 65 and over, at least have one medication record, 
(2) Weighted estimate of % of visits recording age 65 and over, at least have one medication record with 
HRM, 
(3) Weighted estimate of % of visits recording age 65 and over, at least have one medication record with 
DDIS. 
a Original unweighted sample size of visits= 13,156;  
b Original unweighted sample size of visits with HRM=1,320;  
c Original unweighted sample size of visits with DDIS= 135. 
  
1 For the target population and HRM, 13 different types of chronic conditions were included. These 
chronic diseases included Arthritis, Asthma, Cancer, Cerebrovascular disease, Chronic renal failure, 
Congestive heart failure, Chronic obstructive pulmonary disease, Depression, Diabetes, Hyperlipidemia, 
Hypertension, Ischemic heart disease, and Osteoporosis. For individuals with DDIS, 3 chronic conditions 
were excluded from the sum (i.e., Chronic Renal Failure, Depression, and Osteoporosis).   
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Table 3.2 Ten Most Commonly Administered High Risk Medications in Visits (Among the Target Population)  
Medication Total 
Estimated  
Number of 
Visits 
where the 
Rx were 
Used 
Continued 
Medication (%) 
New Medication 
(%) 
Blank    (%) % of 
Visits 
95 % CI 
Acetaminophen-Propoxyphene 
Napsylate 
7,187,089   5,573,347 (77.0) 1,613,742 (22.3)   53,464  (0.7) 15.0 11.9-18.6 
Conjugated estrogens  6,563,599   6,045,738 (91.5)    517,861 ( 7.8)   40,483  (0.6) 13.6 11.1-16.7 
Nifedipine  5,809,907  5,489,176 (92.3)    320,731 ( 5.4) 137,842  (2.3) 12.3  9.4-15.9 
Cyclobenzaprine  5,111,934   3,758,842 (73.4) 1,353,092 (26.4)      9,058  (0.1) 10.6   8.4-13.2 
Diazepam  3,012,241   2,318,850 (73.9)    693,391 (22.1)  124,652  (4.0)   6.5   4.4 -9.5 
Nitrofurantoin macrocrystals  2,347,120   1,733,868 (68.2)    613,252 (24.1)  193,761  (7.6)   5.2   4.0 -6.9 
Diphenhydramine  2,475,483   1,867,297 (74.7)   608,186 (24.3)  24,012  (1.0)   5.2 3.6 -7.4 
Thyroid desiccated  1,450,073   1,450,073 (86.8)    N/A        (0.0) 220,295 (13.2)   3.4 2.4 -5.0 
Hydroxyine hydrochloride  1,701,400   1,390,988 (78.3)    310,412 (17.5)   75,349  (4.2)   3.7   2.5 -5.3 
Dicyclomine  1,536,760   1,156,656 (75.3)    380,104 (24.7)     N/A    (0.0)   3.2   2.1 -4.7 
      (Source: NAMCS 2009-2010) 
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Table 3.3 Ten Most Commonly Administered DDIS combinations in Visits (Among the Target Population with specific diseases, 
including Fall/Hip Fracture, Dementia, and CKD) 
Medication Total Estimated  
Number of Visits 
where the Rx 
were Used 
Identify as 
Continued 
Medication (%) 
Identify as New 
Medication (%) 
Blank 
(%) 
% of 
Visits 
95 % CI 
Quetiapine +Fall/Hip Fracture 712,276 611,980 (85.9) 100,296 (14.1) N/A (0.0) 16.7 9.1-28.6 
Tolterodine +Dementia 592,925 566,374 (95.5) 26,551 (4.5) N/A (0.0) 13.9 7.7-23.8 
Zolpidem +Fall/Hip Fracture 385,001 309,055 (80.3) 25,508 (6.6) 50,438 (13.1) 9.0 4.8-16.3 
Cyclobenzaprine+ Dementia 371,237   183,038 (49.3)  188,199 (50.7) N/A (0.0) 8.7 2.9-23.1 
Naproxen + CKD 288,075 137,733 (47.8) 150,342 (52.2) N/A (0.0) 6.8 2.2-19.0 
Olanzapine +Fall/Hip Fracture  241,652 201,997 (83.6)  39,655 (16.4) N/A (0.0) 5.7 2.5-12.1 
Oxybutynin + Dementia 199,857 199,857 (100.0) N/A (0.0) N/A (0.0) 4.7 1.8-11.4 
Ibuprofen + CKD 160,949 69,069 (42.9)  91,880 (57.1) N/A (0.0) 3.8 1.2-11.4 
Risperidone + Fall/Hip Fracture 160,592   133,852 (83.3)  26,740 (16.7) N/A (0.0) 3.8 1.6-8.9 
Celecoxib + CKD 143,038 143,038 (100.0) N/A (0.0) N/A (0.0) 3.4 1.1-9.8 
(Source: NAMCS 2009-2010) 
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Table 3.4 Weighted Multiple Imputation Estimates of Bivariate Associations Between Patient 
and Practice Variables and Use of HRM/ DDIS  
 HRM DDIS 
Patient Characteristics OR 95 % CI OR 95 % CI 
Age (referent: 65-74 years)  Wald X2 (1)= 7.7, 
p<0.05 
  
  75 and older 0.80* 0.68-0.94 1.33 0.76-2.35 
Gender Wald X2 (1)= 57.6, 
p<0.05 
  
  Female 2.04* 1.70-2.45 1.39 0.87-2.34 
Race (referent: White) Wald X2 (2)= 3.59, 
p<0.05 
  
  Black 1.41* 1.05-1.91 2.06* 1.03-4.15 
  Others 0.70 0.41-1.17 1.34 0.37-4.89 
Number of Chronic Condition 
(referent: None) 
  Wald X2 (2)= 4.42, 
p<0.05 
  One 0.89 0.68-1.17 0.34* 0.16-0.71 
  Two and over 1.04 0.82-1.31 0.45* 0.21-0.97 
Number of Medication Use 
(referent: Two or Less Rx ) 
Wald X2 (2)= 35.06, 
p<0.05 
Wald X2 (2)= 3.82, 
p<0.05 
  3-6 Rx 1.9* 1.4-2.6 2.18 0.90-5.28 
  7-8 Rx 3.7* 2.7-5.1 3.09* 1.36-7.00 
Reported Household Income  
(referent: Income below $40,627) 
Wald X2 (1)= 8.67, 
p<0.05 
  
  $ 40,627 and over 0.77* 0.65-0.92 0.68 0.38-1.23 
Insurance Type (referent: Private 
insurance) 
    
  Medicare/Medicaid 0.97 0.78-1.20 0.46 0.19-1.09 
  Else 1.06 0.57-1.99 0.35 0.08-1.45 
Practice Characteristics     
PCMH Level (referent: Not accredited)     
  Level 1  1.27 0.94-1.71 0.72 0.29-1.81 
  Level 2 1.31 0.89-1.92 0.66 0.35-1.24 
  Level 3 1.22* 1.01-1.47 0.98 0.51-1.90 
Region (referent: Northeast) Wald X2 (3)= 2.97, 
p<0.05 
  
  Midwest 1.27 0.88-1.85 0.58 0.26-1.30 
  South 1.67* 1.16-2.42 1.16 0.63-2.14 
  West 1.28 0.87-1.89 0.91 0.46-1.78 
Location of practice (referent: Non-Metropolitan Statistical Area) 
  Yes 0.92 0.67-1.26 0.91 0.50-1.67 
Type of Practice (referent: Group 
practice) 
    
  Solo 1.03 0.84-1.27 1.42 0.85-2.35 
Type of Physician (referent: Doctor of Medicine) 
  Doctor of Osteopathy 1.01 0.69-1.46 2.07 0.69-6.26 
Physician Specialty Group  
(referent: Surgical Care) 
Wald X2 (2)=10.35, 
p<0.05 
  
  Primary Care Specialty  1.58* 1.30-1.94 0.97 0.44-2.12 
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  Medical Care Specialty 1.19 0.94-1.51 1.11 0.53-2.36 
Employment Status of Physician (referent: Owner) 
  Employee or Contractor 1.09 0.89-1.35 0.99 0.52-1.89 
(Source: NAMCS 2009-2010) 
Note. * p<0.05 
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Table 3.5 Final Weighted Multiple Imputation Estimates of Odds Ratios in Logistic 
Regression Models for the Probability of HRM or DDIS 
 HRM DDIS 
Parameter OR 95 % CI p-
value 
OR 95 % CI p-
value 
Age  0.98 0.97-0.99 <0.001 1.02 0.99-1.06 0.223 
Gender       
  Female 2.00 1.64-2.43 <0.001 1.26 0.74-2.14 0.395 
Race (referent: White)       
  Black 1.22 0.94-1.60  0.140 1.95 0.94-4.07 0.075 
  Others 0.78 0.46-1.31  0.350 1.91 0.54-6.78 0.316 
Number of Chronic Condition (referent: None) 
  One 0.72 0.54-0.96  0.026 0.81 0.30-2.21 0.679 
  Two and more 0.62 0.48-0.80 <0.001 0.23 0.08-0.67 0.008 
Reported Household income (referent: Income below $40,627) 
  $ 40,627 and over 0.86 0.70-1.05  0.143 0.74 0.37-1.47 0.390 
Total number of past visits 1.02 1.00-1.03  0.005 0.99 0.92-1.07 0.866 
Total number of visit medications 1.26 1.20-1.32 <0.001 1.27 1.12-1.45 <0.001 
Insurance Type (referent: Private Insurance) 
 Medicare/Medicaid 0.92 0.74-1.15  0.457 0.38 0.15-0.96 0.041 
 Else 1.17 0.63-2.17  0.613 0.24 0.05-1.18 0.079 
PCMH (referent: Not accredited)       
  Level 1  1.20 0.86-1.69  0.280 0.90 0.30-2.74 0.855 
  Level 2 1.10 0.77-1.55  0.617 0.85 0.40-1.81 0.679 
  Level 3 1.18 0.96-1.45  0.108 0.96 0.44-2.11 0.928 
Region (referent: Northeast)       
  Midwest 1.10 0.76-1.58  0.617 0.69 0.26-1.84 0.454 
  South 1.59 1.06-2.39  0.025 1.27 0.64-2.53 0.492 
  West 1.30 0.88-1.93  0.185 1.02 0.48-2.13 0.966 
Metropolitan Statistical Area       
  Yes 1.07 0.81-1.41  0.640 0.90 0.44-1.83 0.764 
Type of Practice (referent: Group practice) 
  Solo 1.08 0.88-1.34  0.457 1.53 0.78-3.01 0.221 
Type of Physician (referent: Doctor of Medicine) 
  Doctor of Osteopathy 1.04 0.74-1.48  0.811 1.67 0.52-5.51 0.378 
Physician Specialty Group (referent: Surgical Care Specialty) 
  Primary Care  1.27 1.05-1.53  0.016 0.85 0.32-2.27 0.743 
  Medical Care Specialty 0.94 0.74-1.19  0.596 0.94 0.37-2.37 0.887 
Employment Status of Physician (referent: Owner) 
  Employee or Contractor 0.92 0.75-1.12  0.404 1.38 0.63-3.03 0.416 
(Source: NAMCS 2009-2010) 
Results of the final logistic regression model provide adjusted ORs for associations between 
variables of interest and HRM/DDIS prescription. The Archer-Lemeshow goodness-of-fit 
statistics range from 0.31-0.59 (p value= 0.81-0.97) for HRM and 0.54-1.96 (p value =0.05-
0.84) for DDIS, suggesting that the models fit well across the imputed datasets.  
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CHAPTER IV. PAPER 3: DOES THE EXTENT OF PATIENT CENTERED MEDICAL 
HOME ADOPTION REDUCE THE OCCURRENCE OF ADVERSE DRUG EVENTS? 
Introduction 
Adverse drug events (ADEs) pose a large risk to patient medication quality of care and have 
been regarded as one of the most important patient safety and public health concerns in today’s 
healthcare system.1 ADEs are simply defined as injury resulting from medication intervention 
related to a drug.2 ADEs can occur in either the medication use process (i.e., prescribing, 
dispending, administering, or monitoring) or as a result of an undesirable clinical manifestation 
that is consequent to and caused by the administration or omission of medication. Previous 
studies have indicated that ADEs are extremely common in medical practices.2,3 For example, 
the prevalence of ADEs is known to be high in both ambulatory care as well as inpatient care, 
with median ADE prevalence rates of 20% and 50%, respectively.4 To further illustrate the scope 
of ADEs, another study focused on inpatient care reported that the annual ADE-related 
emergency department and inpatient visits were estimated to be 700,000 and 120,000, 
respectively.5 Most ADE-related studies have been conducted in the in-patient setting and 
additional research is needed in the ambulatory setting. In addition, ADEs affect individuals at 
all ages whenever the treatment of disease condition involves medication use.6,7 Yet, the 
 153 
 
youngest (0 to 4 years old) and oldest (age 65 years old) individuals are the most vulnerable 
populations to the adverse outcomes of ADEs.8,9  
The high prevalence of ADEs is of concern not only because of their impact on health but 
also because of their contribution to higher overall healthcare costs including hospitalizations 
and prolonged hospital stays.10-12 National surveillance data have shown that ADEs account for 
$3.5 billion spent on extra medical expenditures annually.13 The financial impact of ADEs even 
influences indirect healthcare costs, such as lost productivity.14-16 Given the large and ever-
increasing magnitude of the development of new medications, discovery of new uses for older 
medications, the rising aging population, the demand of using medications for disease 
prevention, and increased coverage for prescription medications in the U.S., ADEs represent a 
major public health challenge.17 
The growing concern about ADEs has caused both government institutions and professional 
organizations to seek a reduction in ADE prevalence through the development of national ADE 
Action Plan as well as prioritizing healthcare delivery strategies for their prevention.1,13 Despite 
the need to prevent ADEs, few studies have investigated individual-level characteristics 
associated with their occurrence. In the limited literature available, studies have reported that 
patients with a greater amount of medication use,8,9,18 being of older age,8,19 being female,8 and 
having cognitive disability19 were more likely to experience ADEs. Surprisingly, no studies have 
considered whether the occurrence of ADEs can be reduced in response to the transformation of 
healthcare settings, in which promising new models of integrated delivery services have emerged 
for ensuring quality of care. One such model is the Patient-Centered Medical Home (PCMH). 
The PCMH is defined as a model or philosophy of primary care that is patient-centered, 
comprehensive, team-based, coordinated, accessible, and focused on quality safety by the 
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Patient-Centered Primary Care Collaborative (PCPCC). With the adoption of the PCMH model, 
practices are expected to comprehensively improve access to care, quality of care services, and 
overall health care utilization.20 To be recognized as a PCMH practice, there are three common 
options through which practices can be certified, including the Accreditation Association for 
Ambulatory Health (AAAH), the Joint Commission, and the National Committee for Quality 
Assurance (NCQA).21 Among the options, the NCQA PCMH guideline is the most widely used 
voluntary program to evaluate the adoption of PCMH in the current literature.22  The NCQA 
PCMH guideline program has a complex scoring rubric that comprises different domains of 
evaluations and identifies three general levels in PCMH attainment of practices. When the level 
of achievement is high, the practice has a relatively more comprehensive care environment and is 
expected to offer a better quality of care, reduced cost of care, enhanced experience of care, and 
a better professional experience.  
         Previous PCMH related studies have demonstrated mixed results in terms of the impact of 
PCMH on healthcare utilization and quality improvement.23-25 A further weakness in the 
literature is the lack of comprehensiveness in terms of outcome assessment. In this regard, it is 
notable that the potential benefits of adopting PCMH in relation to the occurrence of ADEs 
remain largely unexplored. Given the efforts to reduce the incidence of ADEs, it is important to 
consider whether a reduction can be achieved in the context of PCMH adoption. This is because 
ADEs can be viewed as one of the significant health outcomes related to quality of medication 
use, which is consistent with the PCMH goal of improving the overall quality of care for 
patients.23  
         To our knowledge, no study has examined the value of PCMH adoption in relation to the 
occurrence of ADEs and the potential for reducing their numbers. To fill this void, the objective 
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of this study was to explore the association between the level of PCMH adoption and ADE 
prevalence. In order to have generalizable estimates, this study employed features of the NCQA 
PCMH recognition program and used a nationally representative database to investigate the 
influence of PCMH adoption on ADE-related visits. The study hypothesized that a higher level 
of PCMH adoption of practices will be associated with less frequently reported ADEs.   
Methods 
Study Design and Data Sources 
This study consists of cross-sectional analyses utilizing data from the National Ambulatory 
Medical Care Survey (NAMCS). The patient visit was the unit of analysis. The selection criteria 
for the sample of analysis included individuals of all ages who had at least one medication 
record. The study was approved by the Institutional Review Board of University of Michigan. 
The 2009 and 2010 NAMCS were the primary data sources. The NAMCS is a nationally 
representative survey, designed as a multistage probability sample survey with appropriate 
weighting methods. The weights are designed to produce national estimates of the provision and 
use of ambulatory medical care services in the United States. Non-federal employed office-based 
physicians are randomly selected to respond to the NAMCS questionnaires. The content of the 
NAMCS includes patient, clinical, and practice information for each selected visit and is 
classified into patient and physician related forms. The selection criteria for visits into this study 
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were that visits were for patients of all ages who had at least one medication record in the 
outpatient visit.26 
Measures  
Determining Level of PCMH Adoption   
The main variable of interest was the level of PCMH adoption in physician practices. Since 
no direct measure exists in the NAMCS to measure PCMH adoption, the 2009-2010 NAMCS 
data were mapped onto the 2008 NCQA PCMH guideline elements for PCMH recognition. This 
mapping technique involved two steps. The first step was to calculate the score of PCMH 
adoption that was determined by the practice characteristics on each patient visit.  That is, each 
patient-level/visit record was assigned to a practice-level PCMH adoption status, and the PCMH 
score was the same for all visits from the same practice. The scoring method was determined by 
a complex mapping approach based on a calculation method used in a previous study.27 In 
Hollingsworth’s study, the authors mapped the 2007-2008 NAMCS survey items to the NCQA 
PCMH guidelines, which contained detail scoring criteria to determine PCMH scores for primary 
care practices. This study further advanced Hollingsworths’ investigation by adding the must-
pass elements criteria to designate medical home scores. In the original NCQA PCMH 
guidelines, nine standards with thirty subsumed elements have specific points awarded. Ten out 
of thirty elements were designated as “MUST PASS” elements for the purpose of categorizing 
different levels of PCMH. However, not all elements could be mapped in NAMCS and some 
items were added or eliminated in the 2009 and 2010 NAMCS. This study first identified seven 
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standards with 15 elements of the NCQA PCMH standards that could be mapped in NAMCS 
2009, and six standards with 15 elements of the NCQA PCMH standards that can be mapped in 
2010 NAMCS. The unit of observation in NAMCS is patient visit, and the level of PCMH 
adoption that each patient visit was assigned was determined from the characteristics in each 
visit record. Each visit received a “passed” (1=yes) point for each measurable element and a 
cumulative point total by summing points across all passed elements. A PCMH infrastructure 
score on each visit record was calculated by dividing its cumulative point total by the total 
number of available points, expressed as a percentage. The maximum denominators for this 
score were 55 points and 60 points in 2009 and 2010, respectively. The detailed mapping 
technique can be visualized in Appendix E.   
The second step to measure PCMH adoption was to categorize the level of PCMH. In the 
original NCQA PCMH guidelines, the scores and number of “MUST PASS” elements 
determined the levels of PCMH. The scores were then classified into four categories: not 
accredited (fewer than 25 percent of total points), Level 1 (25 to 49 percent of points and a pass 
on 5 of 10 MUST PASS elements), Level 2 (59-74 percent of total points and a pass on all 10 
MUST PASS elements), and Level 3 (points more than 75 percent and pass all 10 MUST PASS 
elements). Since not all the NCQA PCMH elements were included in the NMACS, this study 
defined the classification of the NCQA PCMH level recognition as follows: not recognized, 
(fewer than 25 percent of total points), Level 1 (25-49 percent of total points and a pass on 2 out 
of 4 MUST PASS elements), Level 2 (50-74 percent of total points and a pass on all 4 MUST 
PASS elements), and Level 3 (over 75 percent of total points and a pass on all 4 MUST PASS 
elements). The comparison between original NCQA PCMH criteria and the modified version 
based on NAMCS survey items is shown in Appendix E.   
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Defining Adverse Drug Events  
The outcome for this study was the occurrence of ADEs in a patient visit. To identify 
whether a patient visit in NAMCS involved ADEs, two approaches were used to code dummy 
variables (1 = yes, 0 = no) for each visit. Visits were identified as having ADEs if one of the 
approaches was confirmed. The first approach depended on a single question that physicians 
were instructed to mark: “whether this visit of the patient is related to adverse effect of 
medical/surgical care or adverse effect of medicinal drug.” The response was coded as yes or no. 
The second approach to identify whether the visit was ADEs related was determined by a review 
of diagnostic codes and reasons for visit codes. Since this study included all age levels for 
investigating ADE-related visits, all the diagnostics and reasons for visit codes that had been 
important in previous studies were used. For the diagnostic codes, the International Classification 
of Disease, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used as follows, 960-
979, (poisoning by antibiotics, sedatives and hypnotics, and poisoning by agents primarily 
affecting the cardiovascular system), 995 (unspecified adverse effect of unspecified drug, 
medicinal, and biological substance, anesthesia shock), 535 (aspirin gastritis), 692 (dermatitis 
due to drugs and medications in contact with skin), 693 (dermatitis due to drugs and medications 
taken internally), 779 (drug reaction in newborn), 292 (drug-induced mental disorders), 708 
(allergic uticaria), and 357 (polyneuropathy due to drugs). As to the reason for visit codes, if a 
patient’s visit was coded as 5905 (allergy to medication, anaphylactic shock, and bad reaction to 
prescribed medication), a visit was viewed as related to an ADE. In summary, if the single 
question or an ICD-9 code indicated an ADE, the visit was coded as 1=yes. If not, the visit was 
coded as 0=no.  
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Other Covariates  
Based on the proposed merged theoretical model (i.e., the Wagner’s chronic care and the 
Hogg’s primary care organization model), this study examined the impact of PCMH adoption  
(i.e., process of care) on quality (i.e., the occurrence of ADEs represented medication-related 
outcomes) and other covariates are necessary to be included.   
  Previous ADE-related studies showed that several patient characteristics are significantly 
associated with the occurrence of ADEs.4 Therefore, the following variables were considered in 
this study:  age, gender (female/male), race (White/Black/Other), number of chronic disease 
(sum of fourteen chronic conditions including arthritis, asthma, cancer, cerebrovascular disease, 
chronic renal failure, congestive heart failure, chronic obstructive pulmonary disease, depression, 
diabetes, hyperlipidemia, hypertension, ischemic heart disease, obesity, osteoporosis), number of 
medications used (sum of up to 8 listed medications), number of past visits in last year, 
household income in patient’s zip code, and primary payment for visits (Private insurance 
/Medicare/Medicaid/Others).   
In addition, the modified theoretical model also included practice structure as an indirect 
effect on outcome. Therefore several physician and practice related variables were used in this 
study for representing the structure domain, such as physician specialty group (Primary care 
specialty/Surgical care specialty/Medical care specialty), physician employment status 
(Owner/Employee/Contractor), physician type (Doctor of Medicine/Doctor of Osteopathy), 
practice type (Solo/Non Solo), region (Northeast, South/ West/ Midwest), and metropolitan 
status (Metropolitan Statistical Area/non- Metropolitan Statistical Area). 
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Statistical Methods 
 All analyses used appropriate NAMCS sampling weights to compute unbiased population 
estimates of the descriptive and regression parameters of interest. Codes in the NAMCS public-
use data sets identifying sampling strata and sampling clusters were also employed in all 
analyses to compute appropriate design-based estimates of standard errors for the weighted 
estimates.  Some variables were missing about 50% of their values, and multiple imputation by 
chained equations was used to provide more statistical power to analyze the relationships of 
interest.39 These imputations generated five completed data sets with all missing values imputed 
based on other observed variables. The five completed sets of analyses were combined with the 
original data set to generate a final overall set of multiple-imputation estimates for each analysis. 
 Descriptive statistics were used to determine the proportion of patient visits with 
occurrence of ADEs. Chi-square tests and Wald tests were employed to test the bivariate 
association between the dichotomous outcomes (i.e., ADE) and patient/provider characteristics. 
Multivariate logistic regression was used to examine the association between PCMH adoption 
and experiencing an ADE, controlling other covariates. The Archer–Lemeshow goodness-of-fit 
tests were used to detect whether the model is a good fit or not. Since the analysis is survey-
based, the -svy- commands in Stata version 13.0 were used for all analyses.  
This study took missing data into account. About 50% of the patient visits had complete 
data for all the individual analysis variables. Multiple imputations by chained equations was used 
for imputing the missing data and aimed to provide more statistical power.28 The Stata 
commands - mi impute chained- were used to perform the multiple imputations. Five imputed 
datasets offered an opportunity to adjust the missing information for each analysis.28     
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Results 
The original NAMCS data contain information for a total of 63,150 sampled outpatient 
clinic visits, which are representative of 2,046,598,491 ambulatory visits during 2009 and 2010. 
Of these visits, 46,641 outpatient clinic visits met the inclusion criteria, and this sample provided 
population estimates for 85 million outpatient ADE-related visits, accounting for 4.2% during 
2009 and 2010. The majority of ADE visits were identified via the ICD-9 codes.  
As to characteristics of the visits with an ADE (Table 4.1), the majority of the visits were by 
adults between the ages of 18 and 64 years (51.2%; CI: 47.9-54.5%), women (62.7%; CI: 59.9-
65.5%), persons who were white (82.3%; CI: 79.3-85.2%), those with one and more chronic 
diseases (51.6%; CI: 45.9-57.1%), those with three or more medication records (52.3%; CI: 48.3-
56.2%), those with one or two patient visits last year (32.1%; CI: 29.2-35.1%), those with 
income $40,627 and over (55.8%; CI: 50.9-60.6%), and those with private insurance (55.6%; CI: 
52.2-59.0%). Considering the system-level characteristics (Table 4.1), the majority of ADEs 
occurred in not accredited PCMH practices (57.8%; CI: 53.6-61.0%), practices resided in the 
South (34.9%; CI: 28.9-40.9%), practices located in metropolitan area (86.9%; CI: 79.5-94.3%), 
practices recognized as group practice (66.3%; CI: 61.8-70.9%), where physician type was 
Doctor of Medicine (94.9%; CI: 93.1-96.7%), where physician specialty group was primary care 
(59.7%; CI: 54.9-64.5%), and where physician employment status was owner (66.8%; CI: 61.4-
72.1%). Approximately 60% of ADEs was due to drug dermatitis and rash or spontaneous 
ecchymosis, whereas the remaining ADEs visits were related to aspirin gastritis, drug 
neuropathy, or unspecified medicinal substance use (Table 4.2).        
The multiple imputation estimates of bivariate associations between level of PCMH, 
patient-level characteristics, system-level characteristics, and the exposure of ADEs are shown in 
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Table 4.3. The Wald tests show that patient age (less than 18-years-old), gender (female), 
number of chronic conditions (fewer), physician with Doctor of Osteopathy degree and primary 
care physician during a patient visits were significantly associated with a higher risk of having 
ADEs. The level of PCMH, however, did not demonstrate a significant bivariate association with 
the occurrence of ADEs during a patient visit.   
 According to the final multiple imputation estimates of the logistic regression model 
coefficients and the adjusted odds ratios (AORs) for ADE-related visits, the level of PCMH was 
not associated with the odds of the patient visits involving ADEs when adjusting for the other 
covariates (Table 4.4). Patient visits where the gender was female (AOR = 1.20; CI = 1.06-1.36), 
being black (AOR = 1.25; CI = 1.05-1.49), having more medication records (AOR = 1.05; CI= 
1.01-1.08), being seen by Osteopathy physicians (AOR = 1.35; CI = 1.00-1.81) or being seen by 
primary care physicians (AOR = 1.45; CI = 1.13-1.86) were significantly associated with a 
greater odds of having an ADE-related visit. Visits where the patients had more than two 
coexisting chronic conditions (AOR = 0.63; CI= 0.52-0.76) or with other insurance coverage 
(AOR = 0.74; CI = 0.57-0.95) were significantly less likely to involve ADEs. The Archer-
Lemeshow tests for all five imputed data sets demonstrated good fits of the model. The test 
statistics range between 1.12 and 1.50 and the p-values of these five tests were all greater than 
0.05.  
Sensitivity analyses were used to examine whether different PCMH categorizations and 
physician types substantially changed the results of the predictive models. Specifically, two 
analyses were done. First, the PCMH categorization was re-categorized, using the Hollingsworth 
Et al. approach (i.e., without having must pass criteria) as well as dichotomizing it into a binary 
variable, i.e., meeting none versus meeting some PCMH criteria. Second, the visits included in 
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the analyses were limited to visits with primary care physicians. The results of the sensitivity 
analyses did not show substantial changes, and the results for primary analysis are presented.  
Discussion 
 The negative effects of ADEs have already become a major public health concern, 
prompting efforts to reduce ADE occurrence and investigate factors that influence the onset of 
ADEs. In an effort to contribute to the strategies to address the issue, this study is the first to 
explore whether higher adoption of PCMH would impact the prevalence of ADEs-related patient 
visits. After adjusting for both individual and practice level characteristics, the adoption of 
PCMH was not associated with whether a visit was ADE-relate. The study further found that 
other covariates, including patient gender, race, medication records, chronic condition status, 
insurance type, and physician specialties types were significantly associated with the odds of 
experiencing an ADE-related visit. 
Although this study found no association between the adoption of PCMH and individuals 
having an ADE-related visit, the findings here are consistent with the results of our previous 
work (Chapter 3) and three other studies, where receiving care in a PCMH was not associated 
with better process or outcomes of care.29-31 These previous, consistent findings give rise to 
concerns regarding the effectiveness of PCMH adoption on patient quality of care. Particularly, 
these studies employed various quality of care measures, such as vaccination rates among 
children, pap smear rates among eligible women, HbA1c values among patients with diabetes, 
blood pressure rates among patients with hypertension, and patient with inappropriate medication 
use, and none of the measures were significantly improved. The findings of this study are 
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consistent, in that this healthcare reform model was not associated with an the expected 
reduction in prevalence of ADE-related visits   
Three reasons may explain the unexpected results. The first is related to the definition of 
what a PCMH means for practices. Although previous studies have shown that the NCQA 
PCMH recognition program is the most common approach to evaluate the delivery services that 
practices can provide, some studies have criticized the measurement of this NCQA PCMH 
recognition program.32,33 Ho Et al. viewed the NCQA PCMH recognition program as costly, 
requiring excessive documentation, and imposing rigid structural and process requirements for 
practices, especially for smaller practices that face more financial and personnel pressure to 
achieve NCQA PCMH recognition. The authors stated that the NCQA PCMH recognition 
program overemphasized documentation (which cannot be equated with the actual services that 
practices can offer), forms (which do not capture the patient-centered collaborative care), and 
technology (which does not correspond to utility and distracts physicians from patient care). 
They suggested a better way to measure PCMH attainment, such as using patient experience of 
care, population health and costs.34-36 The issues surrounding technology have also been explored 
by Miller Et al., who also concluded that the NCQA PCMH recognition program only partially 
recognized the innovation of practices related to information technology (i.e., the adoption of 
electronic medical system) and overlooked the importance of other significant elements that are 
emphasized in the Joint Principles, such as team-based care or the incentives.33 In other words, 
the 2008 NCQA PCMH measure that was used in this study may not adequately represent care 
provided in a PCMH.   
 The second reason that could explain these discouraging results is the mapping technique 
of NCQA PCMH recognition program to the NAMCS. As described in the methods section, 
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some elements of PCMH could be fully captured due to the data limitation, such as referral 
tracking and advanced electronic communication elements. This unavoidable pitfall may lead to 
concerns in terms of comprehensive assessment of the PCMH components. The final explanation 
for the lack of association between the adoption of PCMH and the reductions in rates ADEs may 
be attributed to the overly broad definition of ADEs. This study defined the occurrence of ADEs 
as including heterogeneous event types, such as healthcare-acquired infections, fall-related 
injuries, and postoperative complications. This broad definition may have led to the inclusion of 
events that should have been excluded, thus decreasing the sensitivity to detect ADEs of relevant 
interest. For example, one previous study recommended that if the aim of patient safety 
interventions is to decrease the onset of ADEs, it is necessary to measure specific ADEs instead 
of identifying all sorts of ADEs.37 However, targeting at specific ADEs requires relatively larger 
amount of sample which was the limit of this study.  
Indeed, despite the results presented here, a growing number of PCMH demonstration 
projects have shown improvements in patient medication quality and safety via the involvement 
of medication experts, such as pharmacists, to the PCMH collaborative team. However, these 
studies did not focus on the outcome of patient safety in medication use.38-50 Furthermore, no 
previous study has explored the medication outcomes, such as high risk medication or drug-
disease interaction conditions, for patients receiving care under the PCMH context. This study 
was based on the hypothesis that PCMH will benefit patients, particularly on the basis of 
providing better quality of care.51 Yet, the assumption may be too optimistic regarding the 
influence of the PCMH model. One explanation is because the original PCMH has been focused 
on the quality of disease management rather than the outcomes of medication safety efforts. 
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Overall, this study suggests that there remains a need to be vigilant about medication use 
and safety, as 4% of visits were related to an ADE. This finding is particularly important, given 
the ever increasing complexity of care for patients, as new diagnoses, tests, and medications and 
new types of errors and harms are emerging.52 Opportunities for other non-physician medication 
experts, such as pharmacists, to actively participate in the PCMH team to ensure the medication 
safety may be needed within the PCMH model. 
Future studies may undertake more in-depth investigations through two approaches. First, 
studies could examine the association between PCMH sub-elements and the occurrence of 
ADEs. This would be valuable for stakeholders or researchers who need to be aware of which 
the piece of the PCMH infrastructure may actually improve patient medication use outcomes. 
Second, studies could investigate more specific ADEs during patient visits in order to have a 
relatively targeted evidence-based intervention plan to ensure better patient medication safety.    
 The findings of this study should be considered in light of two limitations, which can 
mostly be attributed to the data constraints. First, the technique for mapping NCQA PCMH 
criteria to the 2009 and 2010 NAMCS was subjective and did not capture all the elements of 
PCMH due to the data limitation. Furthermore, the measures in the NCQA PCMH criteria 
stressed the importance of EMR, other significant components of PCMH were missing, such as 
collaborative and coordinated care. However, this mapping approach is the optimizing one at 
that point of time when using the 2009 and 2010 NAMCS data. Second, the definition of ADEs 
via the ICD-9-CM codes may not be comprehensive enough to detect all ADEs sine previous 
studies showed that the prevalence of ADEs is much lower via ICD-9-CM codes than via chart 
review or other approaches.4 More complex detection strategies appear to be needed to capture 
thoroughly the onset of ADEs, such as the use of chart reviews or voluntary reported from 
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clinicians. Despite the value of using other approaches to identify ADEs, this information 
cannot be found in NAMCS, which only records patient medication use, but lacks further 
detailed care records. Second, this analysis used a cross-sectional study design due to the design 
of NAMCS and causality cannot be inferred. A longitudinal study design may enable 
researchers to observe the trend of PCMH adoption as well as the occurrence of ADEs during 
the study period, yet this study design could not be done using the NAMCS datasets.   
Conclusion 
This study showed that 4.2% of patient visits or 85 million visits were defined as ADE related in 
ambulatory care settings in the United States. The adoption of the PCMH model was not 
associated with patient medication safety in the reduction of ADEs. Individual-level 
characteristics were found to have a greater impact than practice-level characteristics on the 
occurrences of ADE-related visits.  
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Table 4.1 U.S. Population Estimates of Visits Among 1 the Target Population, 2 ADE-related 
Visits during 2009 and 2010 
 Target Population 
(N=2,046,598,491)* 
(100 %) 
With ADEs 
(N=85,957,137)** 
(4.2 %) 
Patient Characteristics Proportion (%)  
[95 % CI] 
Proportion (%)  
[95 % CI] 
Age    
Less than 18 Years 16.9 [15.3-18.4] 21.1 [17.8-24.4] 
Between 18 and 64 Years 54.9 [53.4-56.4] 51.2 [47.9-54.5] 
65 Years and Over 28.3 [26.9-29.6] 27.7 [24.7-30.6] 
Gender   
Female 58.6 [57.7-59.5] 62.7 [59.9-65.5] 
Race   
  White 84.3 [82.6-86.1] 82.3 [79.3-85.2] 
  Black 11.4 [ 9.8-13.1] 13.5 [10.8-16.2] 
  Others 4.2 [ 3.6- 4.9] 4.2 [ 2.6- 5.8] 
Number of Chronic disease2   
  None 40.5 [38.9-42.1] 48.4 [44.7-52.1] 
  One 25.5 [24.6-26.4] 22.0 [19.8-24.1] 
  Two and over 34.0 [32.2-35.9] 29.6 [26.1-33.1] 
Total number medications of visits 
  One 29.8 [28.1-31.6] 28.3 [25.4-31.2] 
  Two 19.4 [18.5-20.2] 19.4 [17.0-21.8] 
  Three or more 50.8 [48.6-53.0] 52.3 [48.3-56.2] 
Number of visits last year   
  None 9.0 [ 8.4- 9.6] 8.5 [ 6.7-10.4] 
  Between 1 and 2 visits 32.2 [31.2-33.3] 32.1 [29.2-35.1] 
  Between 3 and 5 visits 30.6 [29.8-31.5] 31.8 [29.0-34.6] 
  6 Visits or over 28.1 [26.9-29.4] 27.5 [24.4-30.7] 
Reported Household income   
  Below $ 40,627 43.1 [39.2-46.9] 44.2 [39.4-49.0] 
  $ 40,627 and over 56.9 [53.1-60.8] 55.8 [50.9-60.6] 
Insurance Type   
  Private insurance 53.6 [51.7-55.6] 55.6 [52.2-59.0] 
  Medicare/Medicaid 39.6 [37.8-41.4] 39.6 [36.1-42.6] 
  Else  6.8 [  6.0- 7.5] 5.1 [ 3.8- 6.4] 
Practice Characteristics   
PCMH Level    
  Not accredited 57.3 [53.7-61.0] 57.8 [53.6-61.0] 
  Level  12.9 [10.9-14.9] 11.5 [ 8.7-14.3] 
  Level 2        10.3 [ 8.4-12.2] 10.3 [ 7.5-13.1] 
  Level 3 19.5 [16.7-22.2] 20.4 [16.3-24.5] 
Region   
  Northeast 17.4 [14.5-20.5] 17.5 [13.0-22.0] 
  Midwest 23.4 [19.0-27.8] 26.6 [21.0-32.2] 
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  South 38.7 [33.6-43.7] 34.9 [28.9-40.9] 
  West 20.5 [16.9-24.1] 21.0 [16.9-25.2] 
Metropolitan Statistical Area   
  No         12.3 [ 5.9-18.8]           13.1 [ 5.7-20.5]  
  Yes 87.7 [81.2-94.1] 86.9 [79.5-94.3] 
Type of Practice   
  Solo 31.0 [27.8-34.2] 33.7 [29.1-38.2] 
  Group practice 70.0 [65.8-72.2] 66.3 [61.8-70.9] 
Type of Physician   
  Doctor of Medicine 93.1 [91.7-94.5] 94.9 [93.1-96.7] 
  Doctor of Osteopathy 6.9 [ 5.5- 8.3] 5.1 [ 3.3- 6.9] 
Physician Specialty Group   
  Primary Care Specialty 59.8 [56.7-62.9] 59.7 [54.9-64.5] 
  Surgical Care Specialty 14.3 [12.7-15.8]  9.3 [ 7.2- 11.5] 
  Medical Care Specialty 26.0 [23.4-28.5] 30.9 [26.1-35.7] 
Employment Status of Physician   
  Owner 67.4 [64.0-70.7] 66.8 [61.4-72.1] 
  Employee or Contractor 32.6 [29.3-36.0] 33.2 [27.8-38.6] 
(Source: NAMCS 2009-2010) 
*original unweighted sample size of the patient visits n=46,641 
**original unweighted sample size of the patient visits with ADEs n=2,574 
Data are reported as mean or percentage (with 95 % CI) with survey weights incorporated. These 
are weighted Multiple Imputation Estimates of means and proportion of patient and practice 
characteristics for all target population office visits in U.S. from 2009-2010. 
1 Patient visit has at least one medication record.  
2 Overall, 13 different types of chronic conditions were included. These chronic diseases 
included Arthritis, Asthma, Cancer, Cerebrovascular disease, Chronic renal failure, Congestive 
heart failure, Chronic obstructive pulmonary disease, Depression, Diabetes, Hyperlipidemia, 
Hypertension, Ischemic heart disease, and Osteoporosis. 
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Table 4.2 Five Most Commonly Identified ADEs by ICD-9-CM code in the Population of Visits 
(Weighted MI Estimates) 
Symptoms ICD-9-
CM code 
Total 
Estimated 
Number of 
Patient Visits 
% of 
ADE 
Visits 
95 % CI 
Drug Dermatitis 629,623 27,039,685 31.7 23,008,590- 31,070,780 
Rash and Spontaneous 
Ecchymosis 
782 26,446,201 31.0 22,435,814-30,456,588 
Unspecified Adverse 
Effect of Medicinal 
Substance 
995 6,243,904 7.3 4,354,480 - 8,133,328 
Aspirin Gastritis 535 5,954,273 7.0 4,362,977 - 7,545,569 
Neuropathy due to Drugs 357 2,397,187 2.8 1,242,813 - 3,551,561 
(Source: NAMCS 2009-2010) 
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Table 4.3 Weighted Multiple Imputation Estimates of Bivariate Associations Between All 
Independent variables and ADE-related Visits during 2009 and 2010 
 ADE Visit 
Patient Visits Characteristics OR 95 % CI 
Age (referent: Less than 18 Years)**   
   Between 18 and 64 Years  0.73* 0.62-0.87 
   65 Years and Over  0.77* 0.64-0.93 
Gender*   
  Female   1.20* 1.06-1.35 
Race (referent: White)   
  Black   1.22* 1.02-1.46 
  Others 1.02 0.72-1.45 
Number of Chronic Condition (referent: None)**   
  One   0.71* 0.61-0.83 
  Two and over   0.72* 0.61-0.84 
Reported Household Income (referent: Income below $40,627) 
  $ 40,627 and over 0.95 0.83-1.09 
Insurance Type (referent: Private insurance)**   
  Medicare/Medicaid 0.96 0.83-1.10 
  Else   0.71* 0.55-0.93 
Practice Characteristics   
PCMH Level (referent: Not accredited)   
  Level 1  0.88 0.69-1.12 
  Level 2 0.99 0.79-1.24 
  Level 3 1.04 0.84-1.29 
Region (referent: Northeast)   
  Midwest 1.14 0.84-1.56 
  South 0.90 0.68-1.19 
  West 1.03 0.78-1.36 
Metropolitan Statistical Area   
  Yes 0.93 0.71-1.22 
Type of Practice (referent: Group practice)   
  Solo 1.14 0.96-1.35 
Type of Physician (referent: Doctor of Medicine)**   
  Doctor of Osteopathy  1.40* 1.04-1.87 
Physician Specialty Group (referent: Primary Care)**   
  Surgical Care Specialty  0.65* 0.52-0.81 
  Medical Care Specialty 1.20 0.98-1.49 
Employment Status of Physician (referent: Owner)   
  Employee or Contractor 1.03 0.85-1.25 
(Source: NAMCS 2009-2010) 
Note.  
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** The p-value of the Wald test is <0.05, meaning that the specific variable has significant association 
with ADE-related visits.  
* The p-value of the Design-based Rao-Scott Chi-square tests is <0.05, meaning the specific value of the 
variable has a significant association with ADE-related visits 
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Table 4.4 Final Weighted Multiple Imputation Estimates of Adjusted Odds Ratios in the Logistic 
Regression Model for ADE-related Visits 
 ADE-Visits 
Parameter OR 95 % CI p-
value 
Age  (referent: Age under 18 years)    
Between 18 and 64 years 0.79 0.66-0.96 0.924 
Age 65 and over 0.97 0.44-0.98 0.041 
Gender    
Female  1.20* 1.06-1.36 0.005 
Race (referent: White)    
Black  1.25* 1.05-1.49 0.012 
Others 1.00 0.69-1.43 0.984 
Number of Chronic Condition (referent: None)    
  One  0.69* 0.58-0.81 <0.000 
  Two and more  0.63* 0.52-0.76 <0.000 
Reported Household income (referent: Income below $40,627) 
  $ 40,627 and over 0.92 0.80-1.04 0.183 
Total number of past visits 0.99 0.98-1.00 0.264 
Total number of visit medications  1.05* 1.01-1.08 0.005 
Insurance Type (referent: Private Insurance)    
Medicare/Medicaid 0.89 0.74-1.06 0.152 
Else (Worker’s compensation, Self-Pay, Charity)  0.74* 0.57-0.95 0.022 
PCMH (referent: Not accredited)    
  Level 1  0.89 0.69-1.12 0.298 
  Level 2 0.94 0.74-1.20 0.630 
  Level 3 1.03 0.82-1.28 0.811 
Region (referent: Northeast)    
  Midwest 1.16 0.86-1.57 0.319 
  South 0.85 0.64-1.14 0.275 
  West 1.06 0.81-1.39 0.689 
Metropolitan Statistical Area    
  Yes 0.95 0.73-1.23 0.684 
Type of Practice (referent: Group practice)    
  Solo 1.19 0.99-1.44 0.060 
Type of Physician (referent: Doctor of Medicine)    
  Doctor of Osteopathy  1.35* 1.00-1.81 0.048 
Physician Specialty Group* (referent: Surgical Care)    
  Primary Care  1.45* 1.13-1.86 0.003 
  Medical Care Specialty  1.89* 1.40-2.56 <0.000 
Employment Status of Physician (referent: Owner)    
  Employee or Contractor 1.03 0.85-1.25 0.757 
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  (Source: NAMCS 2009-2010) 
The results of Archer-Lemeshow goodness-of-fit statistics for the completed five imputed data 
sets range from 1.12-1.50 and the p-values of these five tests were all greater than 0.05. These 
results suggest that the fits of all models were acceptable.  
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CHAPTER V. DISCUSSION 
 The objective of this dissertation was to evaluate primary care delivery and elucidate how 
PCMH has been adopted in practices and how their subsequent processes of care impact the 
quality of medication use. This dissertation aimed to quantify the association between the levels 
of NCQA PCMH recognition in primary care practices and the quality of care related to 
medication use. The central hypothesis of this dissertation was that a practice achieving higher 
levels of NCQA PCMH recognition, as determined by the NCQA PCMH scoring system, will 
offer better quality care and have higher levels of safe medication prescription, as determined by 
three medication quality indicators. 
 This dissertation was categorized into 5 chapters. Chapter 1 provided a complete review 
of the literature on medication quality and current understanding of PCMH. This review 
specifically included (1) analysis of current existing literature focused on quality, medication 
quality and an overview of the PCMH, and (2) identification of the gaps in our knowledge of the 
association between PCMH implementation and specific medication quality indicators. Chapters 
Two, Three, and Four presented three separate papers with different aims and each analysis 
contributed to the overall objective of the study. Although statistical analyses were conducted 
separately and reported in these different chapters, together the chapters aimed to assess the 
factors associated with the PCMH implementation and impact on patient medication use. The 
study in Chapter 2 applied the proposed PCMH framework to determine whether a significant 
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association existed between physician characteristics and PCMH implementation across the 
nation. Chapter 3 and Chapter 4 then examined whether adopting a PCMH model resulted in a 
noticeable improvement in quality of medication process and outcomes for individuals in the 
United States.   
The present chapter, which built on the results and conclusions from the previous three 
chapters, draws a picture of PCMH adoption and its association with medication quality of care. 
Specifically, this chapter consists of five sections. First, the gaps of past PCMH studies are 
presented. Second, a discussion of how the three chapters address the gap in PCMH knowledge 
is offered. Third, the overall findings of the present studies are compared to those of past 
literature. Fourth, the limitations of this dissertation are discussed. Lastly, the implications of 
these studies for research and policy as well as future research directions are described in detail.  
Gap in Current PCMH Research 
As discussed in the first chapter, numerous studies have emphasized the importance of 
patient medication quality of care and the impact of adopting PCMH for practices, yet three 
major limitations exist in the current literature. First, the approach of how PCMH adoption 
affects medication quality of care has not been examined. While many studies have demonstrated 
that receiving care in a PCMH can improve overall health services utilization, patient 
satisfaction, and some quality of care measures (e.g., having better rates of using preventive 
services, including cancer screening tests or seasonal flu shots),1-3 what remains largely 
unexplored is how and to what extent this promising patient care model can affect patients’ 
process-of-care and health outcomes related to medications. It is important to know whether this 
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promising patient care model can facilitate, ensure, and monitor medication quality of care. This 
process is particularly important if we consider that almost one-half of the U.S. population takes 
at least one medication and more than forty percent of adults age 65 and older use five or more 
different medications per week.4,5 Indeed, previous studies have shown that when medication 
experts, such as pharmacists, are involved in collaborative PCMH team care there is a positive 
impact on several medication-related clinical outcomes for patients with chronic diseases, such 
as an improvement in glycated hemoglobin (HbA1c) and low-density lipoprotein (LDL) tests, or 
blood pressure.6-10 Although PCMH studies of the above selected measures have indicated that 
patients did improve their clinical measures after taking medications, the studies were narrowly 
focused on patients with chronic diseases and failed to consider monitoring of direct medication 
use and medication use consequences.   
A second limitation of previous studies is related to where the data on PCMH adoption 
has been collected. Although PCMH can provide comprehensive, patient-centered, coordinated, 
and accessible care aimed at achieving meaningful quality improvements for patients and has 
become a hot topic in today’s healthcare delivery reform, most of the relevant literature is limited 
to state-level projects.11,12 In other words, most of the results in the current PCMH literature 
reflect only partial success of the implementation of PCMH with no comprehensive assessment 
across the nation. Chapter 1 revealed that nationwide assessments of the factors associated with 
PCMH adoption are lacking, yet PCMH is one of the significant tools of today’s Affordable Care 
Act. Few studies have evaluated PCMH adoption via a nationally representative database to 
clearly identify the extent of PCMH adoption.13-15 To our knowledge, only the paper by 
Hollingsworth Et al. employed and described how to use the NCQA PCMH recognition program 
to assess the adoption of PCMH practices across the nation.   
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A third limitation in previous studies is related to the comprehensiveness of examination 
of what factors might be associated with the adoption of PCMH. Most of the past studies have 
found that practice characteristics, such as size and type, have the most significant influence on 
the extent to which practices have transformed traditional care into a collaborative team-oriented 
care. Missing from these studies are practice-level characteristics and the characteristics of 
physicians who theoretically have a great capacity to determine the extent to which an 
organization (i.e., practice) can transform itself into a PCMH.  
Thus, these three limitations indicate clear gaps in the literature, that, if addressed, would 
offer a more comprehensive view of how the adoption of PCMH affects patient medication 
quality as well as what factors are associated with the practice decision-making in terms of 
transforming care into a PCMH at the national level. 
            In an attempt to more comprehensively examine PCMH adoption, this dissertation used a 
modified theoretical framework, considering two models from health services research, and 
applied these in three separate, but interrelated papers (Chapter 2, Chapter 3, and Chapter 4). The 
objectives of these three papers were to (1) explore the association between the level of PCMH 
adoption in a practice and its impact on processes and outcomes of care related to medication use 
and (2) quantify current primary care practices’ level of PCMH adoption and determine practice-
based and physician-related factors associated with the degree of PCMH implementation.  
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Filling the Gaps in Previous PCMH Research 
Proposed PCMH Framework  
            Past literature has centered on evaluating the implementation of PCMH via various 
avenues. However, there are missed opportunities in the exploration of PCMH adoption to 
improve medication-related quality of care as well as expanding our understanding what factors 
might influence the PCMH adoption. As discussed in detail in Chapter 1, Wagner’s Chronic Care 
Model serves as the central feature for the proposed framework, while the Hogg’s primary care 
model provides a more structured skeleton to interpret the effect of PCMH on medication quality 
of care. Combining these models offers a more complete theoretical framework to examine the 
PCMH infrastructure and impact on the delivery of care.  
The new theoretical framework is shown in Figure 1.1. In this combined model, the 
environmental, structural, and organizational factors of primary care are emphasized, and factors 
from different perspectives are classified into structural, performance, and outcome domains. For 
example, the original structural domain proposed by Hogg Et al. included three perspectives (1) 
health care system, (2) practice context, and (3) organization of the practice. Our study differs 
from Hogg’s original primary care model and investigates only the last two perspectives, which 
are viewed as the structural domain. As to the performance domain, the level of NCQA PCMH 
recognition will quantify the performance of each practice. Since the outcome domain was not 
proposed in Hogg’s primary care model, it was adopted from Wagner’s chronic care model. The 
outcomes of the newly proposed model were three medication use quality indicators. These three 
quality indicators were classified into two categories: (1) process of care, and (2) outcome of 
care. For medication process of care outcomes, the high-risk medication and drug-disease 
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interaction lists were selected to represent the extent of medication-related process of care. The 
occurrence of adverse drug events, on the other hand, was selected as the medication outcome 
quality.    
Overview of Findings 
 Factors Associated with PCMH adoption. In Chapter 2, the study used the structural 
domain of Hogg’s primary care model and merged it with the Roger’s diffusion of innovation 
theory to build a basic conceptual framework, aiming to explore the factors associated with the 
adoption of the PCMH. Based on the notion of diffusion of innovation theory (i.e., assuming that 
specific individual characteristics would affect the spread of new ideas) and the evidence from 
literature review, this study hypothesized that besides practice-level characteristics, physician-
related characteristics would play significant roles in the extent of PCMH adoption among 
practices.   
The classification of different levels of PCMH for practices integrated aspects from the 
NCQA PCMH recognition program and mapped it to the appropriate and available survey items 
listed in the NAMCS. This mapping technique was based on Hollingsworth Et al., the first paper 
to delineate the mapping procedures, including multiple imputations based on chained equations 
to correct for the item-missing data. This study advanced the previous work by updating the data 
sources as well as assigning more restrictive criteria (i.e., taking must-pass elements into 
account) to classify the different levels of PCMH. 
While applying design-based practice-level weights to the 2009 and 2010 NAMCS data, 
it was found that around 54% of practices were recognized as having some level of PCMH 
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implementation. Five physician characteristics (age, gender, employment status, specialty, and 
type) and six practice characteristics (region, metropolitan status, organizational structure, type, 
ownership, and size) were selected to examine the association with the level of PCMH adoption. 
The results showed that younger, male, primary care physicians and larger practices have higher 
odds of being associated with the PCMH adoption. The findings were consistent with the 
diffusion of innovation theory and previous work, wherein physicians with younger age, male, 
and belonging to larger practices had quicker adoption of new ideas. As to the type of physicians, 
this study indicated that primary care physicians were more likely to adopt the PCMH than 
specialties. One reason for explaining this phenomenon is because PCMH tends to be based on 
primary care settings rather than other specialty ones.   
Association Between PCMH and Medication Quality. Chapters 3 and 4 focused on the 
effect of the PCMH model on the process and outcome domains of care. The overall objective of 
these two chapters was to investigate whether the transformation of primary care (i.e., the extent 
to which practices adopt PCMH) would lead to better medication quality of care. The adoption of 
the PCMH model was expected to be associated with the extent to which practices improved 
their process of care for patients. To investigate this hypothesis and the hypothesis related to an 
improved outcome domain of the model, three medication-related indicators were chosen. The 
approach for defining the level of PCMH for practices is the same as that in previous chapter 
(Chapter 2).  
Using the 2009 and 2010 NAMCS data, Chapter 3 examined whether PCMH adoption 
would improve medication process of care quality using two well-representative medication 
quality of care indicators (i.e., high risk medication and drug-disease interaction).. The targeted 
population was limited to adults aged 65 and over because this population is likely to take 
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medications that allow the indication criteria to be met. With the appropriate patient visit 
weights, Chapter 3 demonstrated nationally representative results. Based on the sample of 13,156 
outpatient clinic visits, nearly 11% of older adult visits involved prescription of high risk 
medication, and approximately 15% of older adult visits involved drug-disease interactions, 
including the use of medications that should be avoided with diagnoses of dementia, falls or 
chronic renal failure. Contrary to the hypothesis, the level of PCMH was not associated with the 
odds of older adults visit having either high-risk medication or drug-disease interactions, while 
adjusting for the other covariates.  
Unlike practice characteristics, individual characteristics had an influence on the 
exposure to both high-risk medication and drug-disease interactions. For the high risk medication 
model, elderly visits where the patient was recognized as female, older, had more past visits, 
used more medications, lived in the southern region, and were seen by primary care physicians 
was significantly associated with inappropriate medications. For drug disease interaction lists, 
only two individual characteristics had a significant influence: the number of medication use and 
the number of chronic diseases. The results demonstrated that additional medication use or 
having fewer chronic diseases would increase the odds experiencing a drug disease interaction.  
Chapter 4 also showed similar findings. In Chapter 4, the aim was to assess whether the 
adoption of PCMH would reduce the occurrence of adverse drug events, which represented a 
proxy of medication outcome quality. The data resource (i.e., 2009 and 2010 NAMCS) was the 
same as in Chapter 3. The targeted population of this Chapter included a sample of all ages with 
those having at least one medication record. The results showed that 4.2% of patient visits were 
related to ADEs. Additionally, whether an ADE related patient-visit occurred in a PCMH or a 
non-PCMH practice setting did not show any significant associations, after controlling for other 
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covariates, including both practice-level and individual-level characteristics. The results of this 
chapter were also consistent with Chapter 3 in that individual-level characteristics were more 
significantly associated with the occurrence of ADEs. Patients’ gender female, being black, 
having more medication used, having fewer chronic conditions, and with insurance other than 
private or public were significantly associated with a greater odds of an ADE-related visit.  
Overall, neither analysis found a significant association between PCMH adoption and the 
selected medication process and outcome quality measures.   
Findings Compared to Past PCMH Research 
Findings across the chapters (2, 3, and 4) utilized two innovative approaches which have not 
been investigated in previous studies. The following paragraphs explain the approaches in two 
subsections, as in the previous section.   
Factors Associated with PCMH adoption. While previous studies centered on practice-
level characteristics to explain the extent to which practices adopt the PCMH model, Chapter 2 
offered a more advanced, theoretical, and behavioral-based approach to explore whether 
physician characteristics might also influence PCMH adoption among practices. First, this 
question has never been explored in previous studies, due in part to the restricted access to most 
of the physician-related variables in the NAMCS dataset. If researchers have an interest in 
investigating the physician-related variables, the process of applying for and gaining permission 
to access the variables and the data is quite burdensome. Second, the approach to explain the 
relation between physician characteristics and the adoption of PCMH is novel. None of the 
current literature has combined Hoggs’ primary care theory and Roger’s innovation of diffusion 
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theory to hypothesize that physician characteristic might play significant roles in the extent of 
PCMH adoption in practices (i.e., representing an acceptance of recent health reform) that they 
reside in. To explore more detail association between structure and process domains of the 
proposed conceptual framework, this study even used the diffusion effect within the diffusion of 
innovation theory to explain how the individual characteristics would have influence on adopting 
new ideas. This study did show that the results were consistent with what the diffusion of 
innovation theory hypothesized. And it is important to use a theoretical approach which may 
help further research to explain physician behavior by specifying relations among the selected 
variables.  
 
Association Between PCMH and Medication Quality. Compared to previous studies that 
have examined the association between the PCMH adoption and the quality of care that practices 
offered, the studies in Chapter 3 and 4 provided a relatively specific investigation of patient 
medication quality. Particularly, this study used the process and outcome domains in the 
conceptual theoretical framework to examine whether the transformation of PCMH among 
practices would affect the medication quality of care, using HRM, DDIS, and ADEs as 
examples. The findings of previous studies investigating the adoption of PCMH and its effect on 
improving quality of care have been mixed.16,17 Although it was anticipated that PCMH adoption 
would be associated with improved medication quality of care, the results presented in the two 
chapters did not support this conclusion. This discouraging outcome raises the concerns about 
how to improve patient health through better monitoring of medication use. In particular past 
studies have advocated two approaches to optimize patient medication quality of care: (1) the 
integration of comprehensive medication management under the PCMH model and (2) the 
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involvement of clinical pharmacists to be part of the PCMH team members to help patients 
engage in medication related issues. All of these studies demonstrated positive results.  
Two reasons might explain why the findings were inconsistent with previous studies. 
First, the analysis of medication management integration under the PCMH context was not 
comprehensive. Although several studies have indicated that a PCMH model could improve 
patient medication management, it benefits only specific patients, namely those who are not 
reaching their therapy goals, having trouble understanding/following medication regimen, or 
having frequent readmissions to the hospital.18-20 However, for those patients who do not belong 
to these vulnerable populations, there is no evidence.  
Second, the expansion of pharmacists’ roles in PCMH is still at a very early stage. Over 
the past decade, the pharmacists’ role has generally been shifting from traditional product-
oriented/dispensing activities to a boarder range of patient-centered services. Only in the last five 
years, with the emergence of the PCMH, has the door been opened in primary care to introduce 
patients to the financed roles for other non-physician disciplines to the patient care team, creating 
opportunities and a demand for pharmacists to be involved in patient quality of care to ensure 
safe, effective, and evidence-based medication use. During this time, pharmacists have begun to 
be regarded as significant medication gatekeepers for PCMH to optimize medication use.7 Yet, it 
appears that pharmacists’ efforts under the PCMH are still limited to a small number of tasks, 
including collaborative drug therapy management and medication therapy management for 
chronic diseases.7 What is not known is whether these activities are effective because previous 
studies have lacked thorough assessments of patient medication use on the basis of different 
types of quality indicators, such as those (i.e., high risk medication /drug-disease interaction lists 
and the occurrence of ADEs) used in this dissertation or recommended from previous literature.21 
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Overall, the results of this dissertation imply that there remain roles for pharmacists to participate 
in monitoring medication quality of care within the PCMH. 
Implications and Future Research 
This dissertation is one of the first studies following a theoretical model to explore physician-
related factors associated with the PCMH adoption and its impact on medication quality of care. 
Several significant implications have emerged from the findings of this dissertation and can be 
considered at both policy and practice levels.  
 Two take-away messages are important for policy makers. First, health policy makers 
should not abandon the PCMH. While the results of this study did not provide positive support to 
prove that PCMH was an effective model for controlling/enhancing the medication quality of 
care, the evidence only reflects that from the three medication quality measures. Other 
prevention and screening or disease specific quality measures, such as cervical cancer screening, 
breast cancer screening, adult BMI assessment, or disease modifying anti-rheumatic drug therapy 
for rheumatoid arthritis, should be examined for the effectiveness of PCMH.  
Second, the inclusion criteria or indicators to identify a PCMH may need to be 
reconsidered, especially in the context of its impact on medication use. For example, a criteria 
such as, “are medications reviewed by clinical pharmacist?” may be especially relevant in future 
work. The current NCQA PCMH criteria do not emphasize the quality of medication use in the 
list. Based on the results of this study, it is important to suggest that medication quality is still a 
concern for PCMH practices. The scenario might improve if the NCQA PCMH criteria clearly 
indicated the importance of medication quality in its definition of PCMH.    
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 As for practice, two significant implications are offered. First, there is a need to promote 
the PCMH adoption focusing on specific physician groups. Based on the results of this study, 
physicians of older age, being female, and identified as medical specialties in ambulatory care 
settings were less likely to adopt the PCMH. In order to increase the adoption of PCMH, 
healthcare organizations might design a practical incentive plan that targets these specific 
populations. Second, there is another need for improving medication use in the PCMH. This 
study did not find significant associations between the adoption of PCMH and specific 
medication quality measures. It is critical for medication experts, such as pharmacists, to design 
interventions for improving these quality indicators in PCMH practices. As well, it may be 
important to measure and provide incentives for these particular measures to facilitate their 
improvement. 
 For the future research, two directions can be pursued to expand the results of this 
investigation. The first is to acquire more information about physicians, such as their knowledge, 
skills, and attitudes toward supporting the adoption of PCMH. To determine physician attitudes 
toward the transformation of traditional care into a PCMH, smaller scale studies using qualitative 
methods need to be conducted. The findings of such studies could result in a deeper 
understanding of variation in PCMH adoption across different primary care settings.  
The second direction is to investigate whether the involvement of specific healthcare 
professionals can increase the PCMH adoption rate or the outcomes of care delivered in PCMH. 
This work is possible in the near future because, beginning in 2013, the NAMCS dataset 
included a series of checkboxes for interviewees (i.e., physicians) to indicate directly whether (1) 
their practices adopt PCMH and (2) the presence of any other non-physician professionals (e.g., 
pharmacists, nurse, and social workers) involved in care. This updated dataset may eliminate the 
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mapping bias that this study encountered and provide an opportunity to identify whether a more 
diverse collaboration with other health care professionals can facilitate PCMH adoption as well 
as offer better quality of care to patients.   
Limitations 
Similar to other studies, this dissertation has some limitations, which can generally be divided 
into design and data considerations. First, the design limitations of this dissertation include (1) 
cross-sectional study design, (2) the selection of the three medication quality indicators, and (3) 
the inclusion of physician characteristics in Chapter 3 and Chapter 4.  Indeed, there are 
limitations in using a cross-sectional study design, as it is impossible to make causal inferences. 
In future, the use of longitudinal surveys or study designs comparing pre-post study periods for 
the adoption of PCMH and medication use outcomes would provide an opportunity to identify 
trends in PCMH adoption. As well, results from a longitudinal study would reflect not only the 
scenario at a given time but allow investigators to observe changes over time. However, there are 
still advantages in conducting cross-sectional studies.  For example, it can (a) provide an 
indication of the magnitude of an issue because the data are often taken from the whole 
population, (b) include many outcomes and risk factors, and (c) be used for public health 
planning.22     
As mentioned earlier, HRM, DDIS, and ADEs were chosen to represent medication 
process and outcome indicators. The choice of the three indicators may have resulted in selection 
bias, as they are only a subset of the many medication indicators that can be used to examine the 
provision of medications in the context of a PCMH. Other medication-related quality indicators, 
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such as the avoidance of antibiotic treatment for adults with acute bronchitis, the use of 
angiotensin converting enzyme inhibitors (ACE inhibitors) and angiotensin receptor blockers 
(ARBs) among patients with diabetes, the use of appropriate medications for patients with 
asthma, were other available medication-related quality indicators in the NAMCS dataset. Future 
studies may examine these indicators. Another related drawback of the studies in Chapter 3 and 
Chapter 4 is that they did not control for several restricted physician-related variables in the 
examination of the association with patient medication quality of care outcomes. Access to these 
data was limited to the original models and modifications to the datasets could not be done. 
Therefore, the studies in Chapter 3 and Chapter 4 did not include the physician characteristics as 
the control covariates. Future studies can add these physician characteristics to derive unbiased 
estimates.   
Second, the PCMH mapping technique has limitations, and NAMCS does not contain all 
physician characteristics that may be considered. The mapping technique used to define the 
PCMH may be questioned in terms of how well it captured actual PCMH environments in 
practices. This is because the NCQA PCMH recognition program emphasized the 
implementation of health information technology in practices rather than physician-led care or 
the collaboration of care delivered to patients. Despite this limitation, the mapping technique 
employed here is the most commonly used approach in today’s literature involving a nationally 
representative dataset to reflect the results from a macro-level perspective. Furthermore, some of 
the physician characteristics, such as physician race, years since receiving the medical degree, 
years in practice, participation in any special courses, are not available in the NAMCS data. 
These characteristics may be significant determinants of whether practices adopt a PCMH and 
should be examined.  
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Third, there was an issue in terms of missing data while analyzing the selected variable in 
the NAMCS. Based on the results of the table of fraction of missing information (Appendix F), 
nearly 50% of the patient visits had complete data information. Therefore, the use of multiple 
imputation of chain equation technique was applied to replace missing values with multiple sets 
of simulated values and to adjust the parameter estimates for missing data uncertainty. The 
approach represents a sound scientific approach to manage missing data.   
Conclusion 
 Medication quality of care remains an unsolved public health problem and innovative 
ways to solve it are still needed. Three medication quality indicators (HRM, DDIS, and ADEs) 
were not significantly improved in the PCMH context. The findings regarding the adoption of 
PCMH by physician practices were consistent with previous studies that showed 
individual/physician-related characteristics had a greater influence than did practice-level 
characteristics. Policymakers need to be aware that effective strategies are needed to improve the 
medication quality of care for patients under the promising PCMH model. 
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APPENDICES 
APPENDIX A. BEERS CRITERIA, ZHAN CRITERIA AND NCQA LISTS 
Criteria Medications Pros Cons 
Beers 
(1997) 
Propoxyphene and combination products, Indomethacin (Indocin, Indocin SR), 
Phenylbutazone (Butazolldln), Pentazocine (Talwin), Trimethobenzamide (Tlgan), 
Methocarbamol (Robaxin), carlsoprodol (Soma), oxybutynin (Dltropan), 
chlorzoxazone (Paraflex), metaxalone (Skelaxin), and cyclobenzaprine (Flexeril) 
Flurazepam (Dalmane), Amitrlptyline (Elavil), chlordiazepoxldeamitriptyline 
(Limbitrol), and perphenazlne-amltrlptyline (Triavil) Doxepin (Slnequan), 
Meprobamate (Miltown, Equanll), Lorazepam (Ativan), 3 mg; oxazepam (Serax), 
60 mg; alprazolam (Xanax), 2 mg; temazepam (Restoril), 15 mg; zolpidem 
(Amblen), 5 mg; triazolam (Halcion), 0.25 mg, Chlordiazepoxlde (Librlum), 
chlordiazepoxide-amltrlptyline (Limbitrol), clidlnium-chlordlazepoxide (Librax), 
and diazepam (Vallum), Disopyramide (Norpace, Norpace CR), Digoxin 
(Lanoxln), Dlpyridamole (Persantlne), Methyldopa (Aldomet); methyldopa/ 
hydrochlorothlazide (Aldoril), Reserpine (Serpasil); reserplne hydrochlorothlazide 
(Hydropres) Chlorpropamide (Diablnese), Dlcyclomine (Bentyl); hyoscyamine 
(Levsin, Levsinex); propantheline (Pro-Banthine); belladonna alkaloids (Donnatal 
and others); and clldinium-chlordiazepoxide (Librax), Examples include single and 
combination preparations containing chlorphenlramine (Chlor-Trimeton), 
diphenhydramine (Benadryl), hydroxyzine (Vistaril, Atarax), cyproheptadine 
(Periactln), promethazlne (Phenergan), tripelennamine, and dexchlorphenlramlne 
*First 
medication list 
for the use of 
inappropriate 
medication 
among the 
elderly 
population. 
*Add the 
severity noting 
high or low 
risk 
Quantified the 
appropriateness 
of medications 
mostly for 
nursing home 
residents, and 
added the 
severity noting 
high or low 
risk in 1997 
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(Polaramine), Diphenhydramine (Benadryl), Ergot mesyloids (Hydergine), 
cyclospasmol, Iron supplements, >325 mg, All barbiturates except phenobarbital, 
Meperidlne, Ticlopidine 
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Beers 
(2002) 
Medicines Modified Since 1997 Beers Criteria: Reserpine (Serpasil and 
Hydropres), Extended-release oxybutynin (Ditropan XL), Iron supplements >325 
mg, Short-acting dipyridamole (Persantine) 
Medicines Added Since 1997 Beers Criteria: 
Independent of Diagnoses: Ketorolac tromethamine (Toradol), Desiccated thyroid, 
Orphenadrine (Norflex), Ferrous sulfate 325 mg,  Guanethidine (Ismelin), 
Amphetamines (excluding methylpenidate and anorexics), Guanadrel (Hylorel), 
Thioridazine (Mellaril), Cyclandelate (Cyclospasmol), Short-acting nifedipine 
(Procardia and Adalat), Isoxsuprine (Vasodilan), Daily fluoxetine (Prozac), 
Nitrofurantoin (Macrodantin), Stimulant laxatives may exacerbate bowel 
dysfunction (except in presence) Doxazosin (Cardura) of chronic pain requiring 
opiate analgesics), Methyltestosterone (Android, Virilon, and Testrad), 
Amiodarone (Cordarone), Non–COX-selective NSAIDs (naproxen [Naprosyn], 
oxaprozin, and piroxicam), Mesoridazine (Serentil), Reserpine doses 0.25 mg/d, 
Clonidine (Catapres), Estrogens in older women, Mineral oil, Cimetidine 
(Tagamet), Ethacrynic acid (Edecrin) 
Considering Diagnoses: Long-acting benzodiazepines: chlordiazepoxide 
(Librium), chlordiazepoxide-amitriptyline (Limbitrol), clidinium-chlordiazepoxide 
(Librax), diazepam (Valium), quazepam (Doral), halazepam (Paxipam), and 
chlorazepate (Tranxene) with COPD, stress incontinence, depression, and falls; 
Decongestants with bladder outflow obstruction; Calcium channel blockers with 
constipation; Phenylpropanolamine with hypertension; Bupropion (Wellbutrin) 
with seizure disorder; Olanzapine (Zyprexa) with obesity; Metoclopramide 
(Reglan) with Parkinson disease; Conventional antipsychotics with Parkinson 
disease; Propanolol with COPD/asthma; Tacrine (Cognex) with Parkinson disease; 
Anticholinergics with stress incontinence; Barbiturates with cognitive impairment; 
Tricyclic antidepressants (imipramine hydrochloride, doxepine hydrochloride, and 
amitriptyline hydrochloride) with syncope or falls and stress incontinence; 
Antispasmodics with cognitive impairment; Muscle relaxants with cognitive 
* Classified 
medications 
into 2 types: 
(1) 48 
medications 
that should 
generally be 
avoided, and 
(2) 
medications 
that should not 
be used under 
20 specific 
medical 
conditions.  
n/a 
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impairment; CNS stimulants with anorexia, malnutrition, and cognitive 
impairment; Short to intermediate and long-acting benzodiazepines with syncope 
or falls; Clopidogrel (Plavix) with blood-clotting disorders receiving anticoagulant 
therapy; Tolterodine (Detrol) with bladder outflow obstruction 
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Zhan  
(2001) 
Always avoid- Barbiturate, Flurazepam, Meprobamate, Chlorpropamide, 
Meperidine, Pentazocine, Trimethobenzamide, Belladonna alkaloids, Dicyclomine, 
Hyoscyamine, Propantheline 
Rarely appropriate- Chlordiazepoxide, Diazepam, Propoxyphene, Carisoprodol, 
Chlorzoxazone, Cyclobenzaprine, Metaxalone, Methocarbamol 
Have some indications but are often misused- Amitriptyline, Doxepin, 
Indomethacin, Dipyridamole, Ticlopidine, Methyldopa, Reserpine, Disopyramide, 
Oxybutynin, Chlorpheniramine, Cyproheptadine, Diphenhydramine, Hydroxyzine, 
Promethazine 
Classified 33 
drugs into 3 
categories. 
n/a 
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NCQA 
(2010) 
aspirin-meprobamate, meprobamate, scopolamine, trimethobenzamide, ketorolac,  
APAP/dextromethorphan/diphenhydramine, APAP/diphenhydramine/phenylephrine,  
APAP/diphenhydramine/pseudoephedrine, acetaminophen-diphenhydramine,  
carbetapentane/diphenhydramine/phenylephrine, codeine/phenylephrine/promethazine, 
codeine- 
promethazine, cyproheptadine, Dexchlorpheniramine, 
dexchlorpheniramine/dextromethorphan/PSE,  
dexchlorpheniramine/guaifenesin/PSE, 
dexchlorpheniramine/hydrocodone/phenylephrine,  
dexchlorpheniramine/methscopolamine/PSE, dexchlorpheniramine-pseudoephedrine, 
dextromethorphan- 
promethazine, diphenhydramine, diphenhydramine/hydrocodone/phenylephrine, 
diphenhydramine- 
magnesium salicylate, diphenhydramine-phenylephrine, diphenhydramine-
pseudoephedrine, hydroxyzine  
hydrochloride, hydroxyzine pamoate, phenylephrine-promethazine, promethazine, 
thioridazine,  
amphetamine-dextroamphetamine, benzphetamine, dexmethylphenidate, 
dextroamphetamine, diethylpropion,  
methamphetamine, methylphenidate, phendimetrazine, phentermine, butabarbital, 
mephobarbital, 
pentobarbital, phenobarbital, secobarbital, amitriptyline-chlordiazepoxide, 
chlordiazepoxide,  
chlordiazepoxide-clidinium diazepam, flurazepam, nifedipine—short-acting only, 
dicyclomine,  
propantheline, atropine, atropine/CPM/hyoscyamine/PE/scopolamine,  
atropine/hyoscyamine/PB/scopolamine, atropine-difenoxin, atropine-diphenoxylate, 
atropine-edrophonium,  
belladonna, belladonna/ergotamine/phenobarbital, 
butabarbital/hyoscyamine/phenazopyridine, hyoscyamine,  
hyoscyamine/methenam/m-blue/phenyl salicyl, ASA/caffeine/orphenadrine, 
ASA/carisoprodol/codeine,  
aspirin-carisoprodol, aspirin-methocarbamol, carisoprodol, 
Chlorzoxazone,cyclobenzaprine metaxalone, methocarbamol, orphenadrine, 
conjugated estrogen, conjugated estrogen-medroxyprogesterone, esterified  
estrogen, esterified estrogen-methyltestosterone, estropipate, chlorpropamide, 
ASA/caffeine/propoxyphene, acetaminophen-pentazocine, acetaminophen-
propoxyphene, belladonna-opium,  
meperidine, meperidine-promethazine, naloxone-pentazocine, pentazocine, 
propoxyphene hydrochloride,  
propoxyphene napsylate, dipyridamole—short-acting only, ergot mesyloid, 
isoxsuprine, methyltestosterone,  
An updated 
and 
comprehensive 
lists 
Not shown too 
often in 
research 
literature but is 
adopted 
common in 
health plans 
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nitrofurantoin, nitrofurantoin macrocrystals, nitrofurantoin macrocrystals-
monohydrate, thyroid desiccated 
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APPENDIX B. DESCRIPTION OF DDIS IDENTIFIED BY THE HEDIS MEASURE 
Disease States Drugs Class  Drugs to Avoid 
Dementia Anticholinerg
ics , Tricyclic 
Antidepressa
nts 
Alavert, Alkabel-SR, Allermax, Altaryl, Ambien, Amrix, Anaspaz, Antihistamine, Antivert, Arbinoxa, 
Atreza, Atropine, Axid, Banaril, Banflex, Belladonna, Bellatal, Benadryl, Bentyl, Bidhist, Bonine, 
Bromaphen, Bromax, BroveX, Carbinoxamine, Carisoprodol, Chlorpheniramine, Cimetidine, Claritin, 
Clemastine, Cogentin, Cyclobenzaprine, Cystospaz, Darcalma, Darpaz, Detrol, Dicyclomine, 
Dimenhydrinate, Diphedryl, Diphenhydramine, Diphenmax, Ditropan, Donnatal, Dramamine, Driminate, 
Edluar, Enablex, Famotidine, Fexmid, Flavoxate, Flexeril, Genahist, Histaprin, Homatropine, Hycodan, 
Hydramine, Hydromet, HyoMax, Hyophen, Hyoscyamine, Intermezzo, Levbid, Levsin, Lodrane, Lomotil, 
Loratadine, Maldemar, Meclizine, Nizatidine, Orphenadrine, Oscimin, Oxybutynin, Palgic, PediaTan, 
Pepcid, Periactin, Pharbedryl, Phosenamine, Phosphasal, Probanthine, Quadrapax, Quenalin, Ranitidine, 
Sanctura, Scopace, Servira, Siladryl, Siltane, Soma, Sominex, Stahist, Taladine, Tavist, Tolterodine , 
Toviaz, Tranquil, Trihexyphenidyl, Triptone, Trospium, Tussigon, Twilite, Urelle, Uribel, Uta, Valudryl, 
Vanadom, Vazol, Verticalm, Vesicare, Vistaril, Wal-finate, Wal-itin, Wal-Zan, Zanaflex, Zantac, 
Zolpidem, Zzzquil 
Fall or Hip 
Fracture 
Antipsychoti
cs, Tricyclic 
Antidepressa
nts, Sleep 
Agents 
Abilify, Adgan, Alprazolam, Amitriptyline, Amoxapine, Anafranil, Anergan, Ativan, Chlordiazeproxide, 
Chlorpromazine, Clonazepam, Clorazepate Dipotassium, Clozapine, Clozaril, Compazine, Compro, 
Dalmane, Desipramine, Diastat Acudial, Diastat Pediatric, Diazepam, Doral, Doxepin, Estazolam, Fanapt, 
FazaClo, Fluphenazine, Geodon, Halcion, Haldol, Haloperidol, Haloperidol, Imipramine, Invega, 
Klonopin, Latuda, Librax, Librium, Limbitrol, Lorazepam, Loxapine, Midazolam, Moban, Navane, 
Niravam, Norpramin, Nortriptyline, Olanzapine, Orap, Oxazepam, Pamelor, Permitil, Perphenazine, 
Phenadoz, Phenergan, Prochlorperazine, Promethegan, Protriptyline, Quetiapine Fumarate, Restoril, 
Risperdal, Risperidone, Saphris, Seroquel, Surmontil, Temazepam, Thioridazine, Thiothixene, Tofranil, 
Tranxene, Triazolam, Trifluoperazine, Trilafon, Trimipramine Maleate. Valium, Vanatrip, Vivactil, Xanax, 
Ziprasidone, Zyprexa 
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Chronic Renal 
Failure 
NSAIDS 
(nonsteroidal 
anti-
inflammatory 
drugs) 
Advil, Aleve, Anaprox, Cambia, Cataflam, Celebrex, Clinoril, Daypro, Diclofenac, EC-Naprosyn, 
Etodolac, Feldene, Flurbiprofen, Genpril, IBU, Ibuprofen, Ibuprohm, Indocin, Indomethacin, Ketoprofen, 
Ketorolac Tromethamine, Meclofenamate Sodium, Mefenamic Acid, Meloxicam, Mobic, Motrin, 
Nabumetone, Nalfon, Naprelan, Naprosyn, Naproxen, Nuprin, Oxaprozin, Piroxicam, Ponstel, Sprix, 
Sulindac, Tolmetin, Voltaren, Wal-Profen, Zipsor 
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APPENDIX C. NCQA 2008 STANDARDS AND GUIDELINES FOR PHYSICIAN PRACTICE CONNECTIONS ® 
PATIENT-CENTERED MEDICAL HOME (PPC-PCMH™) 
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Continued 
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Continued 
 
The National Committee for Quality Assurance. Patient-centered medical home recognition. 
http://www.ncqa.org/Programs/Recognition/Practices/PatientCenteredMedicalHomePCMH.aspx. Accessed 07/15, 2014.  
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APPENDIX D. MAPPING THE 2008 NCQA PCMH ELEMENTS TO THE 2009 2010 NAMCS Survey Items 
Variable 
Name 
Corresponding question from NAMCS Response  Point 
Standard 1: Access and communication  
Element 1. Access and Communication Processes   
SASDAPPT Does your practice set time aside for same day appointments? (MUST PASS) (a)No (b)Yes        4 
Element 2: Access and Communication Results (MUST PASS)          (No correspond questions from NAMCS)                         5 
Standard 2. Patient tracking and registry functions   
Element 1. Basic System for Managing Patient Data  
EDEMOG Does your practice have a computerized system for Patient history & 
demographic information? 
(a)No (b)Yes        2 
Element 2. Electronic System for Clinical Data  
EMEDREC Does your practice use an EMR or EHR system (not including billing records)? (a)No (b)Yes        3 
Element 3. Use of Electronic Clinical Data  
EIMGRES Does your practice have a computerized system for viewing imaging results? (a)No (b)Yes        3 
Element 4. Organizing Clinical Data  
EPNOTES Does your practice have a computerized system for clinical notes? (MUST PASS) (a)No (b)Yes        6 
Element 5. Identifying Important Conditions   
EPROLST If practice has a computerized system for patient demographic information, does 
it include patient problem lists? (MUST PASS) 
(a)No (b)Yes        4 
Element 6. Use of System for Population Management   
EMEDS 
 
If practice has a computerized system for patient demographic information, does 
it include a list of medications that patient taking? (2010) 
(a)No (b)Yes        3 
Standard 3. Care Management  
Element 1.  Guidelines for Important Conditions  (MUST PASS)       (No correspond questions from NAMCS) 3 
Element 2. Preventive Service Clinician Reminders  
EREMIND Does your practice have a computerized system for reminders for guideline-based 
interventions and/or screening tests? 
(a)No (b)Yes  4 
Element 3. Practice Organization  
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PHYSASST, 
NPNMW, 
RNLPN 
Was a PA seen at this visit? Was a Nurse practitioner/Midwife seen at this visit? 
Was a RN/LPN seen at this visit? 
(a)No (b)Yes  3 
Element 4. Care Management Of Important Conditions  
NHVISR, 
HOMVISR, 
TELCONR,E
CONR 
Did you make encounters of the following types with patients? (nursing home 
visits/other home visits/ hospital visits/ telephone consults/ email consults) 
(a)No (b)Yes  5 
Element 5. Continuity of Care                                   (No correspond questions from NAMCS)  5 
Standard 4. Self-management support  
Element 1. Documenting Communication Needs (MUST PASS)       (No correspond questions from NAMCS) 2 
Element 2. Self-Management Support   
HEALTHED Was any health education ordered or provided at the visit? (a)No (b)Yes  4 
Standard 5. Electronic prescribing  
Element 1. Electronic Prescription Writing   
ECPOE Does your practice have a computerized system for orders for prescriptions? (a)No (b)Yes  3 
Element 2. Prescribing Decision Support—Safety   
EWARN If practice has a computerized system for orders for prescriptions, are there 
warnings of drug interactions or contraindications provided? 
(a)No (b)Yes  3 
Element 3. Prescribing Decision Support—Efficiency          (No correspond questions from NAMCS) 3 
Standard 6. Test tracking  
Element 1. Test Tracking and Follow-Up   
ERANGE If your practice has a system for viewing lab results, are out of range levels 
highlighted? (MUST PASS) 
(a)No (b)Yes  7 
Element 2. Electronic System for Managing Tests   
EORDER 
 
(1)If your practice has a computerized system for orders for test, are orders sent 
electronically 
(a)No (b)Yes  
 
6 
Standard 7. Referral Tracking  
Element 1. Referral Tracking       (MUST PASS)                 (No correspond questions from NAMCS)   4 
Standard 8. Performance reporting and improvement  
Element 1. Measures of performance (MUST PASS)                 (No correspond questions from NAMCS) 3 
Element 2. Patient Experience Data                               (No correspond questions from NAMCS) 3 
Element 3. Reporting to Physicians  (MUST PASS)                 (No correspond questions from NAMCS)  3 
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Element 4. Setting Goals and Taking Action                        (No correspond questions from NAMCS) 3 
Element 5. Reporting Standardized Measures                       (No correspond questions from NAMCS) 2 
Element 6. Electronic Reporting External Entities   
EPUBHLTH Does your practice have a computerized system for electronic public health 
reporting? (2009) 
(a)No (b)Yes  1 
Standard 9. Advanced electronic communications  
Element 1. Availability of Interactive Web Site                      (No correspond questions from NAMCS) 1 
Element 2. Electronic Patient Identification                         (No correspond questions from NAMCS) 2 
Element 3. Electronic Care Management Support                    (No correspond questions from NAMCS) 1 
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APPENDIX E. COMPARISON BETWEEN ORIGINAL NCQA PCMH CRITERIA AND SURVEY ITEMS 
 
 Original 2008 NCQA PCMH criteria Mapping Results from 2009 2010 NAMCS 
Standards 9 7 
Elements 30 20/21 
Must Pass 
Elements 
10 4 
Scores 100 55/60 
Level of PCMH  Relative scores  (the number of available 
points/cumulative total scores) 
 Not Accredited Less than 25 points  Less than 25 %   
 Level 1 25 points–49 points + Must-pass elements = 5 of 10 Between 25-49 % + Must-pass elements = 2 of 4 
 Level 2 50 points–74 points + Must-pass elements = 10 of 10 Between 50-74 % + Must-pass elements = 4 of 4 
 Level 3 75 points or more  + Must-pass elements = 10 of 10  75 % or more    + Must-pass elements = 4 of 4 
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APPENDIX F. FRACTION OF MISSING INFORMATION ESTIMATES FROM MULTIPLE IMPUTATION ANALYSES 
Variable 
Name 
Explanation  Mean 
% 
Fraction of 
Missing 
Information %  
Missing 
Proportion 
% 
Variables for composing the PCMH 
SASDAPPT Does practice set time aside for same day appointments? 64.28 2.76 3.68 
EDEMOG Does practice have computerized system for patient history & demographic 
info? 
85.44 0.34 0.70 
EMEDREC Does practice use EMR or EHR system (not Including billing records 
systems)? 
54.22 0.20 6.4 
EIMGRES Does practice have computerized system for viewing imaging results? 52.20 0.05 1.74 
EPNOTES Does practice have computerized system for clinical notes? 54.50 0.31 9.6 
EPROLST If yes, does this include a patient problem list? 54.06 4.50 7.98 
EMEDS If yes, do they include list of medications patient is currently taking? 55.30 0.06 1.92 
EREMIND Does practice have computerized system for reminders for interventions 
/tests? 
39.77 2.73 5.55 
PHYSASST Physician assistant seen 6.05 0.00 0.00 
NPNMW Nurse Practice/ Midwife seen 1.81 0.00 0.00 
RNLPN RN/LPN seen 24.62 0.00 0.00 
NHVISR During last normal week of practice, nursing home visits? 15.35 0.75 2.64 
 HOMVISR During last normal week of practice, other home visits? 6.30 1.46 2.91 
TELCONR During last normal week of practice, telephone consults w/pats? 52.84 2.18 4.35 
ECONR In last normal week of practice, internet/email consults w/pats? 7.97 1.03 4.07 
HOSVISR During last normal week of practice, hospital visits? 55.52 3.52 4.36 
HEALTHED Was health education ordered or provided? 39.93 0.08 1.44 
ECPOE Does practice have computerized system for orders for prescriptions? 49.39 0.04 1.09 
EWARN If yes, are warnings of drug interactions/ contraindications provided? 48.44 3.45 4.41 
ERANGE If yes, are out of range levels highlighted? 51.36 3.88 5.79 
EORDER If yes, are orders sent electronically? 34.26 1.67 3.15 
EPUBHLTH Practice has computerized system for public health reporting? 16.27 2.16 6.82 
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Variables for practice characteristics  
RETYPOFF Type of office setting 100 0.00 0.00 
REGION Geographic region 100 0.00 0.00 
MSA MSA or non-MSA area 100 0.00 0.00 
MDDO MD or DO 100 0.00 0.00 
SPECCAT Physician specialty 100 0.00 0.00 
SOLO Solo or group practice 31.44 0.01 1.30 
OWNS Who owns the practice? 97.60 0.07      2.40 
EMPSTAT Employment status of physician 96.20 0.09 3.80 
PAYTYPER Recoded type of payment 92.30 4.50 7.70 
Variables for patient characteristics  
AGE Patient age 100 0.00 0.00 
SEX Patient gender 100 0.00 0.00 
RACER Patient race 100 0.00 0.00 
NUMMED Patient number of medication use 100 0.00 0.00 
PASTVIS How many visits in past 12 months? 100 0.00 0.00 
ARTHRTIS Does patient now have arthritis? 100 0.00 0.00 
ASTHMA Does patient now have asthma? 100 0.00 0.00 
CANCER Does patient now have cancer? 100 0.00 0.00 
CEBVD Does patient now have cerebrovascular disease? 100 0.00 0.00 
CRF Does patient now have chronic renal failure? 100 0.00 0.00 
CHF Does patient now have congestive heart failure? 100 0.00 0.00 
COPD Does patient now have COPD? 100 0.00 0.00 
DIABETES Does patient now have diabetes? 100 0.00 0.00 
HYPLIPID Does patient now have hyperlipidemia? 100 0.00 0.00 
HTN Does patient now have hypertension? 100 0.00 0.00 
IHD Does patient now have ischemic heart disease?  100 0.00 0.00 
HINCOMER Median household income in patient's ZIP 94.61 3.84 5.39 
PAYTYPER Recoded type of payment 92.30 5.11 7.70 
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APPENDIX G. IRB DOCUMENTATION 
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